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Background: Metabolic syndrome (MetS) is a cluster of metabolic disturbances, 
including hyperglycaemia, hypertension, dyslipidaemia and abdominal obesity, 
increasing the risk of non-communicable diseases, such as cardiovascular disease and 
type 2 diabetes mellitus. Animal and clinical studies have observed favourable effects 
on glucose regulation and lipid metabolism after the intake of fish protein. As large 
amounts of residual raw materials are generated within the fishing industry every year, 
it is of interest to investigate if these already harvested marine resources may have 
similar beneficial metabolic effects in human.  
 
Aim: To investigate the effect of supplementation of hydrolysed proteins, made from 
residual materials from cod fillet production, on glucose metabolism in healthy adults 
and components of MetS in overweight and obese adults. 
Methods: Three clinical intervention studies were conducted. Study 1 was a 
randomised, double-blinded crossover trial in 41 healthy adults aged 40-65 years. The 
study included two study visits, with 4-7 days washout period in between the visits. 
The intervention was 20 mg/kg body weight (BW) of cod protein hydrolysate (CPH), 
or casein as control, given before a standardised breakfast meal. Study 2 was a dose-
range crossover study in 31 adults aged 60-80 years old. The participants received four 
different weight-adjusted doses of 10, 20, 30 or 40 mg/kg BW of CPH in random 
order. Each dose level was taken daily for one week, with seven days washout period 
between different dose levels. The primary outcome of Study 1 and 2 was postprandial 
response in glucose metabolism, measured by serum samples of glucose, insulin and 
plasma glucagon-like peptide 1 (GLP-1) (Papers I and II). Study 3 was a randomised, 
double-blinded placebo-controlled trial in 30 overweight or obese adults with MetS. 
The participants received a once-daily supplementation of 4 g of CPH (n=15) or 
placebo (n=15) for 8 weeks. The primary outcomes were fasting and postprandial 
response in glucose. Secondary outcomes were changes in other components of the 
MetS, body composition, total serum cholesterol, insulin, GLP-1, ghrelin, 
inflammatory markers and adipokines (Papers III and IV).  
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Results: The postprandial insulin concentration was statistically significantly lower 
when subjects were given one single dose of CPH compared to control, with no 
statistically significant differences observed for postprandial concentrations of glucose 
or GLP-1 (Paper I). We observed no differences in estimated maximum value of 
glucose, insulin or GLP-1 when comparing the lowest dose of 10 mg/kg BW of CPH 
with the higher doses (20, 30 or 40 mg/kg BW) (Paper II). In subjects with MetS, 
supplementation with CPH for 8 weeks had no effect on postprandial glucose, insulin 
or GLP-1, lipid profile or body composition, when compared to placebo (Paper III). 
Furthermore, no effect on circulating levels of ghrelin, adiponectin, leptin or 
inflammatory markers were observed after CPH supplementation (Paper IV).  
Conclusion: A single dose of CPH given before a standardised breakfast meal, 
resulted in reduced postprandial insulin concentrations in healthy adults, with no 
effects on glucose or GLP-1 levels (Study 1). We observed no effect of increasing 
doses of CPH on glucose, insulin or GLP-1 in healthy adults above 60 years (Study 2). 
A daily intake of 4 g of CPH for eight weeks, was not capable of affecting glucose or 
lipid profile, body composition, ghrelin, adipokines or inflammatory markers in  
overweight and obese participants with MetS (Study 3). The possible effects of CPH 
in subjects with metabolic abnormalities such as MetS should be further explored, due 
to the limited number of included participants.  
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1. INTRODUCTION 
1.1 METABOLIC SYNDROME  
Metabolic syndrome (MetS) is a cluster of metabolic disturbances, including 
hyperglycaemia, hypertension, dyslipidaemia and abdominal obesity (1-3). It has 
become a common metabolic disorder, resulting from the increasing proportion of  
overweight and obese individuals observed globally (3). The presences of MetS 
increases the risk of non-communicable diseases (NCDs), such as cardiovascular 
disease (CVD) and type 2 diabetes mellitus (T2DM) (4). The NCDs caused 71% of all 
deaths in 2016 and represents a major global health challenge, with cancer, chronic 
respiratory disease, diabetes and CVD responsible for the majority of these deaths (5, 
6). The NCDs is a challenge for sustainable development (7), defined by the 
Brundtland Commission in 1987 as a development that “meets the needs of the present 
without compromising the ability of future generations to meet their own needs” (8). 
The reduction of the burden and mortality of the NCDs through prevention and 
treatment, are set as goals in both the World Health Organization (WHO) Global NCD 
Action Plan (9) and the United Nations’ 17 Sustainable Development Goals (SDGs) 
(7).  
1.1.1 Definition  
MetS originates back to the 1920’s, first described as the “hypertension-
hyperglycaemia-hyperuricemia-syndrome” by the Swedish physician, Eskil Kylin (3, 
10). In 1947, Vague observed that android obesity (upper body adiposity) was 
associated with abnormalities in the metabolism involved in the development of 
T2DM and CVD (11, 12). In the following years, several research groups described 
the clustering of different components of the MetS, and it was given different names 
such as the “metabolic trisyndrome” or the “plurimetabolic syndrome” (13). In 1988, 
the role of insulin resistance was emphasized by Reaven, who named it the “Syndrome 
X” (14). This was followed by Kaplan that added central obesity, and described the 
syndrome as the clustering of central obesity, hypertension, hypertriglyceridaemia and 
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impaired glucose tolerance, calling it “The Deadly Quartet” (15). In later years, it has 
also been referred to as the insulin resistance syndrome (3, 13).  
Several different diagnostic criteria and definitions of MetS have been proposed over 
the years. The first attempt to create an internationally acknowledged consensus 
definition came in 1998, when WHO proposed a working definition for MetS (16). It  
included glucose intolerance, impaired glucose tolerance, diabetes mellitus and/or 
insulin resistance, with two or more of the following components: hypertension, 
increased levels of triacylglycerol (TAG), reduced levels of high-density lipoprotein 
cholesterol (HDL-C), central obesity or body mass index (BMI) >30 kg/m2, or 
microalbuminuria (16). A modification was presented by the European group for the 
Study of Insulin Resistance in 1999, but with rather small changes from the proposal 
by WHO (17). The National Cholesterol Education Program Adult Treatment Panel III 
(NCEP ATP III) released a new definition in 2001, where three out of five risk factors 
qualified for the diagnosis of MetS (abdominal obesity, elevated TAG, fasting glucose 
or blood pressure (BP), and reduced HDL-C (18). In 2005, The International Diabetes 
Federation (IDF) released a definition where abdominal obesity was made obligatory 
as one of the five factors required to qualify for MetS, with the remaining criteria 
identical to the definition by NCEP ATP III (1).  
In 2009, the IDF; the American Heart Association; National Heart, Lung, and Blood 
Institute; International Atherosclerosis Society; World Heart Federation and 
International Association for the Study of Obesity, formed a harmonized, unified 
definition of MetS called the Joint Interim Statement (JIS) (1). In this definition, any 
three of five risk factors qualify for a diagnosis of MetS: increased waist 
circumference (WC), elevated BP, fasting glucose or TAG, or reduced level of HDL-
C. The specific criteria and cut-off points are given in Table 1. For WC, it is 
recommended to use population- and country specific cut-off points, because of the 
complexity of defining a threshold for abdominal obesity similar in all ethnic groups 
and populations (1). Several different thresholds are proposed. The IDF suggests using 
the threshold ≥80 cm (women) and ≥94 cm (men) in European population (19). The 
WHO propose that the above-mentioned thresholds indicate an increased metabolic 
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risk in Caucasian populations, with WC ≥88 cm in women and ≥102 cm in men, 
indicating an even higher metabolic risk (1). 
Table 1. Criteria and cut-off points for defining the Metabolic Syndrome according to the 
Joint Interim Statement definition.  
Criteria  Cut-off points 
Waist circumference Population and country-specific 
Fasting serum glucose* ≥5.5 mmol/L (100 mg/dL) 
Serum TAG* ≥1.7 mmol/L (150 mg/dL) 
Blood pressure*  SBP ≥130 mmHg and/or DBP ≥85 mmHg 
Serum HDL-C* Men:      <1.0 mmol/L (40 mg/dL)  
Women: <1.3 mmol/L (50 mg/dL)  
Adapted from Alberti et al. 2009 (1). TAG; triacylglycerol, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, HDL-C: 
High-density lipoprotein cholesterol. Three of five risk factors qualify for a diagnosis of MetS. *Drug treatment for elevated TAG, 
fasting glucose or reduced HDL-C, or antihypertensive drugs are alternative indicators for MetS.  
 
1.1.2 Prevalence 
It is challenging to compare the prevalence of MetS across different studies (20). The 
prevalence estimates are affected by the definition used for MetS and the population 
studied, with factors such as gender, age, race, ethnicity, lifestyle and socioeconomic 
status affecting the estimates (20). A consistent finding across studies, is the increasing 
prevalence of MetS with increasing age (3).  
The prevalence of MetS is relatively high globally, and it appears to increase with a 
parallel rise in prevalence of obesity (21). In a study comparing subjects from 12 
different cohorts across 10 European countries and one from the United States, the 
overall prevalence of MetS was 24.3% (22). In Norway, similar numbers have been 
reported. The prevalence of MetS was investigated among participants in a Norwegian 
population study, the Nord-Trøndelag Health Study 1995-1997 (HUNT 2), by using 
the IDF-definition and 2005 ATP III criteria for MetS (23). For both definitions, the 
prevalence of MetS increased with increased age. A higher prevalence of MetS was 
reported in all demographics groups when using the IDF-definition compared to the 
2005 ATP III criteria, with the exception of men aged 20-29 years. In total, 29.6% 
(95% CI: 28.8, 30.5) of the population had MetS when using the IDF-definition, 
compared to 25.9% (95% CI: 25.0, 26.7) with the 2005 ATP III criteria (23). This is 
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similar to estimates reported among participants (age 40-49 years) in the Hordaland 
Health Study (1997-1999): 30% had MetS according to the JIS-definition, with a 
higher prevalence among men (37.3%) than women (24.6%) (24). When using the 
same definition, data from the Tromsø 4 (1994-1996, age 26-70 years) and Tromsø 6 
study (2006-2008, age 30-87 years), revealed that the prevalence of MetS was 8.1 % 
and 22.7 %, respectively, in these populations (25, 26).  
1.1.3 Management  
The primary goal in the management of MetS, is to reduce the risk of CVD and T2DM 
development (27). By targeting underlying, modifiable factors of MetS, such as 
obesity, physical activity, and diet, it is possible to improve metabolic components 
affected by the syndrome and thereby alleviating the risk of CVD and T2DM (3, 27). 
Lifestyle changes, combining weight reduction, increased physical activity and diet 
modifications, are the first-line therapy for MetS. As some individuals with MetS are 
at high or moderately high risk for major CVD events within the next 10 years (short 
term), additional drug therapy might be necessary to be able to reduce the CVD risk. If 
a given risk factor (e.g., BP or glucose levels) is severely abnormal, drug therapy may 
also be required. It is important to underline that irrespective of risk status and the 
need for drug therapy, lifestyle changes should be part of the management (3, 27). 
The American Heart Association and the National Heart, Lung and Blood Institute 
recommends that weight reduction is achieved through behavioural change, with a 
combination of reduced caloric intake and increased physical activity (3, 27, 28). The 
initial goal is to achieve a weight loss of between 5-10% of initial body weight, by 
reducing weight by 0.5-1 kg per week, during a period of 6 to 12 months (27, 29). The 
metabolic risk factors of MetS, such as dyslipidaemia, hypertension, hyperglycaemia, 
will be reduced by achieving the recommended weight loss, thereby reducing the 
severity of the syndrome (27). These recommendations for weight reduction are in line 
with the Norwegian Directorate of Health’s advice for individuals with obesity, and it 
is emphasized that patients with MetS may achieve significant health benefits by 
weight loss, such as reduced risk of T2DM (30). A recent meta-analysis observed 
significant improvements in metabolic risk factors and reduced prevalence of MetS, 
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after a supervised multifaceted lifestyle intervention, combining dietary intervention 
and physical activity (31). The combination of dietary intervention with physical 
activity seems to result in greater weight loss in the long-term, compared to a dietary 
intervention alone (32). Additionally, increased weight loss and beneficial effects on 
metabolic risk factors are observed with increased adherence (33, 34).  
In general, it is important that the initial phase is followed by monitoring and long-
term follow-up, with maintenance of weight loss, physical activity and diet change (3, 
27, 30). Adhering to a dietary intervention and sustaining the weight loss over time are 
proven to be difficult (33, 35), and weight-regain is common (36). Furthermore, there 
is conflicting evidence regarding conventional strategies and long-term weight loss 
(37-39). Pharmacotherapy is often used adjunct to lifestyle change, increasing and 
maintaining the weight reduction (40). These therapies have great potential, but there 
is a need for development, due to moderate weight loss, weight regain after drug 
termination and side effects (41). Bariatric surgery is an alternative weight-loss 
strategy (41). Compared to conventional therapies, this method is effective in the 
short-term, resulting in a greater weight loss, with improved metabolic risk factors and 
comorbidities (42, 43). However, these procedures are associated with greater risk and 
possible side effects on short- and long-term (41, 44).  
Considering the challenges of a achieving a successful long-term weight loss, and side 
effects of alternative strategies, exploring other strategies that may prevent the 
development of MetS is of interest. The intake of fish is suggested to play a protective 
role (45), and the consumption of fish is associated with reduced risk of MetS in cross-
sectional studies (24-26). There is also evidence of beneficial changes in the specific 
components of MetS after the consumption of lean fish (46, 47). Despite a growing 
number of animal studies reporting beneficial effects on metabolic risk factors after 
supplementation with fish protein hydrolysates (48-52), there are few intervention 
studies in humans, with conflicting results (53-57). 
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To the best of our knowledge, a dietary supplement with a low dose of a fish protein 
hydrolysate has not been explored in overweight and obese humans with MetS, which 
is the primary focus of this thesis.  
1.1.4 Pathophysiology  
The development of MetS is complex, and not fully understood. Various 
pathophysiological explanations have been proposed, with insulin resistance as the 
most widely accepted hypothesis (3, 58). An overview of the proposed organ systems 
and mechanisms involved in the development of MetS is given in Figure 1. A 
sedentary lifestyle and excessive caloric intake over time, combined with a genetic 
predisposition, are suggested to be involved in the initiation of MetS (59). Nutrient 
surplus leads to increased storage of fat in adipocytes, including increased number and 
size. Over time, the adipocytes ability to store TAGs are exceeded or impaired, 
resulting in increased secretion of free fatty acids (FFAs) to circulation and lipid 
accumulation in the liver and skeletal muscle, causing insulin resistance (59). 
In the skeletal muscle, overabundance of FFA inhibit the insulin-mediated glucose 
uptake and result in reduced insulin sensitivity in muscle tissue (3). The increased 
glucose levels in circulation, will lead to increased secretion of insulin from the 
pancreas, causing hyperinsulinaemia. This may further contribute to the development 
of hypertension, through enhancement of sodium reabsorption in the kidneys. In the 
liver, the overabundance of FFA increase the production of TAG and glucose, and the 
secretion of very-low-density lipoprotein cholesterol (VLDL-C), resulting in increased 
density of low-density lipoprotein cholesterol (LDL-C) and decreased levels HDL-C 
(3). A low-grade inflammation has also been implicated as part of the pathophysiology 
of the MetS, with increased secretion of pro-inflammatory cytokines from the adipose 
tissue (3, 58). This is further reviewed in subchapter 1.1.9.  
In the next subchapters, the pathophysiology of MetS will be elaborated further by 





Figure 1. Pathophysiology of the metabolic syndrome. As a result of an increased and 
expanded adipose tissue, free fatty acids (FFAs) are released to circulation (1). In the liver, 
the FFAs causes increased production of glucose and TAG, including increased excretion of 
VLDL (2). Related lipoprotein-alterations are decreased levels of HDL-C, with increased 
density of LDL-C. In skeletal muscle, the increased FFAs causes insulin resistance (3), and 
inhibit the uptake of glucose. Increased levels of glucose in blood (4) will cause the pancreas 
to release more insulin (5), resulting in hyperinsulinaemia. At the same time, an inflammatory 
process in the adipose tissue, cause the secretion of inflammatory cytokines, such as IL-6 
and TNF-α (6). The increased adipose tissue will also inhibit secretion of adiponectin (7). The 
figure is inspired by Eckel et al (2005) (3). The medical images are taken from Smart Servier 
Medical Art. The figure is made in Adobe Illustrator by Jensen 2020. FFA: Free fatty acid, 
TAG: triacylglycerol, VLDL: very-low density lipoprotein, IL-6: Interleukin-6, TNF-α: Tumor 
necrosis factor alpha.  
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1.1.5 Glucose metabolism  
The MetS is characterized by alterations in glucose metabolism, with fasting glucose 
levels above 5.5 mmol/L considered one of the criteria for the diagnosis of MetS (1). 
In healthy individuals, fasting glucose levels are regulated within a narrow range of 4 
to 6 mmol/L, with abnormal levels quickly regulated to maintain glucose homeostasis 
(60). In response to low glucose levels, glucagon is secreted from the α-cells of the 
pancreas, leading to the breakdown of glycogen in the liver and release of glucose, 
(61). This results in increased glucose levels (61). On the other hand, high glucose 
levels in circulation causes secretion of insulin from the pancreatic ß-cells (60). This 
results in increased uptake of glucose in the skeletal muscle and adipose tissue, 
returning the glucose levels to their normal fasting levels (60). Insulin works through 
binding to an insulin receptor at the plasma membrane of the cells, activating 
signalling pathways such as phosphatidylinositol 3-kinase (PI3K), protein kinase B 
(Akt), resulting in the translocation of the glucose transport protein 4 (GLUT4) from 
storage site in the cells to the plasma membrane, enabling uptake of glucose into the 
cell (60, 62). The activation of PI3K is inhibited by reduced phosphorylation of 
tyrosine, which is linked to increased fat accumulation in peripheral tissue seen in 
MetS (58). There is also an inhibited activation of Akt, which is associated with 
increased levels of Acyl-CoA, known to be involved in metabolism of fatty acids (58). 
When target tissues, such as muscle and liver, are unable to respond to normal 
circulating concentration of insulin, insulin resistance has developed (63). This causes 
less glucose to be absorbed into the cell, resulting in elevated glucose concentration in 
blood. To compensate, the ß-cells secretes more insulin to maintain euglycaemia, 
causing hyperinsulinaemia. Over time, the ß-cells will not be able to maintain the high 
insulin production due to functional defects, leading to impaired glucose tolerance and 
eventually the development of T2DM (63). It is suggested that increased levels of FFA 
released from a saturated adipose tissue contribute to the development of insulin 
resistance seen in MetS (3, 58).  
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Observed effects on glucose metabolism after the intake of cod 
protein or fish protein hydrolysates  
Several animal studies have observed beneficial effects on parameters of glucose 
metabolism after the intake of cod protein (64-67). These findings are partly confirmed 
in human intervention studies. Insulin-resistant individuals consuming a cod protein-
containing diet had improved insulin sensitivity after 4 weeks, when compared to other 
animal proteins (68). Postprandially reduced insulin levels and higher glucose 
response were observed in an acute-effect study, after participants consumed a test 
meal with cod protein, compared to meals with milk or soy protein (69). Decreased 
postprandial levels of insulin-C peptide were observed in healthy adults consuming a 
diet with 60% of dietary protein from lean seafood (cod, pollock, saithe and scallop) 
for 4 weeks, compared to a non-seafood diet (70). No effect on fasting or postprandial 
levels of insulin or glucose were observed in the latter study (70), in line with studies 
reporting no effect on fasting or postprandial levels of glucose or insulin after a high 
intake of cod (750 g/week) in normal-weight (71) or overweight and obese (72) 
subjects. A daily consumption of 100 g lean fish per day for 8 weeks, did not 
significantly affect serum levels of glucose or insulin, or insulin resistance in 
individuals with MetS (47).  
The large amounts of by-products occurring within the fisheries and aquaculture every 
year, are increasingly recognized as a high-quality source of protein (73). A promising 
approach for utilization is the production of fish protein hydrolysates, elaborated on in 
subchapter 1.2.4 (74). Protein hydrolysates made from salmon and herring are reported 
to have antidiabetic effects in animals (49). Reduced postprandial glucose level (49) 
and improved insulin sensitivity (51) have been observed in rats fed with diets 
containing salmon protein hydrolysate, with no effect on fasting glucose levels or 
glucose tolerance when rats were fed protein hydrolysates from herring, mackerel, 
bonito or salmon (51). A lack of effect on parameters of glucose metabolism was also 
observed in rats fed a diet with saithe protein hydrolysate, compared to casein- or soy-
fed rats (75). Reduced non-fasting insulin and glucose in serum and the liver were 
observed in rats fed a high-fat diet containing salmon protein hydrolysate as the only 
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protein source (50). These changes, combined with a reduced expression of a specific 
gene, the PcK1-expression, are proposed to indicate better insulin sensitivity in the 
salmon-hydrolysate fed rats (50).  
In humans, few studies have investigated the supplementation of low doses of fish 
protein hydrolysates on glucose metabolism (53, 54, 57), with inconclusive findings 
and various study populations. No effect on serum levels of insulin or glucose were 
observed after supplementation with 5.2 g of blue whiting hydrolysate for 6 weeks in 
21 older adults living in a nursing home setting, when compared to placebo (53). In an 
acute-effect study in overweight and obese individuals, levels of glucose, insulin and 
insulin C-peptide were not significantly affected by a single dose of 3 g fish peptide 
hydrolysate made from bonito (54). In contrast, 2 g of blue whiting hydrolysate (1 g 
taken twice daily) supplemented to overweight subjects, resulted in reduced 
postprandial glucose levels after an ad libitum lunch meal compared to placebo, with 
no effect on insulin concentrations (57). Other studies have evaluated the effect of low 
doses of unhydrolysed cod protein in healthy normal weight, overweight and obese 
subjects, with varying results. A daily supplement of cod protein (3 or 6 g per day) for 
8 weeks, had beneficial effects on postprandial glucose and reduced fasting glucose 
levels in overweight and obese subjects, with no effects on insulin or insulin C-peptide 
(76). In line with these results, reduced postprandial glucose were observed after 8 
weeks supplementation with 2.5 g of cod protein in overweight and obese individuals 
(only within-group difference), with no effect on insulin, insulin C-peptide or fasting 
glucose levels (77). A daily intake of a higher dose of cod protein (6 g/day), with the 
same intervention length, did not significantly affect fasting glucose or insulin levels 
in overweight and obese subjects, when compared to placebo (78). Similarly, 8 weeks 
supplementation with 8.1 g/day of cod protein in healthy, normal weight adults, had no 
effect on fasting serum concentration of glucose and insulin, or postprandial 
concentration of insulin, with postprandial glucose concentrations only decreased at 
one time point (60 minutes), when compared to control (79). They did however 
observe decreased concentrations of α-hydroxybutyrate, β-hydroxybutyrate and 
acetoacetate compared to the control group, suggested to reflect early changes in 
regulation of glucose (79).  
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1.1.6 Dyslipidaemia  
MetS is characterised by dyslipidaemia, with elevated levels of TAG and reduced 
levels of the lipoprotein particle HDL-C, including increased levels of VLDL-C and 
LDL-C (80). As TAG and cholesterol are lipophilic molecules, they must be 
transported in blood in the form of lipoproteins (81). Lipoproteins are water-soluble 
macromolecules, composed of an inner, hydrophobic core of TAG and cholesteryl 
ester, with an outer membrane made up of apolipoproteins, phospholipids and 
unesterified cholesterol. Based on density, the lipoproteins can be classified into 
different subclasses: chylomicrons, VLDL-C, intermediate density lipoprotein, LDL-C 
and HDL-C (81). Each class of lipoprotein contain a specific combination of 
apolipoprotein, important for their function and metabolism of lipoproteins (82). The 
chylomicrons are formed in the gastrointestinal (GI) tract, transporting TAG and 
cholesterol derived from diet from the intestine to various cells (82). As the 
concentration of TAG are reduced in the chylomicrons, cholesterol-rich particles 
called chylomicron remnants are formed. VLDL-C is formed in the liver from the 
chylomicron remnants, transporting TAG and cholesterol to peripheral tissue. Through 
hydrolysis of TAG by lipoprotein lipase, the VLDL particle is depleted of TAGs, 
leading to the formation of smaller cholesterol-enriched particles (82). LDL-C, a 
breakdown product of VLDL-C, is rich in cholesteryl esters and delivers cholesterol to 
peripheral tissue and liver (83). Through the reverse cholesterol transport, excess 
cholesterol from peripheral tissues is removed and transported to the liver for uptake 
by HDL-C (81).  
During development of MetS, ectopic fat accumulation and overabundance of FFAs 
released to circulation (59), causes increased hepatic production and secretion of 
VLDL-C to the bloodstream (3). Additionally, insulin resistance may cause reduction 
in peripheral tissue levels of lipoprotein lipase (3), an enzyme degrading TAG to fatty 
acids and glycerol (82). These events contributes to the development of elevated TAG, 
or hypertriglyceridemia, a common metabolic disturbance seen in individuals with 
MetS (3). Elevated levels of TAG above 1.7 mmol/L is one of the criteria for MetS 
when using the JIS-definition (1). It has been observed that when elevated fasting 
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TAG levels are above 2.0 mmol/L, most individuals will exhibit changes in the 
composition of LDL-C, having more of atherogenic small, dense LDL-particles (3). 
Reduced levels of HDL-C is another criterion for MetS in the JIS-definition (1). The 
homeostasis of cholesterol is maintained through the interactions of de novo 
biosynthesis, uptake, export and storage of cholesterol (84). Cholesterol is a vital 
molecule, produced in the body or derived from the diet. The major site of cholesterol 
synthesis in the body is the liver (84). A reduced cholesterol content of HDL-C is 
observed in the presence of hypertriglyderdaemia (3). This is caused by changes in the 
lipoprotein core of HDL-C, with reduced levels of cholesteryl ester and increased 
levels of TAGs, resulting in a small, dense lipoprotein particle. The changes in 
composition and metabolism of the lipoprotein particles play a role in the reduced 
levels of HDL-C observed in some patients with MetS (3).  
Observed effects on lipid metabolism after intake of cod protein or 
fish protein hydrolysates  
In cross-sectional studies, increased consumption of lean fish has been associated with 
decreased levels of TAG and increased levels of HDL-C (24, 25, 46). In animal 
studies, beneficial effects on cholesterol (85-87) and TAG (65) have been observed 
after the intake of cod protein, with no significant effects on lipid markers in other 
studies (64). Conflicting results are also reported from human intervention studies. 
Reduced fasting and postprandial serum concentrations of TAG, with prevention of 
VLDL particle concentration elevation, were observed in healthy subjects consuming a 
lean seafood diet for 4 weeks, compared to a non-seafood diet (88). No significant 
effects on fasting or postprandial levels of total cholesterol (total C), LDL-C or HDL-
C were observed (88). Decreased levels of TAG have also been reported after daily 
consumption of cod (150g/day) for two weeks in healthy subjects (89), whereas no 
significant effects on lipid markers were observed after a high intake of cod (750 
g/week) in normal weight subjects after 4 weeks (71) or in overweight subjects after 8 
weeks (90). In individuals with MetS, a daily consumption of 100 g lean fish for 8 
weeks significantly reduced LDL-C levels, with no significant effect on other lipid 
markers (47).  
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Bioactive peptide sequences with potential cholesterol-lowering effects have been 
observed in protein hydrolysates made from salmon and herring (49). Decreased 
concentration of HDL-C was observed in rats fed a diet with herring protein 
hydrolysate (49) or salmon protein hydrolysate (52), with no effect observed in rats 
fed a diet with saithe protein hydrolysate (75). In rats fed a high-fat diet containing 
salmon protein hydrolysate, reduced levels of postprandial TAG in both serum and 
liver were observed (50), with lower fasting levels of plasma TAG reported in rats fed 
a diet with saithe protein hydrolysate (75). Other animal studies report of no 
significant effect on fasting levels of TAG after supplementation with fish protein 
hydrolysates (48, 49, 51), with increased levels reported in some (49). Conflicting 
results are also observed for total C, with reduced levels reported in rats fed a salmon 
protein hydrolysate containing-diet (52), with no significant effects in mice fed a diet 
with salmon protein hydrolysate (48) or rats fed saithe protein hydrolysate-containing 
diet (75).  
An acute-effect study observed no significant effects on postprandial levels of TAG in 
overweight and obese subjects, after a single, low dose of fish protein hydrolysate (3 g, 
made from bonito), when compared to placebo, a vitamin D-supplementation or a 
combined intervention of both (54). To our knowledge, no other study has evaluated 
the effect of a low dose of a fish protein hydrolysate on lipid metabolism in a human 
intervention study. Other studies have investigated the effect of low doses of non-






1.1.7 Abdominal obesity  
Overweight and obesity are defined as “abnormal or excessive fat accumulation that 
may impair health” (92). Obesity is a risk factor for the development of NCDs (93), 
and associated with increased risk of CVD and T2DM (92, 94-96), musculoskeletal 
disorders (97) and certain cancer forms (98). The prevalence of obesity is increasing 
across all regions of the world (99, 100), with obesity recognised as a significant 
driving force behind MetS (3). According to the latest report from the WHO, 39% of 
adults were overweight and about 13% were obese in 2016 (92). BMI is a simple and 
widely used index to classify overweight and obesity in adults, and is defined as “a 
person’s weight in kilograms divided by the square of his height in meters (kg/m2)”. 
Overweight is defined as a BMI between 25-29.9 kg/m2, whereas obesity is defined as 
BMI ≥30 kg/m2 (92). A BMI ≥30 kg/m2 is observed among the majority of individuals 
with MetS, and those with abdominal obesity seems to be of higher risk for MetS (80). 
Clinically, abdominal obesity is presented as increased WC (101). Abdominal obesity 
is associated with the metabolic risk factors, and the different products secreted from 
an expanded adipose tissue, such as cytokines and nonesterfied fatty acids, seems to 
worsen these risk factors (101).  
Observed effects on abdominal obesity after the intake of cod 
protein or fish protein hydrolysates  
Inconclusive findings are reported on the consumption of lean fish in humans and 
effects on WC (25, 26, 46, 47, 102, 103). In animal studies, rats fed a high-fat diet 
containing salmon protein hydrolysate had lower body weight gain and less visceral 
adipose tissue (51), with reduced abdominal tissue mass observed in rats fed a diet 
with saithe protein hydrolysate (75). A dietary supplement with 1.4 g or 2.8 g of fish 
protein hydrolysate taken daily for 3 months in overweight subjects combined with a 
caloric deficit of 300 kcal, had a beneficial effect on abdominal obesity in overweight 
subjects, shown as reduced WC, with reduced body weight, fat mass and BMI (56). 
No effect on body weight, percentage body fat or muscle were observed after a daily 
intake of a low dose of cod protein (3-6 g, intact) for 8 weeks in overweight subjects, 
without caloric restrictions (76).  
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1.1.8 Arterial hypertension  
An elevated blood pressure, defined by the JIS-definition as SBP ≥130 mmHg and/or 
DPB ≥85 mmHg or the use of antihypertensive medications, is considered another 
component of the MetS (1). It has been suggested that insulin resistance, seen as part 
of the MetS, is involved in the development of hypertension by increasing the 
reabsorption of sodium in the kidneys (3). Other mechanism proposed in combination 
with this, is activation of the sympathetic nervous system and renin-angiotensin-
aldosterone system, increased secretion of angiotensin from adipose tissue and an 
expanded intravascular volume (80).  
Observed effects on blood pressure after the intake of cod protein 
or fish protein hydrolysates  
The development of high blood pressure was prevented in rats fed cod protein (104), 
with conflicting results in human intervention studies. A lower blood pressure was 
observed after the consumption of lean fish in patients with coronary heart disease 
(105) and with MetS (47), whereas others report of no significant effects (106) or even 
increased blood pressure (102). Peptide sequences with known inhibitory effects on 
the angiotensin-1 converting enzyme (ACE) have been identified in salmon and 
herring protein hydrolysates (107). High ACE inhibitor activity has also been 
demonstrated in other fish protein hydrolysates (108), but when the different 
hydrolysates (cod, salmon, haddock) were fed to spontaneously hypertensive rats for 
28 days, the expected increase in blood pressure was not inhibited (108). A decreased 
blood pressure and increased levels of plasma angiotensin 1, was observed in 29 
individuals with mild hypertension after daily supplementation with fish protein 
hydrolysate for 4 weeks (55). The fish protein hydrolysate was made from sardine 
muscle and suggested to contain the bioactive sequence valyl-tyrosine (55). Another 
study found no significant effect on vascular function in healthy adults after a single 
low dose of 5 g of fish protein hydrolysate (109). As these results are reported from 
healthy adults, potential beneficial effects in individuals with hypertension or other 
pathological conditions need to be further explored before any conclusion can be 
drawn (109).  
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1.1.9 Low-grade inflammation  
A low-grade chronic inflammation has also been implicated as part of the 
pathophysiology of MetS (58). Inflammation is the immune system’s response to a 
harmful stimulus, protecting the host against infection and other insults, triggered by 
tissue damage, microbial products, or metabolic stress (110). The process activates 
several signaling pathways and releases inflammatory cytokines, resulting in an 
inflammatory response. This response is characterized by symptoms such as swelling, 
redness, pain, heat, and loss of function at the affected site. As soon as the trigger is 
eliminated, the inflammation is terminated through the release of anti-inflammatory 
cytokines and inhibition of proinflammatory signaling cascades, restoring the 
homeostasis of the inflamed area. The acute inflammation is essential for the host, but 
if not terminated properly it may evolve into a chronic inflammation. This is identified 
by change in cell types, with simultaneous destruction and healing of the affected 
tissue. Prolonged tissue damaged may occur, leading to development of disease, e.g., 
inflammatory bowel disease, with elevated levels of inflammatory biomarkers in 
affected tissue and systemic circulation, a so-called high-grade inflammation. Chronic 
inflammation can also be low-grade, observed in MetS and obesity, which is often 
asymptomatic, with a less pronounced increase in inflammatory biomarkers (110). As 
a response to the nutrient overload, the adipose tissue becomes infiltrated by 
macrophages, T cells and other immune cells, leading to an inflammatory response 
and secretion of pro-inflammatory cytokines, such as tumor necrosis factor alpha 
(TNF-α) and interleukin (IL)-6 (58). TNF-α is produced mainly by lymphocytes and 
macrophages, with some in adipose tissue (111). IL-6 is produced by adipose tissue 
and several other cell types, and one of its main tasks is to stimulate production of C-
reactive protein (CRP) in the liver (111). The increased levels of these circulating 
cytokines may contribute to development of insulin resistance in liver, muscle, and 
other tissue, as well as causing increased FFAs in circulation due to degradation of 
TAGs (3, 59). Increased levels of IL-6 have been observed in individuals with obesity 
and T2DM, and in individuals with MetS (58).  
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Observed effects on inflammatory markers after the intake of cod 
protein or fish protein hydrolysates  
There are indications that intake of fish is linked to reduced inflammatory activity 
(112). Results from studies exploring the effect of cod fillet consumption on 
inflammatory markers are inconclusive, with beneficial effects reported in some 
studies (113, 114), with others reporting no significant effects (72). Animal studies 
have indicated that fish protein hydrolysates as part of the diet, may have anti-
inflammatory effects. Reduced levels of TNF-α and IL-6 were observed in rats fed a 
high-fat diet containing protein hydrolysates from herring, mackerel, salmon or bonito 
for 28 days, compared to control fed rats (casein) (51). In a mouse model of chronic 
inflammation, the plasma levels of interferon gamma were reduced after a diet with 
salmon protein hydrolysate compared to control, but with no effects on other cytokines 
(IL-1 β, IL-2, IL-5 or GM-CSF) (48). In humans, two studies have evaluated the effect 
of low doses of fish protein hydrolysate on markers of inflammation (53, 115). 
Reduced levels of monocyte chemoattractant 1 (MCP-1) and increased serum 
concentration of CRP were observed in 21 nursing home residents after a daily 
supplement containing 5.2 g of a fish protein hydrolysate for 6 weeks, compared to 
placebo (53). In a study by our research group (115), a daily intake of 2.5 g fish 
protein hydrolysate made from cod for the same intervention length, did not affect pro-
inflammatory cytokines (IL-8) or any of the gut integrity markers in patients with 





1.1.10 Other manifestations of the metabolic syndrome  
Adiponectin and leptin   
Altered levels of adiponectin are suggested to be involved in the development of the 
MetS (3). Adiponectin is protein of 30 kDa, discovered in the 1990’s (116-119), 
mainly produced and secreted from adipose tissue (111, 120). The adipose tissue has 
traditionally been viewed as a passive organ serving as a pool for energy, but is now 
recognised as an active endocrine organ involved in several physiological processes 
(111, 121). In healthy humans, adiponectin is found in high concentrations in 
circulation (120), with plasma levels reported to range between 5-30 μg/mL (111). 
Reduced levels of adiponectin have been observed in subjects with obesity and 
patients with T2DM (111, 122), including subjects with MetS (121). The levels of 
adiponectin seems to decrease with increased number of components of MetS (123), 
with decreased levels of adiponectin linked to deterioration of the metabolic risk 
factors (101).  
Adiponectin is known to enhance insulin sensitivity (124, 125), by acting through two 
receptors expressed in muscle and liver: AdipoR1 and AdipoR2 (111). In the skeletal 
muscle, adiponectin binds to its receptor and activates adenosine mono phosphate 
activated protein kinase, promoting glucose uptake in muscle cells through 
translocation of GLUT4 to the cell membrane (111, 121). In the liver, adiponectin 
decreases gluconeogenesis by inhibiting the hepatic enzymes phosphoenolpyruvate 
carboxylase and glucose-6-phospatase, and stimulating fatty acid oxidation (111, 121). 
Furthermore, insulin sensitivity is enhanced through increased expression of an insulin 
receptor substrate protein in the liver, and by acting as an agonist in the peroxisome 
proliferator activated receptor gamma, leading to increased glucose uptake (121). 
Adiponectin also appear to have anti-atherosclerotic and anti-inflammatory properties 
(111). The activation and secretion of the pro-inflammatory cytokines in response to 
the infiltration of the oversaturated adipose tissue, may lead to reduced expression and 
secretion of adiponectin, through inhibition by IL-6 and TNF-a (126). The decreased 
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levels of adiponectin, combined with increased levels of pro-inflammatory cytokines, 
are suggested to be involved in the development of insulin resistance seen in MetS (3).  
Furthermore, changes in leptin levels appear to be involved in the MetS (3). Leptin 
was identified as a protein encoded by the obese ob gene, with mutations in the gene 
causing obesity and T2DM in mice, resembling morbid obesity in humans (127). 
Leptin is produced and released by adipose tissue, and involved in regulation of 
appetite and body weight (128). The hormone mediates its effects by acting on regions 
in the hypothalamus involved in the control and regulation of appetite (129). The 
levels of leptin increase with increased fat mass, leading to suppression of appetite and 
a lower energy intake. When fat mass is reduced, the levels of leptin decline, resulting 
in appetite stimulation and increased energy intake. The levels are highly correlated 
with adipose tissue mass, and most obese subjects have high circulating levels of 
leptin. However, absence of an effect on appetite by leptin in obese subjects, suggest 
that they have developed leptin resistance (128, 129). Leptin resistance is proposed as 
an alternative pathophysiological explanation of MetS (3). It has also been suggested 
that the elevated levels of leptin seen in obese individuals contribute to low-grade 
chronic inflammation (130), involved in the progression of MetS (58).  
There are indications that lifestyle modifications may influence adiponectin levels. 
Lifestyle intervention combining physical activity and energy-restricted diets, are 
shown to increase circulating levels of adiponectin, in the presence of weight loss 
(131). There are also observations that a daily intake of fish or long-chain n-3 
polyunsaturated fatty acids (PUFAs) supplements may increase adiponectin levels 
(131). A fish protein hydrolysate fed to mice had no significant effect on fasting levels 
of adiponectin (48). In humans, increased levels of adiponectin (within-group) were 
observed after 8 weeks daily intake of 2.5 g cod protein in overweight and obese 
individuals (77). Reduced levels of leptin have been observed after lifestyle 
interventions (132, 133), with the effect of lean fish consumption on leptin levels 
being more conflicting (77, 102).   
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Appetite hormones  
In recent years, there has been an improved understanding of how appetite regulation 
affects food intake, with more insight into how the gut hormones interacts with the 
central nervous system (134). The GI tract is considered the largest endocrine organ in 
the human body, producing and secreting several different GI hormones from the 
enteroendocrine cells, involved in the digestion, glucose homeostasis and energy 
balance (135). An overview of some of these GI hormones, their site of production and 
secretion, as well as main functions are given in Table 2. The GI hormones glucagon-
like peptide 1 (GLP-1) and ghrelin will be elaborated in further detail in the next 
paragraphs, as these are relevant for the current thesis. 
Table 2. Overview of important gastrointestinal hormones, their site of release and 
main function.  
Hormone Release site  Main function  
Ghrelin  D/P1-cells, stomach  Hunger regulation  
GLP-1  L-cells in small intestine and colon Prolongs gastric emptying 
Stimulate insulin secretion 
GIP K-cells, small intestine  Stimulate insulin secretion  
CKK I-cells in duodenal and jejunal mucosa Inhibit food intake 
Slows gastric emptying 
PYY L-cells in colon Reduce appetite  
INSL5  L-cells in colon Promote appetite during starvation  
GLP-1: Glucagon-like peptide 1, GIP: Glucose-dependent insulinotropic polypeptide, CCK; Cholecystokinin, PYY: Peptide-
tyrosine-tyrosine, INSL5: Insulin-like peptide 5 
 
 
Glucose-dependent insulinotropic polypeptide was the first identified incretin, 
followed by the identification of GLP-1 (136), which are defined as “hormones that 
are secreted from the gastrointestinal tract into circulation in response to nutrient 
ingestion that enhance glucose-stimulated insulin secretion” (136). GLP-1 are secreted 
from L-cells in the distal ileum and colon, rapidly secreted in response to nutrient 
ingestion, promoting the glucose-stimulated secretion of insulin. The hormone 
increase the secretion of insulin, by binding to a specific receptor on the pancreatic ß-
cells, leading to the activation of adenylate cyclase activity, production of c adenosine 
monophosphate and stimulating several mechanisms. GLP-1 also increase the ß-cell 
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mass in the pancreas, through stimulating ß-cell proliferation and inhibition of 
apoptosis. Glucagon secretion and hepatic glucose production are inhibited by GLP-1, 
whereas the uptake and storage of glucose in muscle and adipose tissue are increased 
by the peptide hormone. GLP-1 inhibit gastric emptying, slowing down the transfer of 
nutrients from the stomach to the small intestine and thereby reducing the postprandial 
glucose levels. Beyond this, GLP-1 is known to promote satiety (136).  
In humans, circulating GLP-1 is found mainly as GLP-1(7-36) NH2 (136). The fasting 
levels of GLP-1 in healthy adults range between 5-10 pmol/L, increasing to 15-50 
pmol/L after a meal (137). The secretion of GLP-1 occur in a biphasic pattern, with an 
early phase of GLP-1 secretion within the first 10-15 minutes after a meal, followed by 
longer second phase with GLP-1 secretion after 30-60 minutes. It is especially meals 
rich in carbohydrates and fats that stimulate the release of GLP-1 (136). GLP-1 have 
short half-life in circulation, and are degraded within minutes through cleaving by the 
proteolytic enzyme dipeptidyl peptidase-4 (DPP-4) (136, 138). By inhibiting DPP-4, 
the incretin hormone remains in circulation for a longer time, resulting in reduced 
glucose levels. This have led to the development of DPP-4 inhibitors, reducing the 
activity of DPP-4 by up to 80% and currently used as therapeutics in T2DM (137). In 
hydrolysates from fish, there have been identified bioactive peptides that have a 
similar DPP-4 inhibitory activity (139).  
In contrast to GLP-1, that increase secretion of insulin, slows down gastric emptying 
and decrease appetite (136), the GI hormone ghrelin seems to have the opposite effects 
by inhibiting insulin secretion, accelerating gastric emptying and increasing appetite 
(140). Ghrelin was discovered in 1999, as a ligand to the growth hormone 
secretagogue receptor, stimulating the release of growth hormone (141). Subsequent 
studies reported that the peptide hormone also had effects on appetite and energy 
balance, by increasing food intake and body weight (142-144). Other functions have 
been described, such as involvement in gut motility and secretion of gastric acid, 
modulation of sleep and glucose regulation (140). Ghrelin is a 28 amino acid peptide 
hormone, originating from the cleaving of the precursor molecule preproghrelin (145), 
produced and secreted from enteroendocrine cells mainly located in the stomach, the 
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small intestine and pancreas (146). In circulation, two different forms can be detected: 
deacylated and acylated ghrelin. The latter is the biologically active, formed through 
acylation by the ghrelin O-acyltransferase, needed to activate the ghrelin receptor, 
GHS-R1a (140). The concentrations of ghrelin increase before a meal, followed by 
declining levels postprandially. After about one hour, ghrelin reach the lowest level, 
before it gradually increases until the next meal (147, 148). This profile fits well with 
the idea that ghrelin has a physiological role as a “meal initiator” or a “hunger 
hormone” (147). Despite large interindividual variations in ghrelin levels, reduced 
levels have been observed in overweight and obese subjects, compared to lean subjects 
(149, 150). There is currently no clear reference range for ghrelin, and the reported 
concentrations of ghrelin vary in the literature (151).  
A few studies have reported on the effect of low doses of fish protein hydrolysates on 
circulating appetite hormones (56, 57, 152). Supplementation with 1.4 g or 2.8 g of 
fish protein hydrolysate made from blue whiting muscle for 90 days in overweight 
subjects, combined with a caloric deficit of -300 kcal, resulted in increased serum 
concentrations of GLP-1 and cholecystokinin, compared to placebo (whey protein 
isolate) (56). No statistically significant differences were observed when comparing 
the two different doses of fish protein (56). In contrast, a daily supplementation of 6 g 
cod protein (intact) for 8 weeks in overweight and obese individuals had no effect on 
GLP-1 levels (78). In line with these findings, no effect on GLP-1 or cholecystokinin, 
levels were reported after 2-week supplementation with 2 g of blue whiting 
hydrolysate in overweight subjects (57). The latter study did observe reduced sweet 
craving (self-reported sensation), with no effect on energy intake at an ad libitum 
lunch meal or subjective sensations of hunger (57). In an acute-effect study by our 
research group (152), a single weight-adjusted dose of fish protein hydrolysate made 
from cod had no effect on sensation related to feeling of hunger, serum fasting or 
postprandial levels of ghrelin in healthy subjects after a test meal (152). The last 
literature search for publications related to health effect of low doses of cod protein 
and fish protein hydrolysates in animal and human trials relevant for this thesis was 
done on December 28th, 2020.  
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1.2 FISH PROTEIN HYDROLYSATES 
1.2.1 The importance of marine harvest in nutrition and health  
The global population is estimated to increase from the current 7.7 billion to 9.7 
billion by 2050 (153), increasing the demand for food and pressure on already strained 
natural resources (154, 155). A major global challenge is to transform our global food 
system and ensure food security for the growing population, with a need for 
innovative, sustainable solutions and better utilization of already harvested resources 
(155). According to the United Nations, food security is achieved when “all people, at 
all times, have physical, social, and economic access to sufficient, safe, and nutritious 
food that meets their dietary needs and food preferences for an active and healthy life” 
(156).   
Fisheries and aquaculture plays an important part in global food security through 
providing nutrition and employment, and will be crucial for securing food for future 
generations (73). Almost 60 million people rely on fisheries and aquaculture for 
employment, and 17% of the global intake of animal protein came from fish in 2017 
(73). During the last 30 years the majority of growth within this sector has been from 
aquaculture, with 46% of the total global production of 179 million tonnes in 2018. 
Increased production within aquaculture is possible, and will be important for future 
global food security. To achieve this, a sustainable development is of great 
significance. It has been estimated that 35% of the global marine harvest is lost or 
wasted each year, including large amounts of valuable by-products being wasted (73). 
The sector have an important role towards the achievement of the SDGs by 2030, in 
particular SDG 14 “Conserve and sustainably use the oceans, seas and marine 
resources for sustainable development” and SDG 12 “Ensure sustainable consumption 
and production patterns” (7). 
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1.2.2 Dietary recommendations and nutrients in fish 
Fish is an important part of the Norwegian diet, and we have long traditions of eating 
fish (157) and are one of the countries in Europe with the highest consumption (158). 
The average consumption of fish and fish products were estimated to be 67 g per day 
among Norwegian adults in Norkost 3 (2010-2011) (159). Men consumed more fish 
than women, with a higher consumption with increasing age (159). Despite a high 
intake of fish in Norway compared to other European countries, the consumption of 
fish has decreased since 2015, and only 30% of Norwegian women and 40% of 
Norwegian men reach the recommended intake of fish (160).  
The dietary advice from the Norwegian Directorate of Health, recommending the 
general population to consume between 300-450 g of fish per week, is largely based 
on beneficial cardiovascular effects observed with an increased intake of the long-
chain n-3 PUFAs (161). Overall, the observed health benefits of fish have to a large 
extent been attributed to the content of these fatty acids (162). This interest originates 
from studies published in the 1970s, proposing that the low incidence of ischemic 
heart disease and diabetes observed in Greenlandic Inuits were linked to their lipid 
profile (163). The beneficial lipid profile was suggested to be due the Inuit’s lifestyle 
and a diet consisting of mainly fish and seal, with a high intake of the long-chain n-3 
PUFAs (163, 164). The favourable association between fish consumption and CVD 
have been confirmed in later studies (165-169), while the association between fish and 
T2DM is less consistent (170-177).  
The fatty and medium fatty fish species, such as Atlantic salmon, are considered the 
main sources of the long-chain n-3 PUFAs (161). When comparing different fish 
species, the fat content varies and fish can be classified as lean (<2% fat), medium 
fatty (2-5% fat) and fatty fish (>5% fat) (157). The lean fish species, such as Atlantic 
cod, contain less of the long-chain n-3 PUFAs, but are rich sources of iodine (161). 
Other important nutrients in fish are vitamin D and B12, selenium and protein of high-
quality (178). In the studies by Dyerberg and Bang, the Greenlandic Inuits had a 
higher protein intake compared to Danish controls (164), which might suggest that 
protein content of fish was of importance for the observed beneficial lipid profile. In 
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recent years, several studies have observed beneficial health effects of lean fish 
consumption and proposed that the protein content may contribute to the health 
benefits of eating fish (179). Compared to the fat content, the protein content is 
relatively similar when comparing different fish species, and a fish fillet contains 15-
20 g protein per 100 g fillet (wet weight basis) (178). 
Fish have a lower carbon footprint compared to meat, and according to the report by 
“Nasjonalt Råd for Ernæring”, reviewing the Norwegian dietary guidelines in a 
sustainability perspective, fish is sustainable to eat given that it comes from a 
sustainable fish stock or sustainable aquaculture industry (180). Despite fish 
considered being beneficial for health, it may also be a source of contaminants and 
undesired substances with potential hazard and negative effects, such as dioxins, 
dioxin-like polychlorinated biphenyls and mercury (178). The risk-benefit assessment 
conducted by the Norwegian Scientific Committee for Food and Environment in 2014, 
concludes that “the benefits clearly outweighs the negligible risk presented by current 
levels of contaminants and other known undesirable substance in fish” (178). An 
updated risk-benefit assessment is under preparation based on new available data, 
expected to be completed during the spring of 2021 (181).  
1.2.3 Residual raw material  
Large quantities of residual raw material remains when fish are gutted and further 
processed (182, 183), including heads, tongues, trimmings (cut offs), skin and bone, 
stomach and intestines (183). Residual raw material can be defined as “the parts that 
are not the primary product when using the raw material” (74). They can be classified 
in different groups based on origin and further processing, and if handled according to 
hygiene regulation they can be eaten or sold for animal-feed (183). Correct handling is 
critical for further processing, as fish is a perishable food item (73).  
These residual raw materials have traditionally been discarded, used as feed for 
livestock, aquaculture, pets or animals, or in silage and fertilizer, which are low-value 
products, resulting in low turnover for the fishing industry (73, 184). In 2019, 965 000 
tonnes of residual raw material occurred in Norwegian fisheries and aquaculture (74). 
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The utilization rate of these materials has continuously increased in the last couple of 
years, and the estimated utilization rate of 84% in 2019 is the highest reported (74). 
There is still large amounts of residual raw materials that are discarded every year, 
contributing to a significant loss of value of already harvested resources (74, 183). In 
Norway, it has been mainly residual raw materials from the white fish sector that have 
not been fully utilized, due to lack of space and technological solutions on the fishing 
fleets and economic incentives to bring the residual raw material to land (74). Of 
155 000 tonnes unutilized residual raw material in 2019, 70% was estimated to come 
from the whitefish sector (74). Despite a positive development within this sector, 
almost 40% of the residual material from white fish is still discarded each year (74, 
183).  
In the Norwegian fishing and aquaculture industry, the residual raw materials that are 
further utilized are processed into various products (74). The majority of the residual 
raw materials are processed to silage, ending up as fish and livestock feed, biogas and 
energy. It is estimated that around 70% of residual raw materials end up as various 
components in feed, with 10% processed to products for human consumption. Around 
3% is used indirectly for human consumption, through further processing to cod liver 
oil or protein extracts. In recent years, there has been a growing interest in the 
processing of residual raw material to fish protein concentrates and fish protein 
hydrolysates, with an overall increase of 21% from 2018 to 2019 (74). Increased 
utilization of the residual raw material will contribute to increased profits and reduced 
waste for the industry, contributing to more sustainable fisheries and aquaculture. This 
will also play an important part in the work towards achieving the SDGs within 2030, 
in particular SDGs 12 and 14, and if the residual raw materials can be used for 
improved health in humans, it will be of importance for SDG 3 “Ensure healthy lives 




1.2.4 Production of fish protein hydrolysates 
The residual raw materials from fish are increasingly recognised as a valuable source 
of nutrition that may be transformed into high-value products used for human 
consumption with potential beneficial health effects (73, 184, 185). The production of 
water-soluble fish protein hydrolysates is a promising approach to exploit these marine 
residual materials. A protein hydrolysate can be made by chemically or enzymatically 
degradation of protein to small chains of peptides of various size, by cleaving the 
bonds between amino acids (183). Chemical hydrolysis, including acid and alkaline 
hydrolysis, is an inexpensive and simple method (185). However, it is difficult to 
control the process with unspecific cleaving of peptide bonds, resulting in a 
heterogenous end product (185). 
Enzymatic hydrolysis, on the other hand, allows for a more controlled process, 
resulting in a high-value end product with good functional, biological and nutritional 
properties (185). The hydrolysate is made by adding commercially available enzymes, 
with predefined conditions of pH, temperature and time, to the residual raw material 
(182, 184, 185). Through the hydrolysis process the raw material is degraded, resulting 
in a lipid layer at the top, an aqueous phase in the middle and a mixture of solids and 
non-soluble proteins at the bottom (185). The peptide-containing soluble fraction can 
be collected by separating it from the lipid layer, followed by spray- or freeze-drying 
and storage until use (185). The end product will vary in terms of bioactivity, 
bitterness and taste, depending on the choice of enzyme, type of raw material used and 
hydrolysis condition (184). The protein hydrolysates usually contain between 2-20 
amino acids, and both the size and molecular weight of the peptides will affect the 
properties of the hydrolysate (185). 
1.2.5 Digestion and absorption of protein and protein hydrolysates 
Proteins are made up by long chains of amino acids connected by peptide bonds 
forming polypeptide chains, folded into three-dimensional structures (186). The 
structure and function of the protein is determined by the sequences of amino acids 
(186). Proteins have several important functions in the human body, being essential for 
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growth and maintenance of the human body, incorporated in several hormones and 
enzymes, precursors for neurotransmitters, and serving as a source of energy and 
amino acids (187). The amino acids can be classified as non-essential and essential, 
depending on the human body’s ability to synthesize these amino acids. Whereas the 
majority can be synthesized from other amino acids within the body (non-essential), 
the essential amino acids must be provided through the diet. The essential amino acids 
are isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, 
valine and histidine (187). The protein in fish is considered to be of high-quality, due 
to a balanced amino acid profile with a high content of essential amino acids (178). 
The low amount of connective tissue and a high bioavailability makes fish easily 
digested (178).  
The digestion of dietary protein begins in the stomach, by unfolding and cleaving of 
proteins into polypeptides by the enzyme pepsin (188). In the small intestine, proteases 
secreted from the pancreas and proteolytic peptides located on the brush border of the 
enterocytes, continue the digestion process through further hydrolysis of the proteins 
to di- and tripeptides and free amino acids (188). Free amino acids are absorbed 
through amino acid transporters, whereas the di- and tripeptides are absorbed through 
the peptide transporter, Peptide transporter 1 (PepT1), expressed in abundance in the 
small intestine (189). Some peptides (low-molecular) may also be transported by 
passive diffusion through water channels between the cells (190). A general overview 
of the digestion and absorption of proteins is shown in Figure 2.  
A protein hydrolysate has been shown to increase digestion and absorption, resulting 
in a higher availability in plasma, as compared to its intact protein (191). It may 
therefore by hypothesized that a protein hydrolysate may affect the secretion of GLP-
1, GIP and insulin, resulting in a more efficient uptake of glucose into the cells. 
However, the evidence is unclear, and most studies have investigated the effect on 





Figure 2. Digestion and absorption of proteins in humans. (1) Proteins are unfolded and 
cleaved into polypeptides in the stomach, followed by further digestion to short peptides and 
free amino acids in the small intestine. (2) Free amino acids are absorbed rapidly through 
amino acid transporters. (3) Di- and tripeptides are actively absorbed into the enterocyte 
through the peptide transporter PepT1, followed by (4) degradation to free amino acids and 
transfer to circulation. It is suggested that bioactive peptides is absorbed through the same 
routes as above, and released into circulation as intact di- and tripeptides. The medical 
images are taken from Smart Servier Medical Art. The figure is made in Adobe Illustrator by 
Jensen 2020. 
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1.2.6 Bioactive properties of fish protein hydrolysates 
A bioactive peptide can be defined as a “food derived peptide that in addition to their 
nutritional value exert a physiological effect in the body” (193). These bioactive 
peptides can enter the circulatory system and have a specific physiological effect in 
cells or organs, or a local effect in the GI tract (194). They must be released from their 
inactive state in the parent protein, through either hydrolysis by digestive enzymes, 
microbial fermentation or from enzymatic hydrolysis in food processing (194, 195). 
They usually contain between 2 to 20 amino acids, and the sequence of the amino 
acids is crucial for the specific activity of the peptide (194).   
There has been a growing interest in identifying bioactive peptides that may prevent or 
reduce the burden of chronic diseases, such as CVD and T2DM, with an increased 
interest in nutraceuticals and functional foods (195). Bioactive peptides originating 
from milk have been researched to a large extent, and there are available products on 
the commercial market today, e.g., with suggested antihypertensive effects (194). 
There is emerging evidence that proteins from fish contain bioactive peptides, being 
able to modulate physiological processes in the human body and contribute with a 
number of effects beyond their nutritional value as a source of energy and amino acids 
(196, 197). Bioactive peptides with inhibitory effects on ACE, a key enzyme involved 
in blood pressure regulation, was first reported in sardine meat and has later been 
identified in other fish species and fish protein hydrolysates made from residual raw 
materials (185, 194). Fish protein hydrolysates are also suggested to contain bioactive 
peptide sequences with antihypertensive, antioxidative and antimicrobial activity and 




1.3 RATIONALE  
Given the increasing rates of overweight and obesity, and the concomitant increase in 
lifestyle-related diseases, such as T2DM, CVD, there is a need for effective strategies 
for treatment and prevention. Animal and clinical intervention studies have indicated 
that the intake of cod fillet may have beneficial effects on metabolic health, such as 
glucose and lipid metabolism. Results reported from animal studies investigating the 
effect of fish protein hydrolysate on metabolic outcomes show promising results (48-
52). There are few studies in humans with discrepant findings (53-57), illustrating the 
need for more research, in particular if the potential beneficial effects observed in 
animal studies may be transferred to a human population. To our knowledge, no study 
has explored potential health effects of a low dose with a protein hydrolysate made 
from cod in a population with MetS.  
As Norway is one of the major fishing nations in the world (73), we have a great 
responsibility to utilize the marine resources in terms of sustainability, environmental 
footprint, and value creation. Large amounts of residual raw materials are generated 
within the fishing and aquaculture industry every year, with 320 000 tonnes occurred 
within the whitefish sector in Norway in 2018 (183). These marine residual raw 
materials are rich in proteins, lipids and other valuable components, such as potential 
bioactive peptides. Despite increased utilization of these residual raw materials, 
around 40% is still discarded within this sector every year (74, 183). It is of interest to 
explore if these already harvested marine resources converted to products for human 
consumption, have the potential to improve human health by affecting metabolic 
markers of glucose and lipid metabolism, thereby creating new market opportunities 
for the industry and contribute to more sustainable industry.   
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2. OBJECTIVES  
Main objective 
The overall objective of the PhD project was to investigate if supplementation with a 
protein hydrolysate made by hydrolysis of residual material from cod fillet production, 
would have beneficial effects on glucose metabolism in healthy adults and on 
components of the MetS in overweight and obese adults.   
The effect of supplementation with CPH was investigated in three clinical intervention 
studies. Two of the studies evaluated the effect of supplementation in healthy subjects, 
and the last study aimed to explore the effect in overweight and obese subjects with 
MetS. We hypothesized that dietary supplementation with CPH would beneficially 
affect glucose metabolism in the acute setting (Paper I), and that it was a dose-
response relationship of increasing doses, with a plateau effect observed when 
increasing the doses (Paper II). Lastly, we hypothesized that supplementation with 
CPH for 8 weeks would beneficially affect components of MetS (Paper III), including 
adipokines and inflammatory parameters related to the syndrome (Paper IV). 
Specific objectives:  
Study 1: The aim was to investigate the response of supplementation with a low dose 
of CPH on glucose metabolism in healthy adults aged 40-65 years (Paper I).  
Study 2: The aim was to investigate the response of supplementation with increasing 
doses of CPH on glucose metabolism in healthy adults aged 60-80 years, and to find a 
potential effective daily dose for further use (Paper II).  
Study 3: The aim was to investigate the response of 8 weeks supplementation with a 
low dose of CPH on fasting and postprandial glucose metabolism, lipid profile, body 
composition (Paper III), as well as fasting levels of adiponectin, leptin, ghrelin and 
inflammatory parameters (Paper IV) in subjects with MetS.   
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3. MATERIALS AND METHODS 
Papers I and II are based on Study 1 and 2, respectively, whereas Papers III and IV are 
based on Study 3. All three studies were conducted as multicentre trials at Haukeland 
University Hospital and Ålesund Hospital.  
3.1 STUDY POPULATION AND DESIGN  
3.1.1 Paper I    
The study was a double-blinded, crossover study investigating the effect of a single 
dose of CPH on glucose metabolism. The study included two study visits, with a 
washout period of 4 to 7 days between the two visits. Participants received a drink 
containing 20 mg/kg body weight of CPH or casein (control) in randomised order. The 
primary outcome was postprandial response in glucose metabolism, measured by 
serum glucose, insulin and GLP-1 (Paper I). An overview of the study design is given 
in Figure 3.  
 
Figure 3. Overview of study design of Study 1 (Paper I). CPH: Cod protein hydrolysate,  
d: days. 
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Participants were recruited between October 2017 and February 2018, through an 
online recruitment form on the internet and posters at the two participating hospitals. 
Inclusion criteria were BMI between 20-30 kg/m2, age between 40-65 years and 
signed informed consent. Exclusion criteria were allergy or intolerance to fish and 
shellfish, confirmed diagnosis of milk allergy, pharmacologically treated diabetes 
mellitus, low or fluctuating blood pressure, chronic diseases or therapies that could 
affect the evaluation of study end points, pregnant or lactating women, acute infections 
or unwillingness to comply with study requirements. Participants were not allowed to 
take any supplements containing long-chain n-3 PUFAs for one week prior to the first 
study day, and throughout the study. No change in eating habits or level of physical 
activity were allowed.  
Participants indicating interest, were prescreened for general eligibility and 
compliance with inclusion and exclusion criteria by telephone. Eligible participants 
were invited for a further screening visit, including review of medical history and 
clinical examination by a physician, anthropometric measurements (height and body 
weight), measure of vital sign (BP, heart rate (HR)) and blood sampling. Included 
participants came to the research facilities on two identical study visits. The 
participants were given a standardised evening meal (rice, oatmeal or barley porridge), 
with instruction to eat this before 08:30 p.m. on the preceding day before each study 
visit, followed by fasting until the next morning. On the morning of the study visit, the 
participants came to their designated research unit in a fasting state between 08:00 and 
09:00 a.m. A fasting blood sample were taken, followed by a drink containing CPH or 
control. Both drinks were a lemon-flavoured powder to be mixed with water and was 
served in neutral bottles. A standardised breakfast meal (test meal) was served 
immediately after the participants had finished the drink, with instructions to consume 
the meal within 15 minutes. Blood was collected in the fasting state, at 0 minutes (i.e., 
immediately after the test meal was finished), and thereafter at 20, 40, 60, 80, 100, 120 
and 180 minutes. Blood pressure was monitored during the study visit (fasting state, 
40, 80 and 180 minutes).  
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The standardised breakfast meal consisted of two slices of semi-coarse bread (50% 
whole wheat, 80 g weight), 10 g margarine, 20 g strawberry jam and 20 g white 
cheese. The drink contained 145 kcal and 35.9 g of carbohydrate. The meal provided a 
total of 500 kcal and 77 g carbohydrate.  
3.1.2 Paper II  
The study was a double-blinded, crossover study investigating the effect of increasing 
doses of CPH on postprandial glucose metabolism. The study consisted of four 
different intervention cycles, where the participants received a daily dose of CPH for 
one week, with one week washout period (7 days) between each dose interval. An 
overview of the study design is given in Figure 4. The dose intervals were 10, 20, 30 
or 40 mg/kg body weight and assigned to the participants in a random order. The 
primary outcome was postprandial response in glucose metabolism, measured by 
venous samples of serum glucose and insulin. Secondary outcome was postprandial 
response in plasma GLP-1 (Paper II).  
Participants were recruited between March and July 2018, and the study was 
completed between April and November 2018. An online recruitment questionnaire 
and advertisements on notice boards at the participating hospitals and external 
websites were used to recruit participants. Criteria for inclusion were age between 60-
80 years, BMI between 20-30 kg/m2 and signed informed consent. Exclusion criteria 
were the same as in Study 1, with the exception of milk allergy, and we excluded 
participants with excessive alcohol or drug consumption (assessed by a physician). We 
instructed participants to stop taking any supplements containing long-chain n-3 
PUFAs for two weeks prior to the first study day, and throughout the study. No change 
in eating habits or level of physical activity were allowed.  
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Figure 4. Overview of the study design of Study 2 (Paper II). Each dose period lasted for one 
week, and the participants came to the research facility on the last day in each dose period 
for a study visit. The total study period was 7 weeks. d: day. 
Included participants came to the research facilities on six different occasions: one 
screening visit and five study visits. The screening visit included clinical examination 
and review of medical history by a physician, vital signs (BP, HR), anthropometric 
measurements (body weight and height) and blood sampling. At the first study visit 
(baseline study visit), the participants had not received any doses of CPH. This was 
included to assess baseline postprandial measurements before study commencement. 
Due to a methodological error, the results from this visit is not included in the 
manuscript of Paper II. Further description is given in subchapter 5.1.2.   
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The study consisted of four intervention cycles. The participants received six bottles 
containing powder with CPH, labelled 1 to 6, with written instruction to mix with 
water and consume before breakfast each morning in the intervention cycle. On the 
last day (day 7) of each intervention cycle, the participants came to the research 
facilities between 08:00 and 09:00 a.m. They came in a fasted state and had been 
instructed to not eat or drink anything (except water), and refrain from substances with 
nicotine from 09:00 p.m. the night before. At the study visit, a fasting blood sample 
was drawn from an antecubital vein. The participants were given the last dose of CPH 
in the current intervention cycle, followed by a standardised breakfast meal (test meal) 
10 minutes after the drink. The first postprandial blood sample was taken 25 minutes 
after the drink was served and 15 minutes after the test meal (0-minute sample), 
followed by blood sampling every 20 minutes for 120 minutes (Figure 5).  
 
Figure 5. Timeline of the study visits in Study 2. All study visits were identical. Blood 
samples were taken every 20 minutes for 120 minutes. The first postprandial blood sample 
was taken 25 minutes after the drink was served and 15 minutes after the test meal.  
BS; blood sample. 
At the end of the study visit, six bottles for the next intervention cycle were handed out 
with instructions for when to start the new intervention cycles. A washout period of 
seven days was inserted between each intervention cycle. As a reminder, the 
participants received a text message before starting on the intervention cycle and 
before each study visit. The baseline visit was identical to the other study visit, but the 
participants were given a glass of orange juice instead of a CPH-containing drink.   
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The standardised breakfast meal was the same as used in the previous study, but the 
drink contained 22.5 g carbohydrate and 100 kcal. Overall, the test meal provided a 
total of 455 kcal and 63.5 g carbohydrate.  
3.1.3 Papers III and IV  
The study was a double-blinded, randomised intervention with a parallel-group design. 
Participants with MetS received a daily supplement of 4 g of CPH or placebo for 8 
weeks. The primary outcomes were fasting and postprandial glucose levels (Paper III). 
Secondary outcomes were other metabolic and clinical parameters of MetS (WC, 
fasting TAG and HDL-C), fasting and postprandial levels of insulin, GLP-1 (Paper III) 
and acylated ghrelin, fasting levels of adiponectin, leptin and inflammatory markers 
(Paper IV).  
Recruitment took place between March and September 2019, and the study was 
completed during three intervention periods: April-June 2019, August-October 2019 
and October-December 2019. Participants were recruited through an online 
recruitment questionnaire, with advertisements on social media, notice boards at the 
participating hospitals and at general practitioners in Bergen and the surrounding area. 
Inclusion criteria were age between 40-70 years, BMI between 27-35 kg/m2 and the 
presences of MetS. MetS was defined according to the JIS definition, where the 
presences of any three of five given risk factors qualifies for a diagnosis of MetS: 
elevated fasting serum glucose or serum TAG, reduced HDL-C, increased WC or 
elevated BP. Please see subchapter 1.1.1 and Table 1 for the specific cut-off points 
used. For WC, we used the IDF cut-off points (WC:≥80 cm in women; ≥94 cm in 
men) (19). Exclusion criteria were the same as in Study 2. Since BP was not an 
outcome measure, we allowed participants using certain types of blood pressure 
medications, not known to clinically affect glucose metabolism, to be included. This 
included agents acting on the renin-angiotensin system, calcium channel blockers and 
diuretics, whereas participants using peripheral vasodilators or beta-blocking agents 
were excluded. The participants had to stop the use of nutritional supplements 
containing long-chain n-3 PUFAs for a minimum of four weeks prior to the study and 
during the intervention period. The participants could not be involved in any weight-
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loss program and been weight-stable for 3 months prior to the intervention. No 
changes in physical activity level or food consumption were allowed. An overview of 
the study design is shown in Figure 6.  
 
Figure 6. Overview of the study design of Study 3 (Papers III and IV). MetS: Metabolic 
syndrome CPH; cod protein hydrolysate.  
We prescreened all possible participants that had responded through the online 
recruitment questionnaire by telephone. Potential participants were invited to a 
screening visit to evaluate the presence of MetS and eligibility to inclusion and 
exclusion criteria. The screening visit included a review of medical history and a 
clinical examination by a physician, measure of vital signs (BP, HR) and 
anthropometry (height, body weight, WC), and blood sampling. Included participants 
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met on two identical study visits: a baseline visit (prior to study commencement) and 
end of study visit (after 8 weeks of intervention). The participants came to the study 
centre in the morning, after an overnight fast (after 9:00 p.m. the previous day, the 
participants could not eat, drink or use nicotine). When they arrived, fasting blood 
samples were taken, followed by anthropometric measurements. Body composition 
was measured by a bioelectrical impedance analysis device at baseline and end of 
study visit. The subjects then consumed a standardised breakfast meal (test meal), 
providing a total of 440 kcal and 69 g carbohydrates. The meal had to be consumed 
within 15 minutes and was followed by blood sampling at 0 minutes (i.e., immediately 
after the meal was finished), and thereafter every 20 minutes until 120 minutes. Eight 
weeks supply (56 doses) of the prepacked test material (active or placebo) was handed 
out to the participants at end of the baseline visit. They started the intervention on the 
following day and were instructed to open the sealed bag with powder, mix well with 











3.2 PRODUCTION OF TEST MATERIAL 
The test materials used in this PhD project was produced by Firmenich Bjørge 
Biomarin AS (Ellingsøy, Ålesund, Norway).  
The fish protein hydrolysate was made by enzymatic hydrolysis of fresh frozen meat 
(cutting and trimmings) from Atlantic cod (Gadus morhua) obtained from the filleting 
industry. A batch of 500 kg frozen (-10°C) raw material was grounded, transferred to 
an incubator and mixed with sweet water at a ratio of 1:1. The mixture was stirred at 
80 rpm and heated to 55°C, before adding the enzyme preparation Protamex® 
(Novozymes AS, Copenhagen, Denmark), followed by incubation for 45 minutes, at 
55°C, 80 rpm and pH 7.0. The enzyme was added according to guidelines from the 
producer. To inactivate the enzyme, the preparation (incubate) was heated to 90°C for 
15 minutes. The preparation was then passed through a rotating sieve (Swenco, 
Sweden) to remove any bone fragments. A two-phase centrifugation (Alfa Laval AS, 
Denmark) was used to separate the peptide-containing water-soluble fraction (the 
hydrolysate) from the indigested residue. This was followed by ultrafiltration and 
dehydration of the soluble phase to a 50% dry matter concentrate, which was spray-
dried to a powder. The spray dried CPH powder contained 89% crude protein and 
<0.2% fat, 0% carbohydrate, <3.0% water, 10% ash, 0.1% NaCl, 1.7% sodium and 
0.0% chloride, by weight. It was stored at 12°C in 10-kg diffusion tight packaging 
until used.  
Table 3. The molecular weight profile of the cod protein hydrolysate used in the clinical trials 
included in the PhD project.  
Molecular weight (Da) Amino acid moieties  Percentage (%)   
< 2000 < 18 or less   90 % 
< 1000 < 10 or less  75 %  
< 500  < 5 or less  55 %  
< 200  ≤ 2*  25-30 % 
*Dipeptides and free amino acids. Da: Daltons  
The molecular weight (MW) profile of the CPH was analysed by MW exclusion 
chromatography, with results showed in Table 3. Free amino acids accounted for 
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4.77% of the hydrolysate. The ratio between essential amino acids and non-essential 
amino acids was 0.70. The composition of amino acids and taurine of the CPH is given 
in Table 4. In Papers I and II, lysine has been highlighted as a branched chain amino 
acid (BCAA) in the tables (please see Table 2 in Paper I and Table 1 in Paper II). This 
is not correct, and valine should be highlighted as a BCAA.  
In all three clinical trials, the CPH was provided to the participants in sealed packages 
containing a powder to be mixed with water. Further description of the different 
control or placebo materials used in the individual studies, are given in detail in each 
individual paper.  
Table 4. Composition of amino acids and taurine of the cod protein hydrolysate used in the 
clinical trials included in this PhD project.  
Amino acid Total amino acid (mg/g) 
Alanine 47.8 
Arginine 51.1 
Aspartic acid 73.3 
Asparagine 0.38 

















*Branched-chain amino acids (BCAAs) 
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3.3 BIOCHEMICAL ANALYSES 
In all three studies, baseline biochemistry for safety purposes, serum glucose and 
insulin and plasma GLP-1 were handled the same way.  
We collected samples for safety purposes (albumin, prealbumin, glycated haemoglobin 
(HbA1c), leucocytes, thrombocytes, haemoglobin, sodium, potassium, alanine 
aminotransferase, alkaline phosphatase, creatinine and aspartate aminotransferase) at 
the screening visits and end of study visits. In Study 2 (Paper II), samples for 
determination of vitamin B12 and D were also taken to assess nutritional status. All 
tests were analysed according to standard accredited methods at Department of 
Medical Biochemistry and Pharmacology, Haukeland University Hospital (Bergen, 
Norway), and the Department of Medical Biochemistry, Ålesund Hospital (Ålesund, 
Norway). 
Samples for determination of serum insulin and glucose were collected in serum 
separator cloth activator tubes. Serum was obtained by centrifugation of full blood at 
2000 g x at 20°C for 10 minutes, after 30-60 minutes of coagulation. Concentration of 
serum insulin and glucose were analysed according to standard accredited methods at 
Department of Medical Biochemistry and Pharmacology, Haukeland University 
Hospital.   
Samples for determination of GLP-1 were collected in Vacutte® EDTA-K2 tubes, 
with 20 μl DPP-4 added prior to sampling. Plasma was obtained by centrifugation of 
EDTA blood at 1800 x g at -4°C for 10 minutes, within 20 minutes of blood sampling. 
Plasma GLP-1 was analysed by the ELISA method, the specific details about the kit 
are given in the respective papers.  
In Study 3 (Papers III and IV), samples of Hba1c, high-sensitive CRP (hs-CRP), total 
C, HDL-C, LDL-C and ratio of total C: HDL-C were analysed before intervention and 
at end of study. All these tests were analysed according to standard accredited methods 
at the same routine hospital laboratories as mentioned above. We also measured 
adiponectin, leptin, acylated ghrelin and inflammatory markers. Serum for analyses of 
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hs-CRP, other inflammatory markers, adiponectin and leptin were obtained by the 
same method as previously described for serum insulin and glucose. Serum 
adiponectin, leptin and ghrelin were analysed using ELISA kits, whereas the 
inflammatory cytokines were analysed by the Cytokine human ultrasensitive magnetic 
10-plex panel. More details about the specific kits can be found in Paper IV. Samples 
for ghrelin determination were collected in Vacuette® EDTA Aprotinin tubes, added 
34 µl 4-(2-aminoethyl) benzensulfonyl fluoride hydrochloride Ready-made solution to 
the tubes right after blood sampling. Plasma was obtained by the method as described 
for GLP-1 previously.  
3.4 ESTIMATION OF DIETARY INTAKE  
Participants in all three studies recorded their dietary intake using dietary records. 
Based on the reported intake from the participants, energy and macronutrient intake 
were estimated using “Kostholdsplanleggeren” (Norwegian Food Safety Authority and 
the Norwegian Directorate of Health, Oslo, Norway) (198). In Study 1 (Paper I), the 
participants filled out a 3-day dietary record prior to the first study visit, and a 1-day 
record prior to the last study visit. In Study 2 (Paper II) and 3 (Papers III and IV), the 
participants filled out a 3-day dietary record before study commencement and at end of 
study. In Study 2, the first seven participants also filled out a 1-day dietary record 
before each study visit, but this was omitted for the remaining participants due to the 
high burden on the participants.  
The dietary records were used to evaluate the composition of the diet prior to 
intervention and assess whether any changes were made in the diet during the 
intervention period. In Study 1, we used the 1-day dietary record to compare estimated 
energy and macronutrient intake before each study visit. In Study 3 (Paper III), the 
caloric and protein content of the test material were added to the dietary records at end 




3.5 STATISTICAL ANALYSES  
Statistical analyses were performed using SPSS Statistics version 24.0 (Papers I and 
II) and 26.0 (Papers III and IV) (IBM Corp., Armonk, NY, USA). In Paper II, Stata 
v15.1 (StataCorp LLC, Texas, USA) was used to estimate the effect of dose using a 
mixed effects model. All graphical work was conducted in GraphPad Prism version 
7.0 (Papers I and II) and 8.4.1 (Papers III and IV) (GraphPad Sotfware, Inc., San 
Diego, CA, USA). Data was evaluated for normality using the Shapiro-Wilk test and 
histograms, and non-normally distributed data was log-transformed before using 
parametric tests. Level of significance was set to p <0.05.  
3.5.1 Paper I 
A linear mixed-effects model with repeated measures was conducted to evaluate the 
difference between CPH and control, the model was adjusted for gender. Insulin and 
GLP-1 were log-transformed before statistical testing. An independent samples t-test 
was used to compare total area under the curve (AUC) for postprandial glucose. A 
paired samples t-test was used to assess the difference between energy and 
macronutrient intake between the two different study days. It is stated in Paper I that a 
two-way analysis of variance with repeated measures was used to evaluate differences 
between each time point, this is an error in the publication and was not done.  
3.5.2 Paper II 
A paired samples t-test was used to detect changes in nutrient intake from baseline to 
end of study. To estimate the effect of dose, the maximum observed value and the 
AUC for the time course of each outcome variable were calculated for each 
combination of person and dose. We then fitted mixed models with the outcome 
measures (maximum value or AUC) as the dependent variable, fixed effects of dose 
and random intercepts across person. Carry-over effects were assessed using a 
standard likelihood-ratio test, to test for interaction between dose and ordering.  
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3.5.3 Papers III and IV 
Paper III  
The paired samples t-test was used to assess change from baseline to end of study 
within groups. An independent samples t-test was used to compare changes from 
baseline to end of study between the two groups, and compare AUC between groups 
for postprandial glucose, insulin and GLP-1. A linear mixed-effects model with 
repeated measures was used to examine group differences over time for the 
postprandial measurement of insulin, glucose and GLP-1. The GLP-1 data was log-
transformed before performing the analysis.  
Paper IV 
A linear mixed-effects model with repeated measures was used to examine group 
differences over time for the postprandial measurements of ghrelin. For data not 
improved by log-transformation, non-parametric tests were used. The Wilcoxon’s 
Signed Rank test was used to evaluate changes within groups, and the Independent 
Samples Mann Whitney U test was used to compare changes from baseline to end of 
study between CPH and placebo. A Pearson’s correlation coefficient analysis was used 










3.6 ETHICS  
All three studies were conducted according to the guidelines laid down in the 
Declaration of Helsinki. Written informed consent was obtained from all participants in 
all studies prior to study commencement.  
Study 1 (Paper 1): The study was approved by the Regional Committee for Medical 
and Health Research Ethics of Central Norway (2017/1794). The trial was registered at 
www.clinicaltrials.gov as NCT03669796 
Study 2 (Paper II): The study was approved by the Regional Committee for Medical 
and Health Research Ethics of Central Norway (2017/1795). The trial was registered at 
www.clinicaltrials.gov as NCT03526744 
Study 3 (Papers III and IV): The study was approved by the Regional Committee for 
Medical and Health Research Ethics of Central Norway (2018/2163). The trial was 
registered at www.clinicaltrials.gov as NCT03807752 
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4.  RESULTS 
4.1 PAPER I 
Forty-one participants (26 women, 15 men) were randomized and completed the study. 
Eighteen participants were allocated to receive CPH drink and 23 were allocated to 
receive control drink at the first study visit. The participants received the opposite 
drink at the second study visit. The included participants had a mean age of 51±6 years 
with mean BMI 25.2±3 kg/m2. 
 
No statistically significant difference was observed in the estimated mean energy 
intake before each study visit. Mean fasting glucose and GLP-1 levels were numerical 
equal at both study visits, whereas the insulin levels were numerically higher before 
the CPH drink than control drink. The serum glucose concentration peaked 20 minutes 
after the first postprandial blood samples after both drinks, whereas serum insulin 
concentration peaked at 20 minutes after the CPH drink and 40 minutes after the 
control drink. The concentration of plasma GLP-1 peaked at the first postprandial 
blood samples (0 minutes) after both drinks.  
The AUC calculated from the fasting through the postprandial test point did not reveal 
any significant differences in glucose when comparing CPH and control. A linear 
mixed-effects model with repeated measures did not reveal any differences between 
CPH and control in concentrations of glucose or GLP-1, but the insulin concentration 







4.2 PAPER II 
Thirty-three participants were enrolled in the study, and thirty-one (18 women, 13 
men) completed the study. The participants were randomised to which order they 
would receive the different dose levels (10, 20, 30 and 40 mg/kg BW). Mean age was 
67.8±4.9 and mean BMI was 26.0±2.6 kg/m2.  
No statistically significant difference was observed in estimated energy or 
macronutrient intake over the course of the study. When comparing the lowest dose of 
10 mg/kg BW of CPH (reference category) with the higher doses (20, 30 and 40 
mg/kg BW), no statistically significant differences in estimated maximum value of 
glucose, insulin or GLP-1 were observed. When the participants were given the 
highest dose compared to the lowest dose, the estimated maximum value of glucose, 
insulin and GLP-1 was 0.28 mmol/L, 5.14 mIU/L and 0.34 pmol/L lower, 
respectively. No statistically significant differences in AUC were observed for any of 
the outcome measures, when comparing the lowest dose with the higher doses (20, 30, 
40 mg/kg BW). For glucose, AUC was calculated from t=baseline until t=80, 
excluding t=100 and t=120 minutes, based on the assumption that the glucose levels 
for the majority of individuals had returned to their baseline levels within 80 minutes. 








4.3  PAPERS III and IV 
Thirty-one participants were randomised to receive CPH or placebo for 8 weeks. 
Fifteen participants were allocated to the CPH group and 16 allocated to the placebo 
group. Thirty participants completed the study and was included in the statistical 
analysis, with fifteen in each group. In the CPH group, mean age was 52.8±6.3 years 
and mean BMI 32.7±2.2 kg/m2, with mean age of 53.4±6.8 years and mean BMI 
32.4±3.3 kg/m2 in the placebo group.  
The estimated energy and macronutrient intake were similar between the groups at 
baseline, with no statistically significant changes observed during the study. We did 
not observe statistically significant changes in any of the anthropometric 
measurements during the study. Eight weeks supplementation with CPH did not affect 
fasting or postprandial serum concentrations of glucose, insulin, GLP1 or ghrelin, 
when compared to placebo. HbA1c did not change within the groups during the study, 
and there was no statistically significant difference between the groups after 8 weeks.  
Fasting serum TAG concentration was significantly decreased within the CPH group 
after 8 weeks. When comparing the change in TAG levels from baseline to end of 
study in the CPH group to the placebo group, no statistically significant difference was 
observed. Fasting total C and LDL-C were statistically significantly decreased within 
both groups at end of study, with no differences between the groups. No statistically 
significant changes within or between groups were observed for serum concentration 
of HDL-C or in the ratio of total-C: HDL-C during the study.  
Supplementation with CPH increased fasting serum concentration of adiponectin after 
8 weeks. When comparing the change in fasting levels of adiponectin, no statistically 
significant difference between groups was observed. After 8 weeks, the median change 
in hs-CRP levels from baseline to end of study in CPH group was significantly 
different, compared to the placebo group. The concentrations of the other 
inflammatory parameters or fasting serum levels of leptin were not significantly 
affected by CPH supplementation.  
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5. DISCUSSION  
5.1 DISCUSSION OF METHODS  
5.1.1 Study populations 
The protein hydrolysate used in the three studies summarised in this thesis, had not 
formally been investigated in an intervention study in humans previously. We 
therefore wanted to explore a potential effect of supplementation in healthy adults, 
with a presumed normal glucose regulation. Based on this, we included healthy 
normal- to overweight adults, with a BMI between 20-30 kg/m2 in the first two studies 
(Study 1 and 2). In Study 1 (Paper I), we included participants between the age of 40 
and 65 years, based on the assumption that many adults within this age group develop 
overweight and obesity, including metabolic disturbances (199). Favourable changes 
in glucose metabolism and other potential findings after the intake of a dietary 
supplement with CPH, are of relevance as it might affect development of metabolic 
disturbances such as hyperglycaemia and hyperlipidaemia. In the major perspectives, 
this may prevent or attenuate development of NCDs, such as CVD and T2DM.  
The target group of Study 2 (Paper II) was healthy adults between the age of 60 and 80 
years. The study was designed to establish an optimal dose level for use in further 
studies and future study protocols. We were also interested to investigate the effects of 
a dietary supplement with CPH on glucose metabolism in this age group, as previous 
studies have suggested impairments in glucose metabolism among older adults (200). 
A reduced capacity for glucose disposal is suggested to results from a reduced skeletal 
muscle mass observed in older adults (201). It was initially planned to further conduct 
a study with CPH-supplementation in older adults with loss of muscle mass and 
function, using the current study (Study 2) to determine the appropriate dose level. 
In Study 3 (Papers III and IV), we investigated the effect of supplementation with 
CPH on components of MetS. We included overweight and obese adults with MetS, 
aged 40-65 years, with a BMI between 27 and 35 kg/m2. The lower limit was set 
because we wanted to exclude potential participants that had a high BMI due to 
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increased muscle mass, and not due to increased fat mass. The upper BMI limit was 
set to exclude potential participants with an obesity grade II and above (≥ 35 kg/m2), 
based on the assumption that these individuals were more likely to have comorbidities 
related to their obesity and use medications. It is possible that we lost potential 
participants with MetS due to this upper BMI limit. 
5.1.2 Intervention and control materials  
The cod protein hydrolysate  
The CPH supplement used in the current project contained a large proportion of di- 
and tripeptides, hypothesized to be effective due to the presence of rapidly absorbable 
bioactive peptides. We hypothesized that these peptides affected glucose and lipid 
metabolism in a favourable way, through signaling pathways such as PI3K/Akt and 
mammalian target of rapamycin. The effect of CPH was explored using 
supplementation with low doses in all three studies. The scientific rationale for the use 
of these low doses are limited, and mainly based on unpublished and explorative data 
in animal and humans. An acute-effect study found improvements in postprandial 
insulin and glucose concentrations after supplementation with 20 mg/kg BW of CPH 
before a meal in 12 healthy male individuals, compared to whey and casein protein. 
Supplementation of CPH with the same dose level in nine healthy subjects, had 
beneficial effect on self-reported appetite and appetite hormones, with increased 
secretion of GLP-1 and peptide-tyrosine-tyrosine, and reduced levels of ghrelin 
(unpublished data from studies conducted at Clinical Trial Consultants AB, University 
Hospital, Uppsala University, Sweden provided by Einar Lied, former scientific 
advisor for Firmenich Bjørge Biomarin AS). It was of interest to explore these 
indications of possible beneficial metabolic effects on glucose metabolism. There is 
also some previously published studies reporting favourable metabolic effects after 
supplementation with low doses of fish protein hydrolysates in humans (56, 57), and a 
previous study in overweight and obese adults reported beneficial effects after 
supplementation with 3-6 g/day of unhydrolysed cod protein for 8 weeks (76). Based 
on this background, we chose to use a weight-adjusted low dose of 20 mg/kg BW as 
the starting dose in Study 1 (Paper I). 
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In Study 2 (Paper II), we investigated the effect of different dose levels on glucose 
metabolism. We chose the lowest dose of 10 mg/kg BW, to explore if it was possible 
to observe any effect on glucose metabolism at a lower dose level compared to the 
dose used in Study 1 (20 mg/kg BW). We were also interested in investigating if a 
more pronounced metabolic effect could be observed by increasing the doses, and if 
we eventually reached a plateau effect at the highest dose of 40 mg/kg BW. Based on 
the results from Study 2 (Paper II) and previously reported studies using low doses of 
cod protein (76, 78), we chose to use the highest dose of 40 mg/kg BW as a starting 
point in Study 3 (Papers III and I). As these participants received daily doses for 8 
weeks and we intended to include 60 participants, it was considered too demanding 
logistically to weight-adjust the doses to the individual participant. We therefore used 
a fixed dose of 4 g (corresponding to 40 mg/kg BW in an individual weighing 100 kg). 
Overall, the dose levels of CPH investigated in the current PhD project might have 
been too low to be able to observe any significant metabolic effects, which may in part 
explain the lack of findings.   
In all three studies, the CPH supplement was provided to the participants as a powder 
to be mixed with water. A potential challenge with a hydrolysate made from cod is the 
potential taste and smell of fish, and bitter taste originating from the hydrolysate, 
making it challenging to achieve double blinding. The taste and smell were masked by 
adding lemon flavour, by Firmenich Bjørge Biomarin AS, a company partly 
specialized within artificial fragrance and flavour. We could have provided the 
intervention material to the participants as tablets or capsules. This had been tried by 
Firmenich Bjørge Biomarin AS previously, resulting in a very distinct fish odour. 
Considering that this would make it difficult to achieve blinding, we chose to use a 




Control (placebo) materials  
Casein was chosen as control material in Study 1 (Paper I). The control material was 
provided to the study participants as a powder to be mixed with water, in the same 
dosage as the CPH supplement (20 mg/kg BW). We wanted an isonitrogenic and 
isocaloric control material. The protein content of the control material was in form of 
an intact protein (not hydrolysed protein), which is the main difference between the 
active material (CPH) and the control material. The use of casein as control material 
may be considered a limitation to the study design, as studies have reported beneficial 
effects on glucose and insulin response when high doses of casein have been added to 
a carbohydrate load (202). However, low doses of hydrolysed casein (<6 g added to a 
carbohydrate load of 50 g) do not seem to affect glucose metabolism (203). 
Considering that casein was provided in very low doses, on average 1.5 g in the study 
group, and as an intact protein, we assume that casein did not affect the results in 
Study 1. However, we cannot rule out the possibility that the proteins present in the 
control material have influenced the glucose metabolism and possibly masked an 
effect of CPH. A control material only containing glucose, with no protein, could have 
been a better choice. A limitation with this approach is that it would have been 
difficult to know if a potential effect was observed due to differences in nitrogen and 
energy content, or a “real” difference due to the protein hydrolysate. It might have 
been more appropriate to describe casein as a “positive control”, and the study would 
have been strengthened by adding a control group that received no protein.  
In Study 2 (Paper II) the participants received a glass of orange juice (2 dl) as a control 
drink. This was chosen for two reasons: 1) we wanted to compare the effect of the 
different doses against the effect of no protein, 2) facilitate an iso-caloric breakfast 
meal. A better choice might have been a control material consisting of a powder 
identical to the doses with CPH, but with no protein. The lack of protein would be the 
only difference to the active test material (CPH), making it more comparable to the 
other dose levels. This should be considered in future studies. The participants 
received the control drink at the baseline study visit, intended to be used as a control 
visit, with baseline postprandial measurement of insulin, glucose and GLP-1. At this 
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study visit, the participants were served the control drink with the breakfast meal at the 
baseline visit, while the drinks with test materials were served 10 minutes before the 
breakfast meal at the four study visits. When comparing the postprandial curves for 
glucose, insulin and GLP-1, the curve for the control visit is shifted to the right, with a 
delayed peak, compared to the four study visits during the intervention period. This is 
illustrated in Figure 7. We believe the shift is simply due to the fact that the drink at 
the control visit was given at a later time point compared to the test drinks at the four 
study visits, resulting in a delayed postprandial response at the control visit. This 
mistake was discovered after the study was completed, and we could not use the 
results from the baseline visit as a “control” for the other visits. This “control visit” is 
therefore not reported in Paper II, and the lowest dose level was chosen as a reference 
category. It was discussed to include a control day the first day of each intervention 
cycle, which would have strengthened the design, but it was considered too time 
consuming for potential participants. 
 
Figure 7. Postprandial curves for glucose concentrations after control visit (baseline visit) 
and four intervention cycles. At the control visit the participants received a glass of orange 
juice (control) together with the standardised breakfast meal, while at study visits they 
received the test drink 10 minutes before the standardised breakfast meal at study visits 
during the intervention (n=31). Bw; body weight.  
 
























Test drink, -25 min   
Test meal, -15 min
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In Study 3 (Papers III and IV), maltodextrin, an easily digestible polysaccharide 
extracted from corn starch, was used as placebo material. This was chosen because we 
wanted to evaluate the effect of CPH against the effect of no protein-supplementation. 
The placebo material contained 6.5 g maltodextrin, 5 g glucose hydrate and 
flavourings, whereas the intervention material contained 4 g CPH, 2 g maltodextrin 
and 5 g glucose hydrate, in addition to flavouring. The amount and name of the 
various flavourings used in the intervention and placebo material are given in detail in 
Papers III and IV. The active material (CPH) had a lower content of maltodextrin to 
achieve an iso-caloric supplement to placebo, as the protein content of the active 
material added some calories to the supplement. Overall, the placebo material 
contained 46.5 kcal, with 43.9 kcal in the active material. This small difference in 
caloric content is negligible and is not expected to have caused any impact on the 












5.1.3 Test meals  
In all three studies, the participants consumed a standardised breakfast meal (described 
in subchapter 3.1.1-3) followed by blood sampling, to evaluate changes in postprandial 
glucose response. This breakfast meal, or test meal, resembled a typical Norwegian 
breakfast meal, containing a mix of carbohydrates, proteins and fats. Similar test meals 
have been used in other studies evaluating the effect of fish intake on glucose and lipid 
metabolism (71, 72, 78).  
A mixed meal was chosen to evaluate the effect of CPH supplementation on 
postprandial glucose regulation after the consumption of a meal similar to a regular 
meal. This test meal was used as an alternative to the oral glucose tolerance test 
(OGTT). An OGTT is used to evaluate the glucose and insulin response after the 
intake of a standard amount of glucose (75 g) dissolved in water (204). The test is easy 
to reproduce and requires fewer resources (204). Compared to the OGTT that provides 
one nutrient, the test meal given to our participants might be more physiologically 
relevant as it resembles a normal meal and consists of a mixture of macronutrients, 
including proteins and fats, known to also affect glucose regulation (205). Since there 
is no general standard on how to compose such a mixed test meal, the energy content 
and composition of macronutrients will depend on the choice of food items included. 
This makes the comparison to other studies and physiological settings more difficult, 
which is a disadvantage of the test meals used in our studies. Another limitation is that 
the carbohydrate content of the test meals were different in the three studies, 
containing 77 g carbohydrates in Study 1, 63.5 g in Study 2 and 69 g in Study 3, 
making it difficult to compare the studies. The difference in carbohydrate content was 
due to different composition of the active (CPH) and control materials used in the 
three studies.  
Weight-adjusting the test meal to each individual participant would have strengthened 
the study design, in line with the weight adjustment of intervention doses. This may be 
especially relevant in Study 3, where overweight and obese subjects were included, 
with a mean body weight at inclusion of 94.5 kg, but ranging from 74 kg to 133 kg. It 
is plausible that a participant with a body weight of 75 kg has a different glucose 
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response after a test meal, compared to a participant with a body weight of 130 kg. 
Weight-adjusting the test meals was discussed when planning the different studies. It 
was chosen not to be implemented in the study protocol, as it would have made the 
preparation of the test meal and implementation of study visit very time- and resources 
consuming.  
We cannot rule out that proteins present in the test meal were competing with peptides 
present in the hydrolysate for uptake. This is particular an important point in Study 1 
(Paper I), where the participants only received one single dose of CPH, but also 
relevant in Study 2 (Paper II). The test drink was given to the study participants 10 
minutes before the test meal in Study 2, to avoid potential competition for uptake 
between the peptides present in the drink and proteins in the meal. This would have 
been preferable to also do in the first study, strengthening the design, but it was not 
done. Even though the test drinks were given earlier, there is no guarantee for uptake, 
and we do not know if the peptides present in the drink are preferred over other 
hydrolysed protein present in the small intestine. A limitation with providing the test 
drink 10 minutes before the test meal, is the long time period from the drink was 
ingested until the first postprandial blood sample was taken. In Study 2, the first 
postprandial blood sample was taken 25 minutes after ingestion of the drink 
(illustrated in Figure 7, subchapter 5.1.2), which may have caused us to miss the peak 







5.1.4 Evaluation of dietary intake  
Dietary intake was assessed in all three studies by using dietary records. This is a 
method of assessing dietary intake, where the intake of all foods and beverages 
consumed over a specified period are recorded as they are consumed (206). This 
method provides detailed information about the intake and is not prone to recall bias, 
but it is time consuming, may affect food selection and will not capture food items that 
are less frequently eaten (206).  
In Study 1, the participants filled out a 3-day dietary record at baseline, prior to the 
first study visit, and a 1-day dietary record before the last study visit. A 3-day dietary 
record was not filled out at the end of study, due to the short time period between the 
two study visits (4 to 7 days). We expected that there would not be any major changes 
in the participants’ dietary intake within this short period. The main purpose was to 
compare the energy intake prior to each study visit, to control that there were no major 
differences when comparing the two visits.   
In Study 2, the participants filled out a 3-day dietary record at baseline and end of 
study. Given the long intervention period in total (7 weeks), it would have been an 
advantage to also have a dietary record during this period to assess that no major 
changes in nutrient intake were made during the intervention period. Ideally, the 
participants should have filled out one dietary record within each dose period. This 
would have enabled us to evaluate if any major changes in energy and macronutrient 
intake were made during the different dose levels, possibly influencing the results. To 
decrease the burden on the participants in the study, this was not included in the study.  
In Study 3, the participants filled out a 3-day dietary record at baseline and end of 
study (8 weeks). The study design could have been strengthened by including a dietary 
record during the intervention period, e.g., after 4 weeks. However, these dietary food 
records might not be representative for the total intervention period, and relies on self-
reported dietary intake, which has its limitations (207). 
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5.1.5 Measurement considerations  
Several different anthropometric measurements were made, including height, body 
weight and WC, and body composition. Trained health personnel carried out all 
measurements to increase data reliability. Nevertheless, a limitation is that different 
study personnel performed the measurement at the two study sites. This might in 
particular have influenced the WC measurements in Study 3 (Paper III). In general, it 
can be challenging to measure WC, in particular in obese individuals (208). We 
measured WC according to WHO recommendations (209, 210), reported to be better 
correlated with abdominal obesity compared to e.g., waist-hip-ratio (208).  
 
5.1.6 Power analysis  
A power calculation was not performed for any of the three studies, due to lack of 
relevant data to base a power calculation upon and knowledge regarding what effect to 
expect when supplementing with low dose of CPH in humans. When we planned 
Study 1 (acute-effect study), the available evidence regarding low doses of cod protein 
in humans was studies using either the whole fillet (68, 72) or more long-term use of 
unhydrolysed cod protein (76). Based on the available evidence, we decided to include 
between 30 to 40 participants, as done in previous and comparable studies with cod 
protein (68, 76).  
In Study 3, we planned to recruit 60 participants in total. We did not reach our target 
population size due to difficulties with recruitment of eligible participants. Due to 
limited resources and time constraint, we had to stop the inclusion of new participants 
in September 2019. Since no power calculations were done for any of the studies, it is 




5.2 DISCUSSION OF MAIN RESULTS 
The majority of the global population live in countries where overweight and obesity 
pose a greater threat for society, as compared to underweight (92). Despite 
considerable effort from health authorities and the global community, the rates of 
overweight and obesity are increasing and there is no country to date that has been 
able to reverse this trend (99, 100). MetS has become a common metabolic disorder, as 
a result of the increasing rates of obesity. Obesity has great impact on public health, 
through increased costs and pressure on the health care system, reduced quality of life 
and premature deaths, and there is a need for effective prevention and treatment 
strategies (99, 100).  
We conducted three intervention studies in the current project, summarised in this 
thesis, with the overall purpose of exploring if a dietary supplement with CPH could 
beneficially affect components of MetS, with a special focus on glucose and lipid 
metabolism. In the first study we explored the effect of a single low dose of CPH on 
glucose metabolism in healthy adults (Paper I), followed by a study investigating the 
most effective dose level of CPH for use in future studies (Paper II). The main results 
from these studies, reduced postprandial serum insulin concentration after a single 
dose of CPH (Paper I) and indications that a higher dose (40 mg/kg BW) of CPH is 
more effective on metabolic outcomes (Paper II), formed the basis of the last study 
(Study 3). In this study, we explored the potential metabolic effects of daily 
supplement with 4 g of CPH on components of the MetS in overweight and obese 
subjects. We observed that a low dose of CPH did not significantly affect parameters 
of glucose or lipid profile, inflammatory markers or body composition in individuals 
with MetS after 8 weeks (Papers III and IV). The main results will be discussed in the 




5.2.1 Glucose metabolism and effects of cod protein hydrolysate  
A daily supplement with 4 g of CPH for 8 weeks in individuals with MetS did not 
influence glucose metabolism, and we observed no statistically significant differences 
in fasting or postprandial levels of glucose or insulin when comparing the CPH group 
to the placebo group (Paper III). In agreement with these findings, we did not observe 
any effects on glucose concentrations after a single dose of CPH (Paper I) or with 
increasing doses of between 10-40 mg/kg BW (Paper II). However, we did observe a 
significantly reduced postprandial insulin concentration in Study 1 (Paper I). This is in 
contrast to previous studies with low doses of fish protein hydrolysate, reporting of no 
effect on insulin concentrations (53, 54, 57). It is debatable whether lower postprandial 
levels of insulin are beneficial in otherwise healthy adults. In our study, the results 
might indicate a more efficient utilization of insulin, since the glucose levels did not 
significantly differ between the two study visits and the participants exhibited a 
normal postprandial glucose response after CPH. The difference in insulin 
concentration between the CPH and control group are modest (please see Figure 3 in 
Paper I for a graphical representation of the insulin response), and the clinical 
significance of these findings is uncertain. Since we did not observe any effect on 
fasting or postprandial serum levels of insulin in the two following studies (Study 2 
and 3), this further indicates that the observed decreased postprandial insulin levels 
could be a random finding. These results emphasize the importance of addressing the 
clinical relevance of the data.  
The understanding and mechanisms of why low doses of CPH may beneficially affect 
glucose metabolism in the human body, are not fully understood. A greater rate of 
insulin-stimulated glucose uptake and increased insulin sensitivity have been observed 
in cultured L6 myocytes exposed to a cod protein-derived amino acid mixture, 
compared to cells exposed to casein- or soy-derived amino acid mixtures (66). It has 
been suggested that specific cod-derived amino acids, either individual or groups, 
directly affects the insulin-stimulated glucose uptake in the skeletal muscle cells, 
resulting in improved insulin sensitivity (66). This is suggested to be mediated through 
insulin activation of the PI3K/Akt pathway and translocation of GLUT4 to the skeletal 
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muscle cell (67). In obese rats fed a high-fat diet containing either casein or soy, the 
ability of insulin to activate PI3K was severely impaired, which was prevented in 
high-fat rats fed a diet with cod protein. The normalisation of the PI3K/Akt activation 
by insulin, was linked to an increased number of GLUT4 in the transverse tubules, 
indicating improved translocation of GLUT4, and thereby improved glucose uptake in 
the skeletal muscle cell (67). The content of BCAA in cod protein have also been 
implicated to be involved, by affecting signalling pathways such as PI3K/Akt and 
mammalian target of rapamycin, and thereby beneficially affecting glucose 
metabolism (211). The hypothesized effect of the CPH used in our studies, has been 
presumed to be due to specific cod-derived bioactive peptides present in the 
supplement. Bioactive peptide sequences have been identified in various fish species, 
suggested to be effective through inhibited DPP-4 activity and enhanced secretion of 
GLP-1 and cholecystokinin, beneficially affecting glucose metabolism (139, 196). We 
do not presume it is the protein intake per se causing an effect, since the CPH 
supplement only make up a small proportion of the total daily protein intake. For 
example, in Study 3, the estimated average daily protein intake for the participants 
receiving CPH was 85g/day, with the supplement accounting for only 4.7% of the total 
daily protein intake. We did not analyse for the presence of specific known bioactive 
peptide sequences in our hydrolysate, so the mechanism of action is therefore only a 
hypothesis. 
Overall, the lack of findings on glucose metabolism might suggest that the different 
dose levels used in the three studies were too low to affect glucose metabolism, 
suggesting using higher peptide doses in future studies. In Study 1 (Paper I), there is a 
possibility that the control material (casein) may have masked a potential effect of 
CPH on glucose metabolism and influenced our results. In this trial, the study 
participants were healthy, normal- to overweight adults with no known abnormalities 
of the glucose metabolism. A single low dose of CPH prior to postprandial 
measurements, might therefore not result in any major effects on glucose levels. It 
would be reasonable to assume that a more pronounced effect could have been 
observed in overweight and obese subjects, as this group might exhibit abnormalities 
in glucose metabolism. Beneficial effects on glucose levels and improved glucose 
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tolerance have been observed in healthy overweight and obese individuals after 8 
weeks supplementation with a low dose of cod protein (intact) (76). However, we did 
not observe any significant effects on glucose metabolism after CPH supplementation 
in individuals with MetS, in line with other studies reporting findings from studies 
with low doses of cod protein, ranging from 2.5 to 6 g per day, in healthy overweight 
and obese individuals (77, 78).  
In contrast to our results from Study 3, previous studies exploring the effect of dietary 
interventions on metabolic risk factors in individuals with MetS have shown beneficial 
effects on glucose metabolism after various dietary interventions. A recent meta-
analysis including 10 RCTs in patients with MetS, observed significant improvements 
in fasting glucose levels after multifaceted supervised lifestyle interventions (31). The 
lifestyle interventions consisted of various dietary interventions, targeting either 
healthy eating or caloric restriction, combined with supervised group-based exercise. 
The dietary interventions consisting of caloric restrictions targeting weight loss, 
including studies with longer intervention period and more supervised exercise, were 
more effective and resulted in greater improvements in the metabolic risk factors. It 
should be noted that the included studies had a low to moderate methodological 
quality (31). Furthermore, several dietary interventions with alterations in the 
macronutrient composition of fat and carbohydrates have reported beneficial effects on 
components of the metabolic syndrome, including glucose metabolism (212). A recent 
study observed that both very-high fat low carbohydrate diet and low-fat high 
carbohydrate diet resulted in improved levels of insulin, insulin C-peptide and Hba1c 
after 12 weeks intervention in individuals with an increased BMI and WC, irrespective 
of diet (213). Other proposed dietary strategies with effects on MetS, are energy-
restricted diets, diets with a moderate to high protein intake and the Mediterranean diet 
(214). An intensive lifestyle intervention for 12 months in patients with MetS, 
combining an energy-restricted Mediterranean diet, increased physical activity and 
behavioural support, resulted in significant improvements in glucose metabolism, with 
reduced levels of fasting glucose, insulin and Hba1c (133). Some of the beneficial 
effects on glucose metabolism might be explained by the moderate weight loss 
observed in the intervention group (133). Compared to our study (Study 3), the 
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intervention period of this study is longer, the participants received an energy-
restricted Mediterranean diet combined with increased physical activity and close-
follow up, while we instructed our participants to not change their diet or level of 
physical activity. It is plausible to assume that the observed weight loss may have 
mediated some of the improvements seen on parameters of glucose metabolism. We 
did not observe any weight loss during the intervention. Our lack of beneficial effects 
on glucose metabolism in individuals with MetS, may also suggest that 
supplementation with a low dose of fish protein hydrolysate is not able to reverse 
changes that have already occurred in glucose metabolism of individuals with MetS. It 
would be interesting to investigate the combined effect of a low dose of CPH with a 
dietary intervention aiming at weight-reduction. It should also be noted that the sample 
size in Study 3 might have influenced our results, with too few subjects included in the 
study to be able to observe any effect on glucose metabolism. A full-scale study is 











5.2.2 Lipid metabolism and effects of cod protein hydrolysate 
In Study 3 (Paper III), we observed a statistically significant reduction in fasting serum 
concentration of TAGs within the CPH group. These results are in agreement with 
observational studies reporting reduced levels of serum TAG after lean fish 
consumption (24, 46). Improved levels of TAG have also been reported after the 
intake of a diet containing lean seafood (88), and after a daily consumption of cod for 
two weeks (89). In contrast to these studies, a daily intake of 100-150 g of lean fish 
had no significant effects on TAG-levels in normal-weight (71) or overweight adults 
(90), or patients with MetS (47). It is suggested that the high content of taurine and 
glycine found in fish may contribute to increased excretion of faecal cholesterol and 
bile, thereby improving lipid variables in plasma (50, 75, 215). The improved TAG 
levels observed in some of these studies might also be caused by an increased fish 
intake replacing other major protein sources, such as meat, thereby affecting the intake 
of saturated vs. unsaturated fats. In all of these studies, the participants received fish in 
the form of whole fillet, which is a major difference compared to our study, providing 
only a small dose as a supplement.  
In a more similar study to ours, by Hovland et al. (77), no significant effect on the 
TAG levels or any of the other measured lipid parameters were observed after 8 weeks 
with a daily supplement of 2.5 g of cod protein in overweight and obese individuals 
(77). In addition to using a lower dose compared to our study, they also used an intact 
protein. We have to interpret our results with great caution since the significant 
reduction of TAG only was observed within the CPH group. However, our findings 
might indicate that the protein hydrolysate contain some bioactive peptides released 
during the hydrolysis process contributing to the improved TAG levels. As also 
mentioned in subchapter 5.2.1, this is only a hypothesis since we did not test for the 
presence of known-lipid lowering bioactive sequences prior to starting the project. In 
comparison, no significant effects on postprandial TAG levels were observed in an 
acute-effect study after a single dose of 3 g fish protein hydrolysate made from bonito 
given to overweight and obese subjects (54). Since this study only gave a single dose 
to their participants, and used a fish protein hydrolysate made from another fish 
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species, it might suggest that length of intervention period and type of fish protein 
hydrolysate may be of significance.  
In regard to dietary strategies observing improved effects on lipid markers in 
individuals with MetS, such as energy-restricted diets, diets rich in long-chain n-3 
PUFAs and the Mediterranean diet, the improvements may be related to the 
concomitant weight loss observed in many of these interventions (214). An improved 
lipid profile, with elevated levels of TAG and reduced HDL-C were observed in 
patients with MetS, following an intensive lifestyle intervention, combining an energy-
restricted Mediterranean diet, increased physical activity and behavioural support 
(133). They observed a moderate weight loss in the intervention group, which might 
explain some of the improvements observed in the lipid parameters (133). A recent 
meta-analysis of 9 RCTs found that lifestyle interventions, consisting of a combined 
dietary intervention and exercise, moderately reduced the levels of TAG by an average 
of 0.20 mmol/L, compared to usual care (31). Dietary supplements containing long-
chain n-3 PUFAs taken for at least 3 months in doses above 1 g, have been reported to 
significantly reduce TAG levels with 7-25% (216). In line with these results, we 
observed a reduction of 18% in TAG levels from baseline to end of study within the 
CPH group (Study 3, Paper III). As previously mentioned, since the results were only 
reported within the CPH group, and not when compared to the control group, the 
results should be interpreted with caution. Overall, the potential effect of a low dose of 
a fish protein hydrolysate on lipid metabolism is of interest and should be evaluated in 






5.2.3 Adipokines, inflammatory parameters and effects of cod 
protein hydrolysate  
There are indications that lifestyle interventions may influence adiponectin levels, with 
energy-restricted diets combined with increased physical activity resulting in increased 
levels of adiponectin (131). It seems like the concomitant weight loss during 
intervention is of more importance for the increased levels, compared to type of 
dietary intervention (131). In line with these findings, male individuals with MetS 
consuming a Mediterranean diet combined with weight loss had increased adiponectin 
levels, with no significant effect observed in the absence of weight loss (132). These 
findings also seem to apply to leptin, with reduced levels observed as a result of 
weight loss (132, 133). The intake of fish and long-chain n-3 PUFAs supplements are 
also shown to increase adiponectin levels (131). 
Interestingly, we observed that a daily intake of 4 g of CPH for 8 weeks in individuals 
with MetS significantly increased fasting serum concentration of adiponectin within 
the CPH group, without any significant changes in body weight or body composition 
(Study 3, Paper IV). We did not observe any significant changes in serum 
concentration of leptin. These results are similar to a previous study reporting 
increased levels of adiponectin after supplementation with 2.5 g of cod protein (intact 
protein, within group) in healthy overweight and obese subjects, with no change in 
leptin levels (77). Overall, these findings implies that cod protein in low doses may 
also be capable of increasing levels of adiponectin. When comparing the baseline 
fasting levels of adiponectin in our study, to previous studies in healthy adults (71) and 
overweight adults (77), the levels are lower and similar, respectively. This supports 
evidence suggesting that adiponectin levels are reduced in overweight subjects (121). 
Since we only observed increased levels of adiponectin within the CPH group, and not 
when comparing the groups, the results should be interpreted with caution. Still, the 
findings are of interest and should be further explored in future studies with larger 
sample size.  
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A recent meta-analysis comparing the effect of different dietary approaches on 
inflammatory markers in patients with MetS, observed that a low-fat diet resulted in 
reduced CRP levels (217). However, the effect appeared to be dependent on weight 
loss (217). Furthermore, it has been suggested that energy-restricted diets may 
improve the pro-inflammatory status observed in patients with MetS (214). An 
intensive lifestyle intervention in patients with MetS resulted in reduced levels of IL-
18 and MCP-1, with only minor non-significant effect on hs-CRP, IL-8, IL-6 and 
TNF-α (133). It is suggested that the significant reductions in IL-18 and MCP-1 might 
be explained by the concomitant weight loss observed in the intervention group, 
including increased activity level and dietary changes (133).  
Fish as part of the diet is also suggested to have anti-inflammatory properties, and 
reduced levels of CRP have been linked to consumption of fish (112). Insulin-resistant 
subjects receiving a diet with cod protein had reduced levels of hs-CRP after 4 weeks 
(113), with no effect on CRP levels after a high intake of cod in either normal-weight 
(71) or overweight (72) adults. In our study (Study 3), we found higher levels of hs-
CRP after supplementation with CPH for 8 weeks, when compared to placebo (Paper 
IV). These results are in line with a study reporting of increased CRP levels after 
supplementation with 5.2 g of fish protein hydrolysate, however, in a population of 
older nursing home residents (53). In contrast, a low dose of cod protein did not affect 
CRP levels in overweight and obese subjects (76). Our findings are difficult to 
interpret. It is plausible that the small sample size might have influenced our results, or 
that some individuals may have had on-going low-grade inflammation without 
disclosing a problem. When comparing the overall fasting level of hs-CRP in both 
groups in our study with a previous study (218), our levels are similar to the levels 
reported in obese subjects and higher compared to normal-weight subjects, 
emphasizing how BMI may affect CRP levels (218). These results support findings 
suggesting that elevated levels of CRP may be involved in MetS (219, 220).  
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6. CONCLUSIONS 
A daily supplement of 4 g CPH for 8 weeks, did not significantly affect parameters of 
glucose or lipid metabolism, inflammatory markers or body composition in overweight 
and obese subjects with MetS, when compared to placebo. Furthermore, we did not 
observe any effects on fasting levels of adipokines or fasting or postprandial ghrelin 
concentration. Considering the small sample size, no definitive conclusion can be 
drawn from this study. The tendency of beneficial effect on some lipid parameters and 
adipokines should be investigated in future studies. 
An acute-effect study showed that supplementation with a dose of 20 mg/kg BW of 
CPH before a meal test, decreased postprandial insulin concentrations, with no effect 
on glucose or GLP-1 levels, in healthy adults between 40-64 years old. The reduced 
insulin levels are of uncertain clinical significance, and given the small population, 
these findings need further investigations.  
No effect was observed on concentrations of serum glucose, insulin or GLP-1 levels 
with increasing doses of CPH, ranging from 10 mg/kg BW to 40 mg/kg BW, given to 
adults between 60 and 80 years. The results indicate a tendency that the highest dose 
of 40 mg/kg BW, corresponding to 3 g in an individual weighing 75 kg, was the most 
effective in lowering postprandial insulin and glucose levels. These are only 
indications, also with a need for further investigation.  
Overall, our findings do not support our hypothesis that a low dose of CPH would 
beneficially affect glucose metabolism in the acute setting, and that it was a dose-
response relationship of increasing doses with a plateau effect observed when 
increasing the doses, and that supplementation with CPH would beneficially affect 
components of MetS. Despite lack of findings and clear conclusions, due to 
preliminary findings, small populations and a number of limitations addressed in the 
thesis, these results add valuable information to the scientific field.  
 82 
7. FUTURE PERSPECTIVES 
The clinical studies, summarised in the current PhD thesis, were designed to 
investigate the potential effects of a low dose of protein hydrolysate made from 
residual material from cod fillet production on glucose metabolism in healthy adults, 
and on components of MetS in overweight and obese adults.   
As we did not observe any significant clinical effects on glucose or lipid metabolism 
after the low dose levels used in this PhD project, future studies should preferably 
investigate the effect of supplementing with higher protein doses. The presence of 
peptide sequences with known bioactive sequences were not analysed in the protein 
hydrolysate used in the current project. If the hydrolysate is used in further studies, an 
analysis of peptide sequences with potential metabolic effects, such as glucose- or 
lipid lowering effects, should be conducted.  
In the current project, cuttings and trimmings from the cod fillet production was used 
to produce the hydrolysate. It is of interest to further investigate if also other parts of 
residual materials retained after processing of fish, such as head, skin, entrail and 
backbone, have any beneficial metabolic effects and can be used for human 
consumption. Overall, increasing the utilization of residual materials from the fishing 
industry will contribute to increased profits for the fisheries and aquaculture, reduce 
waste and contribute to a sustainable fishing industry, ultimately contribute towards 
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Abstract
The increased prevalence of lifestyle diseases, such as the metabolic syndrome and type 2 diabetes mellitus (T2DM), calls for more knowledge on dietary
treatments targeting the specific metabolic pathways involved in these conditions. Several studies have shown a protein preload before a meal to be effective
in lowering the postprandial glycaemic response in healthy individuals and patients with T2DM. The aim of the present study was to assess the effect of a
marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose metabolism in healthy, middle-aged to elderly subjects. This
double-blind cross-over trial (n 41) included two study days with 4–7 d wash-out in between. The intervention consisted of 20 mg of MPH (or casein as
control) per kg body weight given before a breakfast meal. The primary outcome was postprandial response in glucose metabolism, measured by samples of
serum glucose, insulin and plasma glucagon-like peptide 1 (GLP-1) in 20 min intervals for 180 min. In a mixed-model regression analysis, no differences
were observed between MPH and control for postprandial glucose concentration (mean difference: −0·04 (95 % CI –0·17, 0·09) mmol/l; P= 0·573) or
GLP-1 concentration (mean difference between geometric means: 1·02 (95 % CI 0·99, 1·06) pmol/l; P = 0·250). The postprandial insulin concentration
was significantly lower after MPH compared with control (mean difference between geometric means: 1·067 (95 % CI 1·01, 1·13) mIU/l; P= 0·032). Our
findings demonstrate that a single dose of MPH before a breakfast meal reduces postprandial insulin secretion, without affecting blood glucose response or
GLP-1 levels, in healthy individuals. Further studies with repeated dosing and in target groups with abnormal glucose control are warranted.
Key words: Marine protein hydrolysate: Fish protein: Marine peptides: Glucose metabolism
The proportion of the population with health problems related
to overweight and obesity is constantly increasing worldwide,
and this constitutes a great risk factor for several lifestyle
diseases such as insulin resistance, the metabolic syndrome
and type 2 diabetes mellitus (T2DM)(1). The ability of the
body to control postprandial glucose metabolism is decisive
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for health. Several dietary treatments for the prevention of
postprandial hyperglycaemia in both diabetic and non-diabetic
individuals have been suggested, but the necessary lifestyle and
diet changes are challenging, and continue to lack adherence(2).
There is a need for more knowledge on dietary treatments tar-
geting the specific metabolic pathways involved in overweight,
obesity, the metabolic syndrome and T2DM.
Diets relatively high in protein (18–30 % energy) have been
shown to be effective in the management of obesity due to
suppression of appetite(3), and are further suggested to reduce
postprandial blood glucose in both healthy individuals and
patients with impaired glucose metabolism(4). Several trend
diets have over the last decades included high-protein diets
to reduce weight and suppress insulin response(5,6), but the
long-term effects of high-protein diets are unknown(7,8).
Furthermore, several studies have shown a protein preload
before a meal to be effective in lowering the postprandial gly-
caemic response both in T2DM patients and healthy
subjects(9–13).
Due to limited access to high-quality protein in the world, it
is neither sustainable nor possible for the world’s population
to increase the proportion of protein in the diet. Thus, the
potential benefit of altering the source and quality of protein,
rather than increasing the amount, is of great interest. Marine
resources in excess should be evaluated as a possible high-
quality protein source for human consumption(14).
Previous studies in rats and human subjects have shown
that the intake of both fish proteins and marine protein hydro-
lysates (MPH), even in low doses, has a desirable effect on
insulin sensitivity and postprandial glucose(7,15–19), lipids in
serum and adipose tissue, bile acids, fatty acid composition
and growth, and possibly has antihypertensive and immune-
modulating effects(14,19–23). It is indicated that MPH may con-
tain marine bioactive compounds with potentially important
biological effects in humans, beyond the known effect of pro-
tein as a source of amino acids(24,25). The use of MPH as a
dietary supplement with similar or better health benefits than
a regular fish meal could be both cost-effective, environmen-
tally friendly and sustainable. A low dose of MPH is presumed
to be effective due to the content of bioactive peptides not
equally present in other protein sources.
Thus, the present study was designed to assess the effect of
a single, low dose of MPH before a meal on postprandial glu-
cose metabolism in healthy, middle-aged to elderly subjects.
Subjects and methods
Trial design
The study was a double-blind cross-over trial, including two
different study days, with a 4–7 d wash-out period in between.
The intervention implemented 20 mg of MPH per kg body
weight (test material) or control (casein). MPH or casein pow-
der (identical, both flavoured with lemon) was mixed with
water and taken before a standardised breakfast meal, in ran-
domised order. The primary outcome was postprandial
response in glucose metabolism, measured by venous samples
of serum glucose and insulin, and plasma glucagon-like
peptide 1 (GLP-1). The secondary outcome was adverse
events measured by symptom questionnaires.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing human subjects were approved by the Regional
Committees for Medical and Health Research Ethics of
Central Norway (2017/1794). Written informed consent was
obtained from all subjects. The trial was registered at clinical-
trials.gov as NCT03669796.
Participants
Participants were recruited through advertisements on the
Internet and posters at Haukeland University Hospital and
Ålesund Hospital between October 2017 and February
2018. Potential participants were interviewed for general eligi-
bility and compliance with inclusion and exclusion criteria, and
suitable candidates were invited for a further screening visit. A
total of forty-one healthy and active individuals between 41
and 64 years old were included in the study (male, n 15; female,
n 26). The inclusion process is depicted in Fig. 1.
Inclusion criteria were aged 40–65 years old and BMI 20–
30 kg/m2. Exclusion criteria were fish allergy, pharmacologic-
ally treated diabetes mellitus, elevated blood pressure, chronic
diseases (that might affect the evaluation of the study end-
points) and acute infections. The participants were instructed
not to take any nutritional supplements containing n-3 fatty
acids for 1 week before the study start, and while participating
in the study.
Study protocol
The participants came to the research units on two different
occasions, with a 4–7 d wash-out period (Fig. 2). A clinical
examination by a physician, baseline biochemistry and mea-
sures of height, weight and blood pressure were done before
inclusion. The level of physical activity was assessed, and par-
ticipants were instructed not to change the level of physical
activity or diet composition during the study period.
A 3-d and 1-d prospective dietary record was filled out prior
to study days 1 and 2, respectively. On the day preceding each
study day, the participants were provided with a standardised
evening meal (oatmeal, rice or barley porridge) instructed to
be eaten before 20.30 hours, followed by fasting until the
next morning.
On study days, the participants came to the research units
between 08.00 and 09.00 hours. After blood samples, they
were served a drink with MPH or control, before a breakfast
meal was given. The first post-meal sample (0 min sample) was
taken 15 min after the breakfast was served.
The standardised breakfast meal consisted of two slices of
semi-coarse bread (50 % whole wheat, 80 g bread), 10 g mar-
garine, 20 g strawberry jam and 20 g white cheese, providing a
total of 355 kcal (1485 kJ), 41 g carbohydrate, 12·5 g protein
and 15 g fat. The drink provided on average 35·9 g carbohy-
drate and 145 kcal (607 kJ). Thus, including the drink, the
breakfast provided in total 500 kcal (2092 kJ) and 77 g carbo-
hydrate. The amount of energy and carbohydrates in the
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Fig. 1. Flowchart depicting the inclusion process for the study evaluating the effect of a marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on
postprandial glucose metabolism in healthy individuals aged 40–65 years. Participants were recruited through advertisements on the Internet and posters at
Haukeland University Hospital and Ålesund Hospital between October 2017 and February 2018.
Fig. 2. Study protocol for the evaluation of the effect of a marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose metabolism.
We included forty-one healthy subjects (age range 40–64 years).
3
journals.cambridge.org/jns
breakfast was calculated to induce an adequate blood glucose
response. No coffee or tea was served, but water ad libitum.
The participants spent 4 h at the research units to allow for
repeated sampling of blood, at 20 min intervals until 180 min,
and monitoring of blood pressure.
Assessments
Assessment of the participants’ medical history, and measure-
ment of biochemical variables and safety parameters were con-
ducted at baseline.
During the study days, serum glucose and serum insulin
were measured at baseline and every 20 min for 2 h (120
min), with a final sample at 180 min. GLP-1 was measured
at baseline, time 0, 20, 40, 80 and 180 min. Blood pressure
was measured at baseline, after 40 min and after 180 min, as
a safety parameter.
Two questionnaires evaluating the participants’ self-
experienced symptoms were implemented to identify possible
adverse events during each study day. A visual analogue scale
was filled out six times during the study day, and a question-
naire validated for the evaluation of gastrointestinal symptoms
(Kane) was filled out at baseline and at the end of each study
day(26).
Estimation of nutritional intake
Calculations of energy and macronutrient intake were per-
formed using Kostholdsplanleggeren (Norwegian Food Safety
Authority and The Norwegian Directorate of Health, Oslo,
Norway)(27). The dietary records were used to evaluate the
composition of the baseline diet, to map the participants’ regu-
lar meal pattern and to compare the days prior to each study
day according to energy intake.
Test materials
The MPH and casein powder were delivered from the manu-
facturer (Firmenich Bjørge Biomarin AS) in neutral bottles
coded with participant number and study day. The bottles
were coded by a person not involved in the implementation
of the study and randomised according to a randomisation
list. Both study participants and all persons involved in
study conduction and analysis were blinded. The powder con-
tained 4 % protein (MPH raw material or casein) and 96 %
carbohydrate (maltodextrin). It was flavoured with lemon,
but otherwise neutral. It was not possible to identify the active
ingredient from the control, according to flavour or appear-
ance. Each participant was given 20 mg/kg body weight of
MPH or control. The drinks were made isonitrogenous, and
equal amounts of N in the form of casein were added to
the control drink. This was done to avoid any bias due to dif-
ference in N content between the MPH drink and the control
drink. The amount of protein (N x 6·25) in both drinks was on
average 1·6 g, constituting only a small fraction of the total
protein content of the standardised breakfast meal. Casein
was chosen as the control as it has previously shown to not
affect blood glucose or insulin sensitivity when compared
with proteins from cod and soya(28).
The MPH powder was made by Firmenich Bjørge Biomarin
AS by hydrolysing fish meat of Atlantic cod (Gadus morhua)
with Protamex® (Novozymes AS) followed by spray drying
of the soluble part of the enzyme digest. The MPH raw mater-
ial contained approximately 89 % protein by weight, <0·2 %
fat, 0 % carbohydrate, <3·0 % water, 10 % ash, 0·1 % NaCl,
1·7 % Na and 0·07 % chloride. Free amino acids accounted
for 4·77 % of total amino acids in the MPH, and the essential
amino acids:non-essential amino acids ratio was 0·70. Analysis
of the molecular weight distribution (Table 1) shows that
about 90 % of the peptides in the fish protein hydrolysate
have a molecular weight of 2000 Da or less (eighteen amino
acids or fewer), about 75 % of 1000 Da or less (ten amino
acids or fewer) while about 55 % have a molecular weight of
500 Da or less (five amino acids or fewer). Approximately
25 to 30 % of the peptides have a molecular weight less
than 200 Da, which represents small dipeptides and free
amino acids.
The casein contained approximately 88 % protein. The
amino acid composition of MPH and casein used as control
is presented in Table 2 (data obtained from Firmenich
Bjørge Biomarin AS).
The MPH was analysed at the Allergy Laboratory
(Haukeland University Hospital, Bergen, Norway) for allergen-
icity of the hydrolysate. Direct ELISA showed insignificant
reactivity of specific IgG and IgE to the hydrolysate in com-
parison with the reactivity against cod allergen. The allergen-
icity of the hydrolysate was so low that it was considered
unsignificant.
Analysis of blood samples
Baseline biochemistry was analysed according to standard
accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway) and the Department of Medical Biochemistry,
Ålesund Hospital (Ålesund, Norway).
Glucose and insulin were measured in serum according to
standard accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway). Serum was obtained by centrifugation of full
Table 1. Molecular weight distribution in the dry and solubilised marine








g/100 g in the
spray-dried powder
>10 000 – <0·1 <0·1
10 000–8000 88–71 0·1 0·1
8000–6000 70–53 0·6 0·5
6000–4000 52–36 2·1 1·9
4000–2000 35–18 7·2 6·3
2000–1000 17–10 14·8 13·0
1000–500 9–5 21·0 18·5
500–200 4–2 27·0 23·8
<200 ≤2 27·2 24·0
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blood at 2000 g at room temperature (20°C) for 10 min after
30–60 min of coagulation, using serum separator cloth activa-
tor tubes. Samples were aliquoted and stored frozen at −80°C
prior to analyses.
Plasma for GLP-1 determination was obtained by centrifu-
gation of EDTA full blood at 1800 g at −4°C for 10 min
within 20 min after blood sampling. To EDTA blood sam-
pling tubes were added 10 µl dipeptidyl peptidase-4 inhibitor
(DPP4-010; DRG Diagnostics) per ml EDTA blood prior
to sampling. GLP-1 plasma was aliquoted and stored frozen
at −80°C prior to analysis. The GLP-1 analyses were per-
formed using an ELISA kit from IBL International GmbH
(GLP-1 (7–36) active ELISA, reference RE53121).
Statistical analysis
Statistical analysis was performed using SPSS software (IBM
SPSS Statistics 24) and GraphPad Prism version 7.0
(GraphPad Software, Inc.). The Shapiro–Wilk test was used
to assess normal distribution. Mixed-model regression analysis
was conducted to evaluate the difference between MPH and
control. Non-normally distributed data were log-transformed
before analysis (insulin and GLP-1) and are presented as log
mean and back-transformed values. Paired t tests were used
to evaluate differences in nutrient intake between study days.
Two-way ANOVA with repeated measures was used to evalu-
ate differences between each time point. Graphical work was
conducted in GraphPad Prism. P values <0·05 were consid-
ered statistically significant.
The sample size was not calculated according to a power
analysis, due to lack of similar studies. Previous research
reporting on the effect of cod proteins in human subjects is
based on whole fish(16) or long-term use of fish protein sup-
plement(17,29); thus we did not find any data adequate for mak-
ing a basis for a power analysis representative for our design.
We decided to include forty participants (forty-one were
included), a number higher or similar to previously reported
in studies on cod protein(16,17,29).
Results
Participant characteristics
Overall, forty-one participants completed the trial, of whom
twenty-six were female. Mean age was 51 (SD 6) years, range
40–64 years. Mean BMI was 25·2 (SD 3) kg/m2. The recorded
mean energy intake (2084 (SD 504) kcal/d; 8719 (SD 2109) kJ/
d) was lower than the estimated energy need (2605 (SD 392)
kcal/d; 10899 (SD 1640) kJ/d) at baseline. The standardised
breakfast provided on the study days (500 kcal (2092 kJ)) cov-
ered 19·6 (SD 2·9) % of the participants’ total energy need. All
baseline biochemistry was within the current reference values.
Baseline characteristics are presented in Table 3.
Energy intake
Mean energy intake before study day 1 was 2030 (SD 550)
kcal/d (8494 (SD 2301) kJ/d). Mean intake before study day
2 was 2110 (SD 534) kcal (8828 (SD 2234) kJ/d). The energy
intake did not differ before the two study days (P = 0·201).
Postprandial measurements
Data at each time point are presented in Table 4. In a multi-
variable, repeated-measures linear mixed-effects regression
analysis, no differences were observed between MPH and con-
trol for glucose concentration (mean difference: −0·04 (95 %
CI –0·17, 0·09) mmol/l; P = 0·573). Mean fasting glucose
levels were numerically equal on both study days (5·1 (SD
0·4) mmol/l; P> 0·999). The peak in glucose concentration
Table 2. Amino acid and taurine composition of the marine protein
hydrolysate (MPH) from Atlantic cod (Gadus morhua) and the casein
control used in the present study
Amino acid




Aspartic acid 73·3 70·8
Asparagine 0·38 N/A


















* Branched-chained amino acids.
Table 3. Baseline characteristics of the forty-one participants included in
the study at Haukeland University Hospital and Ålesund Hospital between
October 2017 and February 2018*
(Mean values and standard deviations)
Characteristics Mean SD
Age (years) 51·0 6·0
BMI (kg/m2) 25·2 3·0
Systolic blood pressure (mmHg) 125 18
Diastolic blood pressure (mmHg) 78 11




Energy intake at baseline
kcal/d 2084 504
kJ/d 8719 2109
Carbohydrates (g/d) 226·7 68·5
Fat (g/d) 90·2 33·0
Protein (g/d) 92·9 23·6
* Nutritional values are based on mean values from 3-d dietary records.
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(Cmax) occurred 20 min after the meal for both MPH and
control and was numerically higher after MPH than after
the control drink (7·6 (SD 1·8) v. 7·4 (SD 1·5) mmol/l,
respectively; P = 0·997). The AUC was compared for the
nine glucose measurements. The AUC for the glucose concen-
tration was numerically equal between MPH (1078 (95 % CI
956·0, 1199·0) mmol/l × min) and control (1068 (95 % CI
944·8, 1190·0) mmol/l × min; P= 0·910).
The insulin concentration was significantly lower after MPH
compared with control (mean difference between geometric
means: 1·067 (95 % CI 1·01, 1·13) mIU/l; P = 0·032). Mean
fasting insulin levels were numerically higher before MPH
(6·4 (SD 5·8) mIU/l) than control (6·1 (SD 5·6) mIU/l; P >
0·999), but the insulin concentration peaked at a lower level
and at 20 min (69·6 (SD 52·7) mIU/l) after MPH whereas
the peak after the control drink was numerically higher and
occurred at 40 min (70·3 (SD 53·6) mIU/l). Women had sig-
nificantly lower insulin concentrations than men (mean differ-
ence between geometric means: 0·65 (95 % CI 0·45, 0·93)
mIU/l; P= 0·020), irrespective of intervention.
Table 4. Descriptive statistics* of the forty-one participants included in a study at Haukeland University Hospital and Ålesund Hospital between October
2017 and February 2018, evaluating the effect of marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose
metabolism measured by serum glucose, insulin and glucagon-like peptide 1 (GLP-1) during exposure to MPH and control (casein) drinks
(Mean values and standard deviations)
MPH Control
Outcome Time Mean SD Log mean SD GM Mean SD Log mean SD GM
Glucose (mmol/l) Baseline 5·1 0·4 5·1 0·4
0 min 6·5 0·9 6·7 0·8
20 min 7·6 1·6 7·4 1·5
40 min 6·5 1·8 6·2 1·9
60 min 5·4 1·4 5·4 1·6
80 min 4·9 1·2 5·1 1·4
100 min 4·6 1·1 4·7 1·2
120 min 4·5 1·1 4·4 1·0
180 min 4·4 0·6 4·3 0·6
Insulin (mIU/l)† Baseline 6·4 5·8 1·6 0·7 4·9 6·1 5·6 1·5 0·7 4·6
0 min 33·8 34·3 3·2 0·9 23·8 34·9 30·4 3·3 0·7 27·5
20 min 69·6 52·7 4·0 0·6 57·1 68·0 47·7 4·0 0·6 56·3
40 min 64·8 51·1 4·0 0·6 52·0 70·3 53·6 4·0 0·7 55·1
60 min 57·2 46·2 3·8 0·6 45·7 61·4 49·0 3·9 0·6 49·3
80 min 42·9 33·9 3·6 0·6 35·0 51·7 47·3 3·7 0·7 39·7
100 min 36·4 39·3 3·3 0·7 26·9 40·8 42·0 3·4 0·7 31·3
120 min 28·6 31·3 3·0 0·8 20·6 30·1 37·9 3·0 0·8 21·1
180 min 12·2 17·7 2·1 0·9 8·0 12·4 15·1 2·2 0·8 8·7
GLP-1 (pmol/l) Baseline 6·2 9·5 1·5 0·6 4·4 6·2 9·5 1·5 0·6 4·4
0 min 8·1 9·1 1·9 0·6 6·5 8·8 9·9 1·9 0·6 7·0
20 min 8·0 9·4 1·9 0·5 6·4 7·9 9·3 1·8 0·6 6·2
40 min 7·2 9·1 1·7 0·6 5·6 7·3 9·0 1·7 0·6 5·7
80 min 6·9 10·3 1·6 0·6 5·0 7·0 9·6 1·6 0·6 5·2
180 min 6·8 10·1 1·6 0·7 4·8 6·5 0·8 1·6 0·6 4·8
GM, geometric mean (exp(log mean)).
* Log mean and GM are presented for non-normally distributed data (insulin and GLP-1). Glucose values are only presented as means and standard deviations due to approxi-
mately normal distribution.
† In a mixed-model linear regression analysis, the insulin levels were significantly lower after intake of MPH than control (P = 0·032).
Fig. 3. Metabolic response for serum glucose (a), serum insulin (b) and plasma glucagon-like peptide 1 (GLP-1) (c) concentrations after intake of a standardised
breakfast meal supplemented with a drink containing either marine protein hydrolysate (MPH; –○–) or control (casein; –●–). Results are presented for forty-one
healthy subjects. The study had a cross-over design and all subjects received both treatments in random order. Time point 0 min shows values measured right




No differences were observed between MPH and control
for GLP-1 concentration (mean difference between geometric
means: 1·02 (95 % CI 0·99, 1·06) pmol/l; P = 0·250). Mean
fasting GLP-1 levels were numerically equal on both study
days (6·2 (SD 9·4) pmol/l; P> 0·999). The peak occurred
right after intake of breakfast and test drink (0 min) and was
lower after MPH (8·1 (SD 9·1) pmol/l) than after control (8·8
(SD 9·9) pmol/l; P= 0·092). Results are presented in Fig. 3.
Adverse events
No adverse events were reported in the questionnaires or
otherwise observed.
Discussion
The study was designed to investigate the effect of a low dose
of MPH on postprandial glucose metabolism in healthy indivi-
duals. Our hypothesis was that supplementation with MPH
before a meal would beneficially affect the glucose response,
insulin and GLP-1 concentration compared with control. We
found that a single dose of 20 mg/kg body weight MPH pre-
meal supplement significantly lowered the postprandial insulin
response. Although we did not observe a reduction in post-
prandial blood glucose values and GLP-1 concentrations, we
postulate that our findings could indicate a potential beneficial
effect of MPH in individuals with reduced insulin sensitivity.
We hypothesise that MPH may enhance the insulin sensitivity
and affect other mechanisms involved in the blood glucose
uptake in peripheral tissue. The study participants were healthy
individuals with HbA1c levels within the normal range
(Table 2), thus one would expect normal blood glucose con-
centrations after a meal. We speculate that the effect of
MPH on postprandial glucose metabolism will be more dis-
tinct if further investigated in individuals with the metabolic
syndrome or T2DM.
The target of nutritional diabetic and pre-diabetic treatment
is to maintain a blood glucose level within the normal range.
Several studies have previously shown different sources of
protein preload before a meal to reduce the postprandial gly-
caemic response, both in healthy and diabetic individuals(9–13).
However, to our knowledge, data on the specific acute effect
of a fish protein hydrolysate supplement prior to a meal has
previously not been published.
Our finding is consistent with a previous study, showing
lower postprandial insulin C-peptide levels after a 7-d interven-
tion with cod(30). Furthermore, Ouellet et al.(16) have previously
demonstrated that a diet rich in cod improved insulin sensitiv-
ity in nineteen insulin-resistant individuals, when compared
with a diet rich in other animal protein sources. Also, it has
previously been demonstrated that cod protein-fed rats, in
comparison with casein-fed and soya-fed rats, are protected
against the development of insulin resistance and hypergly-
caemia induced by diets rich in fat and sucrose(28). This effect
was related to enhanced insulin-stimulated glucose uptake in
muscle cells, but not in adipose tissue. It is indicated that
amino acids derived from cod protein can increase the insulin-
stimulated glucose uptake in muscle cells by acting directly on
the glucose transport system(28). Investigations of the mechan-
isms promoting this positive effect of amino acids from cod
revealed that dietary cod protein restored insulin-induced acti-
vation of the phosphatidylinositol 3-kinase (PI3K)/protein
kinase B (Akt) pathway and improved translocation of
GLUT4 to the T-tubes in skeletal muscle cells(31). The glucose
transporter protein GLUT4 facilitates the uptake of glucose
into the cell when expressed at the cell surface, and it has
been proposed that a reduced translocation of GLUT4 to
the T-tubules leads to the development of insulin resist-
ance(31). It is proposed that the amino acids derived from
cod protein, in comparison with amino acids derived from
other protein sources, facilitate a unique pathway leading to
the increased expression of GLUT4 in the T-tubules and
enhanced insulin sensitivity(31).
The assumed beneficial effect of the amino acids derived
from cod can possibly be linked to the high concentration
of branched-chain amino acids (BCAA). It has previously
been demonstrated that serum levels of the BCAA leucine,
isoleucine and valine, as well as the amino acid lysine, is cor-
related with the insulin response(32). The effect has been linked
to the increase of hormones such as glucose-dependent insu-
linotropic polypeptide and GLP-1(33). Although it is estab-
lished that the BCAA leucine and isoleucine are the major
amino acids affecting blood glucose homeostasis, the effect
has not been observed when the amino acid concentration is
low(34). Interestingly, a significant stimulation of glucose
uptake in muscle cells by the PI3K/Akt pathway has been
observed when the BCAA were administered as dipeptides
in low concentrations(35). The MPH used in our trial have a
high concentration of BCAA (Table 1), and analysis of the
MPH used in the present study shows that about 10 % of
the di- and tripeptide fractions are present as leucine- and
isoleucine-containing peptides (data obtained from Firmenich
Bjørge Biomarin AS). Even though we did not observe an
increase of GLP-1 in relation to the intake of single, low
dose of MPH, our findings suggest that low concentrations
of MPH may increase insulin sensitivity. The casein used as
the control has higher concentrations of BCAA than the
MPH, but it differs from MPH regarding the fraction present
as di- or tripeptides. The casein used in the study is not a
hydrolysate, but present as whole protein, and does not con-
tain either peptides or free amino acids. Thus, we assume
that the BCAA-containing peptides present in MPH constitute
the unique, bioactive effect even when given in low concentra-
tions. We postulate that this is due to the rapid absorption of
intact bioactive leucine- and isoleucine-containing peptides via
peptide transporters in the upper jejunum and into the blood.
It has been shown that other sources of protein, such as casein
and whey, are necessary in much higher doses than MPH to
achieve significant alterations in the postprandial blood glucose
and insulin response(36,37).
One could argue that the control drink should be a true pla-
cebo and only contain glucose (maltodextrin), and no protein.
However, then it would be possible that the observed effect
could simply be due to differences in energy and N content.
To avoid this, the control drink contained casein, a protein
shown not to affect blood glucose response and insulin
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sensitivity when given in low concentrations(28,38,39), to facili-
tate an isoenergetic and isonitrogenic placebo material. Both
the MPH and casein control drinks contained an equal amount
of protein, in total on average 1·6 g. This amount is negligible
compared with the total protein content of the breakfast meal
provided (12·5 g protein); thus the effect of MPH can be
attributed to the content of bioactive peptides and not the pro-
tein per se. In a clinical study comprising of 120, slightly over-
weight (BMI between 25 and 30 kg/m2) male and female
subjects, Nobile et al.(40) showed that oral doses of 1·4 and
2·8 g MPH from the codfish species blue whiting
(Micromesistius poutassou) taken daily for 90 d increased the
blood concentrations of both cholecystokinin and GLP-1.
Further, body weight composition was improved in favour
of reduced body fat mass. Daily doses higher than 1·4 g did
not give any further effects, demonstrating that MPH may
show bioactivity in humans when taken orally in the range
of 15–20 mg per kg body weight.
Previous studies have investigated the long-term effect of
fish protein intake in overweight, obese and/or diabetic indivi-
duals. Improvement in postprandial glucose regulation after
intake of 750 g fatty fish/week (for 8 weeks) in overweight/
obese adults has been demonstrated, but this effect was not
observed after intake of lean fish(15). Similar findings have
been reported in T2DM patients; Zhu et al.(41) demonstrated
that treatment with a fish protein hydrolysate improved glu-
cose and lipid metabolism, resulting in reduced fasting blood
glucose, insulin and HbA1c, compared with placebo.
Vikøren et al.(17) were the first to investigate the specific effect
of a fish protein supplement on postprandial blood glucose.
They found that low doses of a fish protein supplement
from cod (3 and 6 g) for 4 weeks resulted in lower levels of
fasting and postprandial glucose, including lower AUC for glu-
cose when compared with placebo, in thirty-four overweight
individuals. Another recent study found that supplementation
with cod protein for 8 weeks in forty-two overweight and
obese individuals had a beneficial effect on postprandial con-
centration of serum NEFA, but no effect was observed in
postprandial glucose or insulin concentration compared with
control(29). The most obvious difference when comparing
these studies with our study design is that they evaluated
the long-term effect of fish intake/fish protein supplement
in overweight and obese patients, while we were interested in
the acute effect of a fish protein hydrolysate after a meal in
healthy individuals.
There are elements with our design that may have affected
the outcome. Previous studies in human subjects have investi-
gated the effect of fish or fish protein supplementation over a
longer period of time. Thus, it will be interesting to investigate
a potential effect using different doses given over a period of
time. Furthermore, we investigated the effect of MPH in
healthy individuals, assumed to have a normal glucose
response. Our findings indicate that further research should
aim to include individuals with hyperglycaemia or abnormal
postprandial glucose control. The participants in this study
might have been too healthy to find a meaningful effect.
The significant lower insulin concentration observed after
intake of MPH could be important in patients with reduced
insulin sensitivity, thus should be further investigated in a
group of patients with the metabolic syndrome and/or
T2DM. It has to be considered that 1 week of wash-out for
the use of n-3 supplements before inclusion might not have
been enough; thus the short wash-out period may be regarded
as a limitation to our design.
Most previous studies have been performed in rodents, and
few data exist on the specific effect of MPH supplement in
human individuals. The effect of a low dose of MPH on the
postprandial glycaemic response has previously just been
hypothesised, and our study is the first to investigate this pos-
sible association. Thus, this double-blinded cross-over trial
investigating the effect of MPH supplement in human subjects
can be regarded valuable for future studies. We suggest that
the potential effect of MPH should be investigated over a
longer period, with higher doses in patients with impaired gly-
caemic response and reduced insulin sensitivity.
In conclusion, our findings demonstrated that a single dose
of MPH before a breakfast meal reduced postprandial insulin
concentration without affecting blood glucose response or
GLP-1 levels when compared with control (casein), in healthy,
middle-aged individuals. The mechanism for this effect is
unknown, and further studies are warranted in target groups
with abnormal glucose metabolism.
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Fig. 1. Flowchart depicting the inclusion process for the study evaluating the effect of a marine protein hydrolysate (MPH) from
Atlantic cod (Gadus morhua) on postprandial glucose metabolism in healthy individuals aged 40–65 years. Participants were recruited
through advertisements on the Internet and posters at Haukeland University Hospital and Ålesund Hospital between October 2017
and February 2018.
Fig. 2. Study protocol for the evaluation of the effect of a marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on
postprandial glucose metabolism. We included forty-one healthy subjects (age range 40–64 years).
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and February 2018.
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Abstract
A large proportion of older adults are affected by impaired glucose metabolism. Previous studies with fish protein have reported improved glucose regu-
lation in healthy adults, but the evidence in older adults is limited. Therefore, we wanted to assess the effect of increasing doses of a cod protein hydrolysate
(CPH) on postprandial glucose metabolism in older adults. The study was a double-blind cross-over trial. Participants received four different doses (10, 20,
30 or 40 mg/kg body weight (BW)) of CPH daily for 1 week with 1-week washout periods in between. The primary outcome was postprandial response in
glucose metabolism, measured by samples of serum glucose and insulin in 20 min intervals for 120 min. The secondary outcome was postprandial response
in plasma glucagon-like peptide 1 (GLP-1). Thirty-one subjects aged 60–78 years were included in the study. In a mixed-model statistical analysis, no dif-
ferences in estimated maximum value of glucose, insulin or GLP-1 were observed when comparing the lowest dose of CPH (10 mg/kg BW) with the
higher doses (20, 30 or 40 mg/kg BW). The estimated maximum value of glucose was on average 0·28 mmol/l lower when the participants were
given 40 mg/kg BW CPH compared with 10 mg/kg BW (P = 0·13). The estimated maximum value of insulin was on average 5·14 mIU/l lower with
40 mg/kg BW of CPH compared with 10 mg/kg BW (P= 0·20). Our findings suggest that serum glucose and insulin levels tend to decrease with increas-
ing amounts of CPH. Due to preliminary findings, the results require further investigation.
Keywords: Fish protein: Cod protein: Marine peptides: Marine protein hydrolysate: Glucose homeostasis
The human body is dependent on a tight regulation of blood
glucose levels to ensure normal function(1). Blood glucose
levels are regulated within a narrow range, and glucose homeo-
stasis is maintained through an intricate network of hormones
and neuropeptides that are released in the body(1,2). With
increasing age, glucose metabolism changes and a large pro-
portion of older adults are affected by impaired glucose
metabolism(3,4). Since skeletal muscle is the major site for
insulin-stimulated uptake of glucose(5,6), it has been suggested
that low skeletal muscle mass observed in some older adults
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with reduced muscle mass and function might result in
reduced capacity for glucose disposal(7). Furthermore, higher
fasting and postprandial values of glucose and insulin have
been associated with lower muscle mass in older adults(8).
The gradual decline in muscle mass and function observed
with increasing age(9–11) is a major threat to healthy ageing,
and causes reduced mobility, increased disability, loss of inde-
pendence and overall reduced quality of life(12,13).
Several previous intervention studies have reported
improved insulin sensitivity(14,15) and glucose tolerance(14,16)
in humans and rodents after supplementation with fish pro-
tein. Furthermore, 3-month supplementation with a daily
dose of 1·4 g protein hydrolysate from blue whiting given to
overweight adults increased blood concentrations of glucagon-
like peptide 1 (GLP-1). No further effects were observed when
the participants were given a higher dose of 2·8 g, which might
indicate a plateau effect starting at 1·4 g(17). GLP-1 is released
from the enteroendocrine L-cells in response to food intake
and lowers blood glucose levels by stimulating insulin secre-
tion, suppressing glucagon secretion and slowing gastric
emptying(18). In general, fish protein and hydrolysates from
fish protein have a well-balanced distribution of amino acids
and should be considered a high-quality protein source, and
there is an increasing amount of evidence supporting a favour-
able effect of these proteins on metabolic health(19).
The evidence of health effects of cod protein as a nutritional
supplement is limited, and only a few studies in healthy and
overweight adults have been conducted. A recent study
reported that an 8-week supplementation with 6 g of residual
material from cod (press-cake meal) in a group of overweight
or obese adults resulted in decreased postprandial concentra-
tions of serum NEFA, which might indicate an effect on mar-
kers for glucose regulation(20). In addition, a small pilot study in
overweight adults observed improved glucose regulation after
daily supplementation with 2·5 g of protein from cod for 8
weeks(21). No changes in insulin, insulin C-peptide or NEFA
in serum were observed(21). Furthermore, we recently demon-
strated that supplementation with a single dose of 20 mg/kg
body weight (BW) of a protein hydrolysate from cod, given
before a breakfast meal, reduced postprandial insulin secretion
in forty-one healthy adults between 41 and 64 years, when com-
pared with control(22). We did not observe any effects on post-
prandial blood glucose response or on the levels of GLP-1.
Based on current knowledge, it is of interest to further
explore potential favourable effects of cod protein on para-
meters closely related to muscle health, including parameters
of glucose metabolism in an older population. To our knowl-
edge, no previous trial has evaluated the effect of increasing
doses of a supplement with cod protein hydrolysate (CPH)
on glucose metabolism in older adults. Therefore, the aim of
the present study was to investigate the effect of supplementa-
tion with four different weight-adjusted doses of a CPH on
postprandial glucose regulation in a group of older adults
aged 60–80 years. Based on the results from the study, we
hoped to create a basis for selecting an effective daily dose
of CPH for further use in clinical study protocols in patient
groups with muscle health issues, inflammatory conditions
or abnormal glucose metabolism.
Experimental methods
Study design
The study was a double-blind cross-over trial. The participants
received four different doses (10, 20, 30 or 40 mg/kg BW) of
CPH daily for 1 week with 1-week washout periods in between
the dose intervals. Each participant received all four different
dose intervals in random order. The participants were
instructed to take the supplement each morning before break-
fast for 7 d. After an initial screening visit, included partici-
pants came to the research unit on four different occasions,
separated by 2 weeks. In total, the study lasted for 7 weeks.
The primary outcome was postprandial response in glucose
metabolism, measured by venous samples of glucose and insu-
lin. Secondary outcomes were plasma GLP-1 and adverse
effects measured by symptom questionnaires.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing human subjects were approved by the Regional Committee
for Medical and Health Research Ethics of Central Norway
(2017/1795). Written informed consent was obtained from
all subjects. The trial is registered at www.clinicaltrials.gov as
NCT03526744.
Participants
Participants were recruited by advertisement on the external
websites and on notice boards at Haukeland University
Hospital, Bergen and Ålesund Hospital, Ålesund.
Recruitment took place between March and July 2018, and
the study was conducted between April and November of
the same year.
Potential participants were screened for general eligibility by
telephone, and suitable candidates were invited for a baseline
evaluation visit, with further information and baseline blood
chemistry. The criteria for inclusion were age between 60
and 80 years, BMI between 20 and 30 kg/m2 and signed
informed consent. Criteria for exclusion were allergy and intol-
erances to fish and/or shellfish, pharmacologically treated dia-
betes mellitus, low or unstable blood pressure, chronic
diseases or medication that were likely to interfere with the
evaluation of the study endpoints, acute infections, substance
misuse (excessive alcohol consumption and/or narcotic sub-
stances assessed by physician) or unwillingness to comply
with the requirements of the study. The participants were
instructed to not take any nutritional supplements containing
n-3 PUFA for 2 weeks before study commencement and dur-
ing the course of the study.
Study protocol
The participants came to the research unit on five different
occasions, including a screening visit. Before inclusion, the
subjects underwent clinical examination by a physician, base-
line biochemistry and measurement of height, weight and
blood pressure.
A 3-d prospective diet diary was recorded prior to starting
the intervention, and at the end of the study period. The
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level of physical activity was assessed at baseline and at the end
of the study by asking the participants two questions regarding
moderate physical activity and vigorous activity (self-reported).
The participants were instructed not to change diet habits or
the level of physical activity during the study period.
The study consisted of four different intervention cycles.
Before each intervention cycle, the participants received six
bottles containing powder with CPH, labelled 1 to 6. We
instructed the participants to take one bottle each morning
during the intervention cycle. On days of study tests, day 7
in each intervention cycle, the participants came to the
research facility in a fasting condition between 08.00 and
09.00 hours. After baseline blood sampling, we gave the last
dosage of CPH followed by a standardised breakfast meal
10 min later. At 25 min after the CPH drink was served and
15 min after the breakfast meal had started, we took the
first postprandial blood sample (0 min sample). Thereafter,
the participants spent 2 h in the vicinity of the research unit
to allow for repeated sampling of blood, at 20 min intervals
until 120 min.
The standardised breakfast meal consisted of two slices of
semi-coarse bread (50 % whole wheat, 80 g bread), 10 g mar-
garine, 20 g strawberry jam and 20 g white cheese, providing a
total of 1485 kJ (355 kcal), 41 g carbohydrate, 12·5 g protein
and 15 g fat. The drink contained 22·5 g carbohydrate and
approximately 418 kJ (100 kcal), and including the drink, the
breakfast provided in total 1900 kJ (455 kcal). The amount
of energy and carbohydrates in the breakfast was calculated
to induce an adequate blood glucose response. No coffee or
tea was served, but water was given ad libitum.
We handed out the six bottles for the next intervention cycle
at the end of the test day and gave instructions for when to
start the next intervention cycle. Between intervention cycles,
the participants had a washout period of 7 d. All participants
received a text message on the morning of the day they
were to start the next intervention cycle.
Assessments
At the screening visit we assessed the participant’s medical his-
tory and measured biochemical parameters for nutritional sta-
tus (albumin, prealbumin, vitamins B12 and D). We measured
biochemical safety parameters at the screening visit and the
end of study visit.
During the test days, baseline fasting serum glucose and
serum insulin were measured 25 min before the first postpran-
dial blood sample (time (t) = 0 min postprandial).
Subsequently, serum glucose and insulin were measured
every 20 min for 2 h (t = 20, 40, 60, 80, 100 and 120 min post-
prandial). Baseline GLP-1 was measured and thereafter post-
prandially at t = 0, 20, 40, 80 and 120 min. Blood pressure
was measured at three time points during the test day as a
safety parameter (t = 0, 40 and 120 min).
Two questionnaires evaluating the participants’ symptoms
were used to identify possible adverse events during each
intervention period and on study visits. In each intervention
period, a visual analogue scale was filled out before the parti-
cipants took the first dose with CPH on day 1 and before the
last dose on day 7. Further, a questionnaire validated for the
evaluation of gastrointestinal symptoms(23) was filled out 2 h
after intake of CPH on day 1 and day 7 (end of test day,
t = 120 min).
Test material
The protein hydrolysate powder was delivered from the manu-
facturer (Firmenich Bjørge Biomarin AS) in neutral bottles
coded with participant number and dose level (1–4). The bot-
tles were coded by a person not involved in the performance
of the study and the different dose levels were randomly allo-
cated to the participants according to a central digital random-
isation list. Study participants and investigators were blinded to
the dose content in the bottles (double-blinded study). The key
of randomisation was provided to the investigators when the
trial had ended, and the statistical analysis was completed.
The powder contained 4 % protein (CPH raw material) and
96 % carbohydrate (maltodextrin) and was flavoured with
lemon. The CPH raw material contained approximately 89
% protein by weight, <0·2 % fat, 0 % carbohydrate, <3·0 %
water, 10 % ash, 0·1 % NaCl, 1·7 % Na and 0·07 % chloride.
The amino acid composition of CPH raw material is presented
in Table 1. The hydrolysation process has been presented in a
previous publication(22).
Estimation of energy intake
Calculations of energy and macronutrient intake were per-
formed using Kostholdsplanleggeren (Norwegian Food Safety
Authority and The Norwegian Directorate of Health, Oslo,
Norway)(24), based on the reported food and drink intake
data from the participants at baseline and at the end of the
study. Participants registered their intake of food and drink
Table 1. Amino acid and taurine composition of the cod protein
hydrolysate used in the present study






















* Branched-chain amino acids.
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for three consecutive days, preferably including one weekend
day, prior to the first dose and at the end of the study. The
dietary records were used to record the participants’ diet pat-
terns and to assess whether the participants made changes to
their diets during the study period.
Analyses of blood samples
Baseline biochemistry was analysed according to standard
accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway) and the Department of Medical Biochemistry,
Ålesund Hospital (Ålesund, Norway).
Glucose and insulin were measured in serum according to
standard accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway). Serum was obtained by centrifugation of full
blood at 2000 g at room temperature (20°C) for 10 min
after 30–60 min of coagulation, using serum separator cloth
activator tubes. Samples were aliquoted and stored at −80°C
prior to analysis.
Plasma for the determination of GLP-1 was obtained by
centrifugation of EDTA full blood at 1800 g at −4°C for
10 min, within 20 min after blood sampling. Prior to sampling,
to EDTA blood sampling tubes were added 10 µl dipeptidyl
peptidase-4 inhibitor (DPP4-010; DRG Diagnostics) per ml
EDTA blood. GLP-1 plasma was aliquoted and stored at
−80°C prior to analysis. The GLP-1 analyses were performed
using an ELISA kit from IBL International GmbH (GLP-1
(7–36) active ELISA, reference RE53121).
Statistical analysis
Statistical analyses were performed using Stata v15.1
(StataCorp LLC) and SPSS software (IBM SPSS Statistics
24). Graphical work was conducted in GraphPad Prism ver-
sion 7.0 (GraphPad Software, Inc.). Data are presented as
means and standard deviations for continuous variables, and
frequencies and relative frequencies for categorical variables.
To estimate the effect of dose we calculated the maximum
observed value and the AUC for the time course of each
outcome variable, for each combination of person and dose.
We then fitted mixed models with the outcome measure
(maximum value or AUC) as the dependent variable, fixed
effects of dose and random intercepts across persons.
Carry-over effects were assessed using a standard
likelihood-ratio test to test for interaction between dose and
ordering. Paired-samples t tests were used to compare changes
in energy intake and macronutrient intake from baseline to the
end of the study. P values <0·05 were considered statistically
significant.
The sample size was not feasible to calculate for power ana-
lysis, due to lack of similar studies. Possible health effects of
supplementation with residual material from cod as protein
hydrolysate has previously not been studied in a group of
older adults, and therefore we had no basis for calculating




From April to June 2018 we screened fifty-one subjects for
study participation and thirty-three were enrolled in the
study (Fig. 1). Two of the included participants were excluded
before the first test day due to difficulties with blood sampling.
Overall, thirty-one subjects aged 60–78 years completed the
trial (thirteen males and eighteen females). One participant
had to be excluded on the final study day due to difficulties
with blood sampling; therefore data on glucose, insulin and
GLP-1 are only available for three of the dose levels. Four
of the participants were excluded from the final statistical ana-
lysis of GLP-1 due to analytical errors. Baseline characteristics
of the participants are presented in Table 2.
Energy and macronutrient intake
No statistically significant differences were observed in energy
intake or macronutrient intake during the course of the study
(Table 3). One participant did not fill out the 3-d food record
at the end of the study. Based on the reported intake of protein
from the food diaries at baseline and at the end of the study,
an average intake of 1·2 g protein/kg BW at baseline was esti-
mated and this did not change during the study period (P =
0·36; estimated average intake at end of study 1·1 g protein/
kg BW).
Postprandial measurements
In a mixed-model analysis, no statistically significant differ-
ences in estimated maximum value of glucose, insulin or
GLP-1 were observed when comparing the lowest dose of
10 mg/kg BW of CPH with 20, 30 or 40 mg/kg BW
(Table 4). The estimated maximum value of glucose was on
average 0·28 mmol/l lower when the participants were given
the highest dose of 40 mg/kg BW CPH compared with the
lowest dose of 10 mg/kg BW (P = 0·13). The estimated
maximum value of insulin was on average 5·14 mIU/l lower
after participants were given the highest dose of 40 mg/kg
BW of CPH compared with the lowest dose of 10 mg/kg
BW (P = 0·20). The estimated maximum value of GLP-1
was on average 0·34 pmol/l lower when given the highest
dose (40 mg/kg BW) compared with the lowest dose of
CPH (10 mg/kg BW) (P= 0·48). No carry-over effect was
observed for glucose (P= 0·19), insulin (P = 0·21) or GLP-1
(P = 0·08).
No statistically significant differences in AUC between the
four different doses were observed for any of the outcome
measures when comparing the lowest dose of 10 mg/kg BW
of CPH with the higher doses of 20, 30 or 40 mg/kg BW.
For glucose, AUC was calculated from t = baseline until
t = 80, excluding t = 100 and t = 120 (Fig. 2), based on the
assumption that for the majority of individuals, glucose levels
had returned to their baseline levels. The AUC for glucose was
on average 1·16 mmol/l × min higher when given 20 mg/kg
BW of CPH (P = 0·14), on average 0·27 mmol/l × min higher
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Fig. 1. Flowchart depicting the inclusion and randomisation process. BW, body weight.
Table 2. Baseline characteristics of the thirty-one participants





Age (years) 67·8 4·9
Weight (kg) 76·6 11·3
BMI (kg/m2) 26·0 2·6
Systolic BP (mmHg) 137 15
Diastolic BP (mmHg) 82 10
HbA1c (mmol/mol) 36·7 4·3
Fasting glucose (mmol/l) 5·4 0·6
BP, blood pressure; HbA1c, glycated Hb.
Table 3. Dietary intake at baseline and at the end of the study*
(Mean values and standard deviations)
Baseline End of study
P†Mean SD Mean SD
Energy intake (kJ) 7765 1586 7807 1506 0·84
Protein (g) 86·9 20·6 84·2 18·1 0·32
Fat (g) 73·1 19·3 75·2 18·6 0·50
Carbohydrates (g) 215·2 65·4 213·8 55·8 0·95
* Food and drink intakes were registered for 3 d at baseline and at the end of the
study.
†Paired-samples t tests were used to compare changes in energy intake and
macronutrient intake from baseline to the end of the study. No significant differences
were observed during the course of the study.
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mmol/l × min lower when given 40 mg/kg BW (P= 0·32),
when compared with the lowest dose of 10 mg/kg BW of
CPH. If all measuring points were included in the statistical ana-
lysis of glucose, also including t = 100 and t = 120, the
significance of the results did not change (Fig. 2). For insulin,
the AUC was on average 11·3 mIU/l × min higher
when given 20 mg/kg BW of CPH (P = 0·49), on average
6·84 mIU/l × min higher when given 30 mg/kg BW of CPH
(P= 0·67) and on average 7·4 mIU/l × min lower when given
40 mg/kg BW (P = 0·65), when compared with the lowest
dose of 10 mg/kg BW of CPH. For GLP-1, the AUC was on
average 1·38 pmol/l × min lower when given 20 mg/kg BW
of CPH (P = 0·36), on average 0·01 pmol/l × min lower
when given 30 mg/kw BW of CPH (P = 0·99) and on average
1·09 pmol/l × min lower when given 40 mg/kg BW of CPH
(P= 0·47), when compared with the lowest dose of 10 mg/kg
BW of CPH. A graphical representation of the metabolic
response for serum glucose, serum insulin and plasma GLP-1
concentration on the test day, the last day in the four different
intervention cycles, is presented in Fig. 2. A bar chart showing
total AUC for serum glucose, serum insulin and plasma GLP-1
is presented in Fig. 3.
Adverse effects
No adverse effects were reported in the questionnaires, from
the biochemical safety parameters or from the biochemical
parameters for nutritional status.
Discussion
The overall objective of the present study was to evaluate the
effect of increasing doses of a supplement with CPH on glu-
cose metabolism in older adults, aiming to find a dose
response and creating a basis for an optimal daily dose for
future clinical use. We investigated the effect on postprandial
glucose regulation of four different doses of a CPH supple-
ment (10, 20, 30 and 40 mg/kg BW) taken daily for 1 week.
Although no statistically significant differences were observed
between the postprandial measurements after the four differ-
ent doses, our results indicate that the highest dose of CPH
(40 mg/kg BW), equal to 3·2 g/d in an individual with a
BW of 80 kg, is the most efficient in lowering postprandial
blood glucose levels and insulin concentrations, when com-
pared with the lower doses (10, 20 and 30 mg/kg BW).
In a previous publication, we reported that a single dose of
20 mg/kg BW CPH significantly reduced postprandial insulin
concentrations in healthy, middle-aged to older individuals,
without affecting postprandial glucose levels or GLP-1 levels,
compared with control (casein)(22). We hypothesised that the
CPH might enhance the insulin sensitivity and affect other
mechanism involved in blood glucose uptake in peripheral tis-
sue. The significantly lower insulin concentration after intake
of CPH may be of more interest in patients with reduced insu-
lin sensitivity.
To our knowledge, only one small pilot study has been con-
ducted with fish protein hydrolysate in an older population(25).
In this double-blind, randomised controlled study, a daily diet-
ary supplement of 5·2 g fish protein hydrolysate from blue
whiting, or placebo, was given to twenty-four nursing home
residents daily for 6 weeks. No differences in serum concen-
trations of glucose or insulin after 6-week supplementation
with fish protein were observed, when compared with pla-
cebo(25). However, since this was a study population with
Table 4. Estimated maximum values of glucose, insulin and glucagon-
like peptide 1 (GLP-1) derived from a mixed model





difference 95 % CI P
Glucose (mmol/l) 10 0 (Reference)
20 0·33 −0·04, 0·70 0·08
30 0·09 −0·29, 0·46 0·65
40 −0·28 −0·65, 0·08 0·13
Insulin (mIU/l) 10 0 (Reference)
20 3·59 −4·34, 11·5 0·38
30 3·42 −4·60, 11·4 0·40
40 −5·14 −13·1, 2·79 0·20
GLP-1 (pmol/l) 10 0 (Reference)
20 −0·66 −1·59, 0·28 0·17
30 −0·11 −1·06, 0·84 0·83
40 −0·34 −1·28, 0·59 0·48
BW, body weight.
Fig. 2. Metabolic responses for serum glucose (a), serum insulin (b) and plasma glucagon-like peptide 1 (GLP-1) (c) concentrations after intake of a standardised
breakfast meal and the last dosage of the cod protein hydrolysate (CPH). Dose levels were 10, 20, 30 and 40 mg/kg body weight (BW). Results for serum glucose
and insulin are presented for all thirty-one subjects, whereas for GLP-1 the results are presented for twenty-seven subjects (four participants were excluded from the
statistical analysis due to analytical errors). Values are means. Time point 0 min is the first postprandial blood sample, taken 25 min after the drink was served and 15
min after the breakfast meal started. BL, baseline.
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older adults who lived in a nursing home setting, the results are
not directly transferable to our study population with home-
dwelling older adults.
Based on a few previous studies investigating the effect of
supplements containing protein hydrolysates from fish on
metabolic health(17,26), we hypothesised that small doses of
CPH may be effective due to the content of small, easily
absorbable bioactive peptides. These are capable of rapidly
affecting different metabolic pathways involved in glucose
regulation and hence leading to a more rapid glucose response
in the body. Thus, we presume that a potential observed effect
on postprandial glucose metabolism can be attributed to the
content of small, bioactive peptides in the supplement, and
not the protein intake per se, which is negligible compared
with overall protein content in a normal meal. Previous studies
investigating supplements with fish protein or hydrolysates of
fish proteins have reported doses in the range of 1 to 6 g per d
to beneficially influence blood glucose metabolism when com-
pared with control(16,17,21,26).
The results have to be interpreted taking certain limitations
in the design into account. The use of a cross-over design
always implies a risk of a carry-over-effect. According to ana-
lysis of all possible interaction effects between doses and time
periods, the results in this cross-over trial are not biased by a
carry-over effect. We included a washout period of 7 d
between each week of peptide supplementation. We presume
1 week to be a sufficient washout period, as dietary protein
in general has a high turnover rate and the investigated
doses of protein hydrolysate were low(27). On study days, the
supplement was given to the participants 10 min before break-
fast and 25 min before the first postprandial blood sample was
taken. This design might have caused a metabolic response
even before the breakfast was served. As a result, we may
have missed some early information on postprandial glucose
response. Furthermore, a 2-week washout period for the use
of supplements containing n-3 PUFA before starting on the
first dose of CPH may not have been enough and a longer
washout period could arguably have strengthened the design.
It is possible that the short supplementation period of 1
week could have affected the results, and that a longer period
would have been preferable. However, we have previously
observed an effect after only one acute supplementation (20
mg/kg BW) in healthy middle-aged adults(22). A longer inter-
vention period would have made it more challenging to
include participants and avoid drop-outs, due to a long time-
frame of the study. Therefore, due to practical implementa-
tions of the study, 1 week of supplementation (7 d) for each
dose was chosen. Finally, the design could have been strength-
ened by including a postprandial blood sampling at day 0 for
each intervention cycle or a control group (0 mg/kg BW
CPH). However the study was performed based on a previous
study, where we report that a low dose of CPH (20 mg/kg
BW) significantly reduced the postprandial insulin concentra-
tion(22), and we therefore aimed to further evaluate the effect
of different doses in the present study. An additional study day
in each intervention period would also have made it more
challenging to include participants and avoid a high drop-out
rate, and would be difficult to implement due to limited
resources. Based on this, we chose to only include postpran-
dial blood sampling at the end of each intervention period.
To our knowledge, no previous publication has reported on
the metabolic effect of different low doses of fish protein
hydrolysate in an older adult population. Although no signifi-
cant differences were observed in this trial, our findings sug-
gest that low doses of fish protein hydrolysate might be
effective and capable of improving blood glucose regulation
in older adults. According to our findings, further studies
investigating effects of supplements containing hydrolysates
of fish proteins should be able to observe a metabolic effect
from doses starting around 40 mg/kg BW, equal to 3·2 g
per d in an individual with a BW of 80 kg. Based on this,
we suggest that a dose ranging from 3 to 4 g per d is a reason-
able starting point for future clinical studies. Due to prelimin-
ary findings, these results require further investigation.
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Abstract: The risk of cardiovascular diseases and type 2 diabetes mellitus are increased in subjects
with metabolic syndrome (MetS), and hydrolyzed fish protein may have favorable effects on metabolic
health. Here, we investigated the effect of 8 weeks supplementation with 4 g of cod protein hydrolysate
(CPH) on glucose metabolism, lipid profile and body composition in individuals with MetS in a
double-blind, randomized intervention study with a parallel-group design. Subjects received a
daily supplement of CPH (n = 15) or placebo (n = 15). Primary outcomes were serum fasting
and postprandial glucose levels. Secondary outcomes were fasting and postprandial insulin and
glucagon-like peptide 1 (GLP-1), fasting lipid concentrations and body composition. No difference
was observed between CPH and placebo for insulin, glucose or GLP-1 after 8 weeks intervention.
Fasting triacylglycerol decreased in both the CPH group and placebo group, with no change between
groups. Fasting total cholesterol and low-density lipoprotein cholesterol decreased significantly
within both groups from baseline to study end, but no difference was observed between the two groups.
In conclusion, supplementing with a low dose of CPH in subjects with MetS for 8 weeks had no effect
on fasting or postprandial levels of insulin, glucose or GLP-1, lipid profile or body composition.
Keywords: metabolic syndrome; cod protein hydrolysate; glucose metabolism; lipid
metabolism; obesity
1. Introduction
Hyperglycemia, hypertension, dyslipidemia and abdominal obesity form a cluster of
interconnected metabolic abnormalities commonly known as the metabolic syndrome (MetS), which
increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) [1–3].
The prevalence of MetS varies depending on the definition used and the population studied, but it
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is estimated that between 20 and 30% of the adult population in most countries meet the diagnostic
criteria for MetS [4]. Currently, the first-line therapy for MetS is education on lifestyle changes including
physical activity and weight reduction, and improvement of risk factors closely linked to MetS [3].
The syndrome has significant negative impact on public health, and the rate of MetS is expected to
continue to rise in adults and future generations unless we find effective strategies to prevent and
reverse this development [4]. It is of interest to find ways to prevent and alleviate MetS, beyond the
currently used strategies.
Based on associations seen between fish consumption and increased levels of high-density
lipoprotein cholesterol (HDL-C) and reduced levels of triacylglycerols (TAG), increased consumption
of fish may improve metabolic health and prevent development of MetS [5–8]. The nutrients in fish,
such as iodine, vitamin D, taurine, long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) and
high-quality protein, may all contribute to the positive health effects of fish consumption [9]. There
is also emerging evidence that proteins from fish contain bioactive peptides and may potentially
modulate physiological processes in the human body, and contribute with a number of effects beyond
their nutritional value as a source of energy and amino acids [10,11]. Bioactive peptides are released
naturally by gastric digestion, produced by fermentation in the gut or through hydrolyzed protein
added to the diet [12]. Animal and human studies suggest that hydrolyzed fish proteins given in low
doses may have beneficial effects on lipid metabolism [13–15], postprandial glucose [14] and insulin
regulation [16], as well as body composition and appetite [17,18]. Similar indications are observed in
intervention studies with healthy overweight and obese adults given low doses (between 2.5 and 8 g)
of supplements with unhydrolyzed cod protein [19–21].
We have previously investigated supplementation with low doses of a cod protein hydrolysate
(CPH) on glucose metabolism and appetite in healthy adults [16,22], as well as supplementation for
6 weeks on inflammation and gastrointestinal health in patients with irritable bowel syndrome [23].
It is of interest to further evaluate the possible effects of low doses of CPH in a group of participants
with metabolic abnormalities, such as subjects with MetS, over a longer period. Therefore, we aimed
to investigate whether supplementation with low doses of 4 g of CPH per day for 8 weeks would
have an effect on postprandial glucose metabolism and the appetite hormone glucagon-like peptide 1
(GLP-1), lipid profile and body composition in subjects with MetS. We hypothesized that the small
peptides present in the CPH supplement would serve as rapidly absorbed bioactive peptides and lead
to beneficial changes in glucose metabolism and an overall healthier metabolic profile.
2. Materials and Methods
2.1. Study Design
This study was as a multicenter, double-blinded, randomized, intervention with a parallel-group
design. Participants with MetS received a daily supplement of 4 g of CPH (active ingredient) or placebo
(no active ingredient) for 8 weeks. The primary outcome was fasting and postprandial glucose levels.
Secondary outcomes were other metabolic and clinical parameters of the metabolic syndrome (waist
circumference, fasting TAG and HDL-C), as well as fasting and postprandial insulin and GLP-1 levels,
total cholesterol (total-C), fasting low-density lipoprotein cholesterol (LDL-C), and body composition.
All subjects gave their written informed consent for inclusion before participation in this study.
This study was conducted in accordance with the Declaration of Helsinki and all procedures involving
human subjects were approved by the Regional Committee for Medical and Health Research Ethics of
Central Norway (2018/2163). This study is registered at clinicaltrials.gov (NCT03807752).
2.2. Participants and Study Setting
Between March and September 2019, we recruited participants to this study through advertisement
on the internal and external websites, on notice boards at Haukeland University Hospital (HUH), Bergen,
and Ålesund Hospital, Ålesund, and at general practitioners in Bergen and the surrounding area.
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The criteria for inclusion were age between 40 and 70 years, body mass index (BMI) between 27
and 35 kg/m2 and the presence of MetS. Criteria for exclusion were chronic diseases or medication that
were likely to interfere with the evaluation of the study endpoints (e.g., T2DM, medications known to
affect glucose and lipid metabolism), allergy or intolerance to fish and/or shellfish, excessive alcohol
consumption and/or drug as assessed by physician, acute infections or unwillingness to comply with
the study requirements. As blood pressure was not an outcome measure, we allowed participants
using certain types of blood pressure medications, not known to clinically affect glucose metabolism,
to take part in this study. This included diuretics, calcium-channel blockers and agents acting on the
renin-angiotensin system. Participants using beta-blocking agents or peripheral vasodilators were
excluded. Four weeks prior to starting the intervention and during this study, the participants had to
stop using any nutritional supplements with n-3 PUFAs. No changes in food consumption or level of
physical activity were allowed. Lastly, the participants had to remain at a stable weight for the last
three months and not be involved in any weight-loss programs prior to or during the intervention.
2.3. Definition of Metabolic Syndrome
The Joint Interim Statement was used to define MetS, in which the presence of any three of five risk
factors qualifies for a diagnosis of MetS: elevated fasting glucose, s-TAG, reduced HDL-C, increased
waist circumference (WC) or elevated blood pressure [1]. Furthermore, we used the International
Diabetes Federation cut-off points for central obesity (WC ≥ 80 cm in women; ≥94 cm in men) [24].
The cut-off points for the other components were as follows: s-glucose ≥ 5.5 mmol/L, s-TAG ≥
1.7 mmol/L, s-HDL-C < 1.0 mmol/L in men and <1.3 mmol/L in women, systolic blood pressure ≥
130 mmHg and/or diastolic blood pressure ≥ 85 mmHg [1].
2.4. Study Visits
All possible participants responding through the online recruitment form were pre-screened by
telephone. Based on this, we invited potential participants to a screening visit to evaluate the presence
of MetS and eligibility in terms of inclusion and exclusion criteria. The screening visit included a
clinical examination by a physician, a review of medical history, vital sign (blood pressure, heart rate),
anthropometric measures (weight, height and waist circumference) and blood sampling. We measured
height and weight to the nearest 0.1 cm or 0.1 kg using an electronic weight/height scale and used these
parameters to calculate BMI (kg/m2). Furthermore, at screening and end of study visit, we measured
waist circumference (WC) according to WHO recommendations [25,26], i.e., locating the midpoint
between the lower margin of the last palpable rib and the top of iliac crest, with arms relaxed at the side,
at the end of a normal expiration and using a stretch-resistant measuring tape with constant tension.
On days of study visits, the participants came to the study center in the morning. After an
overnight fast (i.e., after 9:00 pm the previous day, the participants could not eat/drink or use nicotine),
all study procedures were performed. Fasting blood samples were taken, and anthropometric measures
were performed. Body composition was measured by a bioelectrical impedance analysis (BIA) device
at baseline and end of study visit (Body Composition Analyzer, BC-418 MA (model used in Ålesund),
MC-180 MA (model used in Bergen), Tanita Corporation, Tokyo, Japan), following the manufacturers’
guidelines—barefoot with light clothing and an empty bladder.
Following the baseline measurement, the participants consumed a standardized breakfast meal
(test meal). It consisted of two slices of semi-coarse bread (80 g bread, 50% whole wheat), 20 g
white cheese, 25 g strawberry jam, 10 g margarine and 1.5 dL orange juice, providing a total of
1840 kJ (440 kcal), 69 g carbohydrate, 13.3 g protein and 14.3 g fat. We calculated the energy and
macronutrient content using “Kostholdsplanleggeren” (Norwegian Food Safety Authority and The
Norwegian Directorate of Health, Oslo, Norway) [27]. The participants consumed the meal within
15 min. Blood was drawn from an antecubital vein in the fasting state (−20 min), at 0 min, i.e.,
immediately after the meal was finished, and thereafter at 20, 40, 60, 80, 100 and 120 min. To induce an
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adequate blood glucose response, we calculated the required amount of energy and macronutrient in
the test meal. We allowed free drinking of water, but did not serve coffee or tea.
The participants started the intervention on the day following the baseline visit. They opened the
sealed bag with powder (active or placebo) and mixed well with 100 mL cold water. The participants
consumed the supplement 10 min before breakfast every day for 8 weeks, except for the morning of
the end of study visit due to required fast.
2.5. Test Material
Firmenich Bjørge Biomarin AS (Ålesund, Norway) manufactured the test material. The flavored
white powder came pre-packed in cardboard boxes from Pharmatech AS (Fredrikstad, Norway), with
56 sealed plastic-coated aluminum bags per box. The boxes were marked with A or B, i.e., blinded for
both participants and personnel involved in this study. The intervention material contained 4 g of
hydrolyzed protein from cod (cuttings and trimmings) in addition to 5 g glucose hydrate (Cargill),
2 g maltodextrin, 0.025 g tastegram powder flavor, 0.7 g citric acid and 0.1 g lemongrass durarome
taste. The placebo contained 6.5 g of maltodextrin, 0.2 g citric acid, and was otherwise identical to
the active material. The active material could not be identified from the placebo according to flavor
or appearance.
The cod protein hydrolysate was produced by enzymatic hydrolysis of fresh frozen meat (cuttings
and trimmings) from Atlantic cod (Gadus morhua). A batch of 500 kg frozen raw material was grounded,
transferred to an incubator and mixed with sweet water at a ratio of 1:1, followed by stirring at 80 rpm
and heating to 55 ◦C. The enzyme preparation Protamex® (Novozymes AS, Copenhagen, Denmark)
was then added, following incubation for 45 min, at 55 ◦C and pH 7.0. The preparation (incubate) was
heated to 90 ◦C for 15 min to inactivate the enzyme. The enzyme-inactivated incubate was passed
through a rotating sieve (Swenco, Sweden) to remove any bone fragments. A two-phase centrifugation
(Alfa Laval AS, Denmark) was used to separate the peptide-containing water-soluble fraction (the
hydrolysate) from the indigested residue. This was followed by ultrafiltration and dehydration of the
soluble phase to a 50% dry matter concentrate, which was spray dried to a powder. The spray dried
CPH powder contained 89% crude protein, 0% carbohydrate, <0.2% fat, 0% carbohydrate, <3.0% water,
0.1% sodium chloride, 1.7% sodium, 0.07% chloride and 10% ash. Of the total amino acid content in the
hydrolysate, the free amino acids constituted 4.77%, and the ratio between essential amino acids and
non-essential amino acids was 0.70. When analyzing the molecular weight (MW) of the hydrolysate,
approximately 90% of the peptides present in the hydrolysate had a MW of 2000 Daltons (Da) or
less, which corresponds to peptides consisting of 18 amino acids or less. Furthermore, approximately
75% had a MW of 1000 Da or below, corresponding to 10 amino acids or less, and 55% had a MW of
500 Da, corresponding to 5 amino acids or less. Approximately 25–30% of the hydrolysate was small
dipeptides and free amino acids, with a MW of less than 200 Da. The composition of amino acids and
taurine content of the spray dried CPH powder are given in a previous publication [16].
2.6. Estimation of Energy and Macronutrient Intake
To determine individual diet habits, the participants recorded food and drink intake in a three-day
prospective food diary, including one weekend day, before the baseline visit and before the end of
study visit. Energy and protein intake from the supplement was added to the end of study dietary
records (CPH group: 44 kcal, 4 g protein; placebo group: 46.5 kcal, 0 g protein). We used dietary
records to evaluate whether any changes were made in the participants diets during the intervention
period and to record diet patterns. Calculations of energy and macronutrient intake were determined
using “Kostholdsplanleggeren” [27].
2.7. Analyses of Blood Samples
Samples for safety purposes (albumin, prealbumin, leucocytes, thrombocytes, hemoglobin, sodium,
potassium, alanine aminotransferase, alkaline phosphatase, creatinine and aspartate aminotransferase)
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were taken at the screening and end of study visit. Glycated hemoglobin (HbA1c), total-C, TAG,
LDL-C, HDL-C and fasting and postprandial serum insulin and glucose were measured at baseline
and end of study visit. All tests were analyzed according to standard accredited methods at the routine
hospital laboratories (Department of Medical Biochemistry and Pharmacology, HUH, and Department
of Medical Biochemistry, Ålesund Hospital).
Samples for GLP-1 determination were collected in Vacuette® EDTA-K2 tubes, ref#454047 (Greiner
Bio-One GmbH, Frickenhausen, Germany), with 20 µL dipeptidyl peptidase-4 inhibitor (DPP4-010; DRG
Diagnostics, Marburg, Germany) added prior to sampling. Plasma for fasting and postprandial GLP-1 at
baseline and end of study was obtained by centrifugation of EDTA blood at 1800× g and −4 ◦C for 10 min,
within 20 min after blood sampling. Plasma GLP-1 was analyzed by ELISA method (GLP-1, Active form
(High Sensitivity ELISA), Code No. 27700, (Immuno-Biological Laboratories Co., Ltd., IBL Japan)).
2.8. Randomization
To allocate the participants, we used a web-based data collection and randomization system
developed and administered by the Norwegian University of Science and Technology, Trondheim,
Norway. We used block randomization to create the random assignment order and stratified for center
(Ålesund or Bergen). A person with no practical involvement in the trial coded the test materials.
The participants, study investigator, and all other personnel involved in this study were blinded to
group allocation. Study investigators were given the key of randomization after the trial was finished
and the statistical analyses were carried out.
2.9. Statistical Analyses
We performed statistical analyses by IBM SPSS Statistics, Version 26.0 (IBM Corp., Armonk, NY,
USA) and GraphPad Prism version 8.4.1 (GraphPad Software, Inc., San Diego, CA, USA. The latter
was used for graphical work. The data is presented as the mean ± SD, unless otherwise stated.
Normality was evaluated by the Shapiro–Wilk test and histograms, and non-normally distributed data
was log-transformed before using parametric statistical tests. We tested changes within groups from
baseline to end of study by the paired sampled t-test, and changes between groups by the independent
samples t-test. We examined group differences over time for continuous outcome (postprandial
measurements of insulin, glucose and GLP-1) in a linear mixed-effects model with repeated measures.
The trapezoid rule was used when calculating the area under the curve (AUC) using only end of study
day, comparing the active and placebo group. Level of significance was set to p < 0.05. Two participants
in the placebo group were excluded from the statistical analysis of lipid parameters (TAG, total-C,
LDL-C and HDL-C), due to the use of lipid-lowering drugs (Simvastatin (Zocor), Atorvastatin).
To our knowledge, the possible effects of supplementation with a hydrolyzed cod protein have
not been investigated previously in overweight and obese subjects with MetS. Due to a lack of similar
studies, a power calculation was not performed. According to the protocol, we planned to recruit
60 participants in this study, with 30 participants in each group (a minimum of 20 in each group). This is
a number similar to what has been previously reported in studies with supplementation of low doses
of cod protein in humans [20,21]. We did not reach the target population due to difficulties with the
recruitment of eligible participants. Participants were recruited between April and September 2019, but
due to time constraints and limited resources, the inclusion of new participants had to stop in September.
3. Results
3.1. Participants
Of 58 participants attending the screening visit, 35 subjects had MetS and could be included in the
trial. Four participants withdrew before randomization. Thirty participants completed the intervention
according to study protocol and were included in the statistical analysis (Figure 1). At the screening
visit, the groups were comparable (Table 1).
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Mean SD Mean SD
Gender (female/male) 11/4 13/2 0.651
Age, years 52.8 6.26 53.4 6.83 0.804
Anthropometric measurements
Body weight, kg 96.5 12.8 93.4 12.2 0.509
WC, cm 107.6 9.72 105.7 10.7 0.630
BMI, kg/m2 32.7 2.24 32.4 3.25 0.751
Blood pressure (BP)
Systolic BP, mmHg 136.9 15.9 138.5 15.1 0.756
Diastolic BP, mmHg 88.2 10.1 86.7 6.44 0.702
Glucose metabolism
Glucose, mmol/L 5.73 0.75 5.63 0.79 0.704
HbA1c, mmol/mol 37.5 4.47 35.7 3.40 0.208
Lipid metabolism
Total cholesterol, mmol/L 5.8 1.1 5.5 0.8 0.466
HDL cholesterol, mmol/L 1.3 0.3 1.4 0.2 0.493
LDL cholesterol, mmol/L 4.2 0.1 3.9 0.8 0.334
Triacylglycerol, mmol/L 2.10 0.7 2.05 0.6 0.870
Numbers using BP medications 5 9 -
Tobacco users 1 2 -
SD, standard deviation; WC, waist circumference; BMI, body mass index BP, blood pressure; BW, body weight;
Hba1c, glycated hemoglobin. Results are presented as the mean ± SD. Groups were compared at baseline using
independent samples t-test for continuous data and Fisher’s Exact Test for categorical data.
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3.2. Estimated Intake of Energy and Macronutrient
The estimated intake of energy and macronutrients calculated from the dietary records did not
differ between the groups at baseline, and we did not observe any changes within or between groups
during the course of this study (Table 2).
Table 2. Estimated energy and macronutrient intake in the cod protein hydrolysate (CPH) group
(n = 15) and the placebo group (n = 15) at baseline and end of study (8 weeks).
Variable
Baseline 8 Weeks
p-Value 2 p-Value 3 p-Value 4
Mean SD Mean SD
Energy intake, kcal/day 0.668 0.726
CPH 1882 485 1777 466 0.177
Placebo 1812 386 1746 410 0.406
Protein, g/kg BW/day 0.922 0.815
CPH 0.91 0.22 0.85 0.24 0.357
Placebo 0.91 0.29 0.87 0.23 0.569
Fat, g/day 0.122 0.396
CPH 84.9 24.4 77.8 24.2 0.128
Placebo 71.9 20.2 70.2 24.99 0.723
Carbohydrate, g/day 0.323 0.488
CPH 193.2 46.0 191.7 51.3 0.848
Placebo 211.1 51.5 198.4 49.3 0.207
Basal metabolic rate1, kcal 0.579 0.743
CPH 1760 334 1774 350 0.211
Placebo 1696 296 1700 264 0.399
SD, standard deviation; BW, body weight. 1 Derived from the bioimpedance analysis. 2 p-values comparing groups
at baseline are based on independent samples t-test. 3 p-values within groups based on paired sample t-test. 4
p-values comparing change between groups are based on independent samples t-test. Data is based on the mean
values from a three-day dietary records. Energy and protein content from the supplement was added to the end of
study data—CPH group: 4 g protein, 44 kcal; placebo group: 0 g protein, 46.5 kcal. Results are presented as the
mean ± SD.
3.3. Anthropometric Measurements
Body weight (kg), fat mass (kg, %), fat-free mass (kg), BMI (kg/m2) or total body water (kg) did
not differ within or between the groups (Table 3). Waist circumference increased within both the CPH
group and the placebo group, but no differences were observed when comparing the two groups
(Table 3).
3.4. Glucose Homeostasis
Adjusted for time and visit, the glucose levels were on average 0.55 mmol/L higher for CPH
compared to placebo, but the linear mixed-effects model with repeated measures did not reveal any
significant differences between the groups (95% CI: (−0.44, 1.53), p = 0.267). We observed no change
in glucose levels from baseline visit to end of study visit in either of the two groups (overall change:
−0.014 mmol/L, 95% CI: (−0.19, 0.16), p = 0.876) (Figure 2a). Similarly, no difference in insulin levels
was observed between the two groups after 8 weeks intervention. The insulin levels were on average
0.63 mIU/L higher for CPH compared to placebo (95% CI: (−31.32, 32.58), p = 0.968), and we did
not observe any changes in insulin levels from baseline visit to end of study in either of the groups
(overall change: 0.57 mIU/L, 95% CI: (−4.79, 5.92), p = 0.836) (Figure 2c). Furthermore, no difference in
fasting or postprandial GLP-1 levels was observed between the two groups. The GLP-1 levels were on
average 0.83 pmol/L higher (back transformed estimate) for participants who received CPH compared
to placebo, but this was not significantly different (95% CI: (0.61, 1.13), p = 0.221). We did not observe
any changes in GLP-1 levels from baseline visit to end of study visit in either of the groups (overall
change: 0.95 pmol/L, 95% CI: (0.90, 1.01), p = 0.079) (Figure 2e).
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Table 3. Anthropometric measurements and results from the bioimpedance analysis (BIA) in the cod
protein hydrolysate (CPH) group (n = 15) and the placebo group (n = 15) at baseline and end of study
(8 weeks).
Variable
Baseline End of Study
p-Value2 p-Value3
Mean SD Mean SD
Body weight, kg 0.557
CPH 96.02 13.6 96.14 13.8 0.715
Placebo 93.15 12.7 92.93 12.2 0.694
BMI, kg/m2 0.603
CPH 32.55 2.43 32.59 2.51 0.741
Placebo 32.27 3.45 32.21 3.49 0.692
Waist circumference1 0.512
CPH 105.5 9.72 108.8 7.25 0.014
Placebo 105.9 10.7 108.2 9.49 0.040
Fat mass, % 0.897
CPH 39.91 6.79 39.50 7.12 0.211
Placebo 40.21 5.37 39.75 5.47 0.105
Fat mass, kg 0.834
CPH 38.16 7.81 37.82 8.12 0.319
Placebo 37.46 7.05 37.03 7.46 0.163
Fat-free mass, kg 0.816
CPH 57.81 11.54 58.33 12.01 0.221
Placebo 55.71 10.08 55.92 9.02 0.301
Total body water, kg 0.325
CPH 42.39 8.47 42.45 8.89 0.974
Placebo 41.29 7.34 40.64 6.77 0.322
SD, standard deviation; BMI, body mass index. 1 For waist circumference, the results are data measured at the
screening visit, and presented for only n = 13 in the CPH group and n = 14 in the placebo group due to missing
values. 2 P-values within groups are based on paired samples t-test. 3 P-values comparing change between groups
are based on independent samples t-test.
We observed no significant interactions between group and visit (baseline vs. end of study), group
and time, time and visit or between group, visit and time for insulin, glucose or GLP-1. The AUC
calculated from the fasting through the postprandial test points did not reveal any significant differences
in insulin, glucose or GLP-1 levels between the CPH group and placebo group after 8 weeks (Figure 2b,
d and f, respectively).
At baseline, HbA1c was on average 37.5 ± 4.47 mmol/mol in the CPH group and
35.7 ± 3.40 mmol/mol in the placebo group, with no differences between groups (mean diff: 1.87,
95% CI: (−1.102, 4.835), p = 0.208). HbA1c did not change during the supplementation period within
the CPH group (mean diff: 0.40 mmol/mol, 95% CI: (−1.15, 1.95), p = 0.589) or the placebo group (mean
diff: 0.00, 95% CI: (−1.24, 1.24), p = 1), and there was no difference between the groups (mean difference:
0.40, 95% CI: (−1.49, 2.29), p = 0.669).
3.5. Lipid Parameters
At baseline, no differences between the groups were observed for fasting TAG, HDL-C, LDL-C,
total-C or total-C: HDL-C ratio. Fasting total-C and LDL-C were significantly decreased within both
groups after 8 weeks of intervention, with no differences between the groups (Figure 3). Fasting TAG
was reduced within the CPH group (mean diff: −0.81 mmol/L (back transformed estimate), 95% CI:
(0.694, 0.948), p = 0.012), but did not differ from placebo (Figure 3). We did not observe any changes
within or between groups for for fasting HDL-C and total-C: HDL-C ratio during the course of the
study (Figure 3).
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Figure 3. Fasting and change in serum levels of triacylglycerol (TAG) (a,b), total cholesterol (total-C)
(c,d), high-density lipoprotein cholesterol (HDL-C) (e,f) and low-density lipoprotein cholesterol (LDL-C)
(g,h) in subjects with MetS after 8 weeks intervention with cod protein hydrolysate (CPH) (n = 15) or
placebo (n = 13). Two subjects from the placebo group were excluded from the statistical analyses of
lipid parameter due to the use of lipid-lowering drugs. A (c,e,g), results are presented as individual
graphs with fasting levels at baseline and end of study for each subject, with bars showing the mean in
each group. p-values were calculated from a paired samples t-test. B (d,f,h), changes were calculated as
individual end of study values minus baseline values for each of the indicators. Results are presented
as the mean difference. p-values were calculated using the independent samples t-test. Significant
p-values are marked with asterisk (*).
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3.6. Adverse Effects
Biochemistry for safety purposes were all within normal range. Seven participants reported
discomfort during the intervention period—four in the CPH group and three in the placebo group.
One participant in the CPH group reported that the supplement tasted bad and caused retching.
Two participants in the CPH group reported heartburn, and two reported nausea at the beginning of
the intervention period, but this was transient. In the placebo group, one participant reported myalgia,
one reported itchy rash in the face and one reported nausea, but all three participants were unsure
whether these experiences were related to the intervention.
4. Discussion
The main aim of this study was to investigate whether daily supplementation with low doses of
CPH for 8 weeks would have effect on fasting and postprandial glucose levels in participants with
MetS. We hypothesized that supplementation with CPH would lead to beneficial changes in glucose
metabolism and an overall healthier metabolic profile. We did not observe any significant effects of
the supplement on the primary outcome measure (fasting and postprandial glucose levels) when
compared to placebo. Furthermore, we found no effect on fasting or postprandial insulin or GLP-1
levels, lipid parameters or body composition after 8 weeks supplementation with CPH.
Previous human intervention studies have reported improvements in postprandial glucose and
insulin levels after supplementation with fish protein [20,28], and similar findings have been observed
in animal studies [14,29,30]. Furthermore, we have previously shown that the postprandial insulin
concentration in serum was significantly lower in normal-weight adults given one single dose of CPH
compared to control (unhydrolyzed casein), without an effect on glucose levels [31]. Considering
that the subjects in the current trial had MetS, the lack of effect is surprising, but there could be
several reasons for this. Firstly, we gave the participants a fixed dose of 4 g of CPH, whereas we used
weight-adjusted doses of CPH in previous studies, to reduce the effect of body weight variations [16,31].
In the current trial, the participants in the CPH group had a body weight ranging from 77 to 133 kg,
meaning variation from 52 to 30 mg/kg body weight of CPH per day, which could possibly affect the
overall results. It was not feasible to weight-adjust the doses in the current trial, and we therefore
chose to use a fixed dose similar to what has been used in other studies and based on results from a
previous study conducted by our research group [20,21,31]. Secondly, the participants in the current
trial only received a daily morning dose of CPH. Previous studies have suggested that distributing
the doses throughout the day might lead to a more potent effect due to a constant flow of bioactive
peptides in circulation [32,33].
The estimated average daily protein intake for participants in the CPH group was 85 g/day, and
only 4.7% of the total daily protein intake came from the supplement. Therefore, we do not presume
the protein intake as such to cause any effect on postprandial glucose regulation and lipid profile. We
believe that an effect may be due to particular peptide sequences in the supplement. Bioactive peptide
sequences have been identified in other fish protein hydrolysates [34]. We did not test for the presence
of such sequences in this particular study, which would have strengthened the design.
Dietary proteins play a role in the regulation of lipid metabolism, and beyond the quantity of
protein, the composition of amino acids and bioactive peptides are suggested to be of importance [35].
Associations between a high intake of lean fish and reduced levels of serum TAG [5,8], as well as
increased levels of HDL-C [8], have been reported in previous cross-sectional studies. Beneficial effects
have also been reported from intervention studies in animals and humans [36–38]. In the current trial,
we observed a significant reduction in serum fasting TAG levels in the CPH group, with a decline of
18% from baseline to end of study. Considering that a weight reduction of 5–10% has been shown to
cause a 20–30% reduction in TAG levels, whereas general improvement of nutrition-related practices
can lead to a TAG-lowering effect of between 20 and 50% [39], a reduction of 18% in TAG levels after
8 weeks of supplementation with CPH, with no change in body weight or composition, is interesting.
However, these changes did not differ from the placebo group, hence the results should be interpreted
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with caution. In line with findings from previous intervention studies with low doses of cod protein in
healthy, overweight adults [20] and normal-weight adults [33], we observed reduced levels of LDL-C
within the CPH group. However, a reduction in LDL-C was also observed within the placebo group,
and no differences were found when comparing the two groups. Overall, we did not observe any
effects of 8 weeks CPH supplementation on lipid parameters.
Proteins are considered to be the most satiating of the macronutrients [40], and there are indications
that fish protein, compared to other animal proteins like beef and chicken, have a greater effect on
satiety [41]. The gut hormone, GLP-1, released in response to intake of food from the enteroendocrine L
cells, is involved in appetite regulation and contributes to glycemic control by slowing gastric emptying,
stimulating insulin secretion and suppressing the secretion of glucagon [42–44]. A previous study
in overweight individuals found increased levels of GLP-1 after 3 months supplementation with 1.4
and 2.8 g of blue whiting hydrolysate, when compared to placebo (whey protein isolate) [17]. In the
current trial, we did not see any effect of supplementation with 4 g of CPH for 8 weeks on fasting
or postprandial GLP-1 levels. In the trial by Nobile et al. [17], all groups had a caloric restriction of
−300 kcal per day, which may have influenced the result and might suggest that a reduction in calories
in combination with supplementation of fish protein hydrolysate is a more effective approach than
supplementation alone.
There are some limitations to the present study. Firstly, the lack of a power analysis and the
small number of subjects per group might explain why we were not able to observe any effect of the
intervention. Secondly, we did not reach the target population according to protocol, due to difficulties
with recruiting eligible subjects and strict inclusion and exclusion criteria. We had to stop the inclusion
period due to time constraints and limited resources, and the low number of subjects might have
compromised this study. By choosing a cross-over design, we could have recruited fewer subjects and
strengthened the design. This was not done in the current trial due to the long intervention period,
which would require at least 4 weeks wash-out period in between the two experimental periods and the
possibility of a high drop-out rate. Furthermore, participating in an intervention study may influence
eating patterns and lead to underreporting of dietary intake. We instructed the participants to continue
eating and activity level as normal during the course of this study, and we did not observe any changes
in dietary intake or body weight. However, the estimated energy intake from the diet diaries were
lower than anticipated according to weight. It should also be mentioned that body composition was
assessed with BIA, which is suggested to be effective in healthy individuals and individuals with a
stable water and electrolyte balance. The results should be interpreted with caution in individuals with
BMI >34 kg/m2 [45], and overestimating of fat-free mass has been observed when using BIA compared
to dual-energy x-ray absorptiometry in obese subjects with BMI >35 kg/m2 [46]. Since the average BMI
in the current study was 32.5 kg/m2, we assume that the results from the BIA analysis are reliable.
No previous publication, to our knowledge, has investigated supplementation with a low dose
of a hydrolysate from cod in a population with MetS. To conclude, in this study, we showed that
consumption of 4 g of a CPH daily for 8 weeks in individuals with MetS had no effect on fasting or
postprandial glucose, insulin levels or GLP-1 levels, lipid profile or body composition. Studies in the
future should further evaluate the effect of fish protein hydrolysate on lipid regulation, and preferably
with a larger group of participants over a longer time period. Furthermore, the presence of potential
bioactive peptide sequences with antidiabetic or lipid-lowering effects in the cod protein hydrolysate
and the potential mechanism of effect should be explored further.
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Abstract: Metabolic syndrome (MetS) is characterised by metabolic abnormalities that increase the risk
of developing type 2 diabetes mellitus and cardiovascular disease. Altered levels of circulating ghrelin,
several adipokines and inflammatory markers secreted from adipose tissue, such as leptin, adiponectin,
tumor necrosis factor alpha, are observed in overweight and obese individuals. We assessed the effect
of supplementation with low doses of a cod protein hydrolysate (CPH) on fasting and postprandial
levels of acylated ghrelin, as well as fasting levels of adiponectin, leptin and inflammatory markers
in subjects with MetS. A multicentre, double-blinded, randomized controlled trial with a parallel
group design was conducted. Subjects received a daily supplement of CPH (4 g protein, n = 15) or
placebo (0 g protein, n = 15). We observed no effect on fasting or postprandial levels of acylated
ghrelin, fasting levels of adiponectin (p = 0.089) or leptin (p = 0.967) after supplementation with CPH,
compared to placebo. Overall, our study showed that 8 weeks supplementation with a low dose of
CPH in subjects with MetS had no effect on satiety hormones or most of the inflammatory markers,
but the levels of high-sensitivity C-reactive protein were statistically significantly different in the
CPH-group compared to placebo group. The robustness and clinical relevance of these findings
should be explored in future studies with a larger sample size.
Keywords: cod protein hydrolysate; satiety hormones; inflammatory markers; metabolic syndrome
1. Introduction
Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities including abdominal
obesity, hypertriglyceridemia, low levels of high-density cholesterol, hyperglycemia and hypertension,
increasing the risk of cardiovascular disease and type 2 diabetes mellitus (T2DM) [1,2]. The pathogenesis
of MetS is not fully understood, but a genetic predisposition combined with a sedentary lifestyle and
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Nutrients 2020, 12, 3421 2 of 13
excessive caloric intake, are known to be important risk factors [3]. A positive energy balance over time
leads to increased storage of fat in the adipocytes with expansion of adipose tissue, resulting in increased
production of pro-inflammatory cytokines such as interleukin 6 (IL-6) and tumor necrosis factor alpha
(TNF-α) [3,4]. These cytokines and other signaling molecules secreted from the adipose tissue are
involved in several physiological processes in the body, such as regulation of energy homeostasis,
body fat accumulation and inflammation [5–7].
Inflammation is the immune system’s response to an injurious stimulus, initiating a cascade of
events promoting healing of the affected tissue [8]. Signaling pathways are activated as part of the
inflammatory response, leading to the release of inflammatory mediators, including interleukin-1
beta (IL-1β), IL-6 and TNF-α [9,10]. Even though the acute inflammatory response is essential,
the process may develop to a chronic inflammatory state, known to be involved in the development of
several chronic diseases, such as diabetes [9]. Fish consumption has been linked to reduced levels of
inflammatory mediators, such as IL-6 and TNF-α in rats [11,12] and healthy adults [13]. Lower levels
of C-reactive protein (CRP), a marker of inflammation, have been observed in insulin-resistant
subjects given a diet with lean fish (cod) for 4 weeks [14], with no effect observed when overweight
individuals were given a low dose of cod protein supplementation [15]. The mechanism behind the
possible anti-inflammatory effect of fish is largely unknown, but it has been suggested that the high
taurine content in fish may have anti-inflammatory properties by suppressing IL-6 and TNF-α [12,16].
There are also indications from cell and animal studies, that bioactive peptides from lean fish have
anti-inflammatory effects [9,17], with a need for further investigation in humans.
The secretion of IL-6, IL-8 and other cytokines are inhibited by adiponectin, a signaling molecule
released from adipose tissue [4,18]. This molecule is known to enhance insulin sensitivity [4],
and reduced levels have been reported in subjects with obesity and T2DM [5,19]. In contrast, increased
levels of leptin, a hormone involved in regulation of food intake and appetite [7,20], have been
reported in obese subjects [19]. Furthermore, consumption of fish and supplementation with n-3
polyunsaturated fatty acids (PUFAs) increase levels of adiponectin [19,21,22], with similar results
reported after supplementation with cod protein in overweight and obese subjects [23]. For leptin,
published data are conflicting [19,21,23,24]. As leptin and adiponectin seem to be altered in subjects
with obesity and associated with factors of MetS, an effect on these adipokines by supplementation
with fish protein, might be a possible preventive strategy for the development of MetS.
Ghrelin, a small peptide hormone secreted from the stomach, is an appetite-stimulating hormone
with the opposite effects of leptin [25]. The levels of ghrelin increase before a meal and decrease
postprandially [26], and is involved in regulation of appetite, energy balance and body weight [27].
Compounds that may inhibit the action of ghrelin and suppress appetite, may be beneficial for both
prevention and treatment of components of MetS, such as obesity, impairments in lipid metabolism
or glucose homeostasis [28]. We have previously reported the effect of low doses of a cod protein
hydrolysate (CPH) on fasting and postprandial levels of acylated ghrelin in healthy adults [29].
We observed that a single dose of 20 mg/kg body weight of CPH did not affect postprandial levels of
acylated ghrelin or sensations related to feeling of hunger, when compared to the control group [29].
Limited data exists on long-term supplementation of cod protein in a population with metabolic
abnormalities, yet it is an important abnormality to study. We have previously reported on the effects
on fasting and postprandial glucose metabolism, as well as lipid metabolism and body composition
in subjects with MetS after supplementation with 4 g of CPH for 8 weeks [30]. In the present study,
we aimed to investigate if daily supplementation with the same low dose of CPH for 8 weeks would
influence circulating levels of ghrelin, adiponectin, leptin, high-sensitivity CRP (hs-CRP) and a selection
of other inflammatory markers.
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2. Materials and Methods
2.1. Study Design
We performed a multicenter, double-blinded, randomized parallel group trial with one daily dose
of 4 g CPH or placebo for 8 weeks. Here, we report secondary outcomes; fasting and postprandial levels
of acylated ghrelin and fasting levels of adiponectin, leptin and inflammatory markers. The study was
conducted according to the Declaration of Helsinki and all procedures were approved by the Regional
Committee for Medical and Health Research Ethics of Central Norway (2018/2163). Written informed
consent was obtained from all subjects. The trial is registered at www.clinicaltrials.gov (NCT03807752).
2.2. Subjects and Study Setting
We recruited participants between March and September 2019 in the Bergen and Ålesund area
(Norway) through an online recruitment questionnaire with advertisements on social media, at the
participating hospitals and at general practitioners’ offices. Inclusion criteria were diagnosis of MetS,
body mass index (BMI) between 27–35 kg/m2 and age between 40–70 years. Exclusion criteria were
intolerance or allergy to fish and/or shellfish, chronic diseases or medication that were likely to interfere
with the evaluation of study endpoints (e.g., T2DM, medications known to affect glucose metabolism),
acute infections, abuse of alcohol or drugs (assessed by a physician) or unwillingness to comply with
the study requirements. We included participants using calcium channel blockers (n = 3) agents acting
on the renin-angiotensin system (i.e., ACE inhibitor n = 2, AII-receptor agonist n = 5, AII-receptor
agonist/thiazide diuretic n = 3), since blood pressure was not an outcome. The participants were
excluded if they had recently started with the current medication, if they had changed the dose level
during the last 3 months or if it was changed during the study. Subjects using beta-blocking agents or
peripheral vasodilators were excluded.
In this study, the Joint Interim Statement definition of MetS was used [1], where three abnormal
findings out of five given risk factors qualifies for a diagnosis of MetS. The following risk factors and
criteria were used: serum triglycerides ≥ 1.7 mmol/L, high-density lipoprotein cholesterol < 1.0 mmol/L
in men and < 1.3 mmol/L in women, serum glucose ≥ 5.5 mmol/L, systolic blood pressure ≥ 130 mmHg
and/or diastolic blood pressure≥ 85 mmHg [1]. For waist circumference (WC), we used the International
Diabetes Federation cut-off points for central obesity: WC ≥ 94 cm in men, ≥ 80 cm in women [31].
2.3. Study Visits
After prescreening by telephone, we invited potential participants to a screening visit to
assess eligibility, including inclusion and exclusion criteria. The screening visit included a clinical
examination by a physician, review of medical history, measure of vital signs (blood pressure,
heart rate), anthropometric measures (height, weight and WC) and blood sampling. We measured
height (to the nearest 0.1 cm) and weight (to the nearest 0.1 kg) with an electronic scale (Seca 285,
SECA GmbH, Hamburg, Germany). For measurements of WC, the WHO recommendation was
followed [32,33]; the midpoint between the lower/inferior palpable rib and the top of iliac crest was
located, the participants had arms relaxed at the side and the measurements were made at the end
of normal expiration, using a measuring tape with constant tension. Changes in physical activity
during the study period, as well as changes to food consumption were prohibited. The participants
recorded their intake of food and drink in a three-day prospective food diary, before the baseline
visit and end of study visit. Energy and protein intake from the supplement were added to the end
of study dietary records (CPH group: 44 kcal, 4 g protein; placebo group: 46.5 kcal, 0 g protein).
Details about the end of study energy intake is reported in a previous publication [30]. Calculations of
energy and macronutrient intake were determined using “Kostholdsplanleggeren” (Norwegian Food
Safety Authority, Norwegian Directorate of Health, Oslo) [34]. The participants had to stop the use
of n-3 PUFA-containing dietary supplements for four weeks prior to starting the study, and this was
prohibited for the duration of the study.
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After inclusion, the participants attended two identical study visits: the baseline visit and end
of study visit (after 8 weeks of intervention). The participants came to the research facility between
08:00 AM–09:00 AM in a fasting state (no eating, drinking or use of any nicotine-containing substance
after 09:00 PM the previous evening). When they arrived, fasting blood samples were taken followed
by anthropometric measurements. Body composition was measured by a bioelectrical impedance
analysis device (Body Composition Analyzer, Tanita Corporation, Tokyo, Japan, BC-418 MA (model
used in Ålesund), or MC-180 MA (model used in Bergen)) according to the manufacturer’s instructions.
The participants then consumed a standardized breakfast meal (test meal) consisting of two slices
of semi-dark bread (50% whole wheat, 80 g weight), 10 g margarine, 25 g strawberry jam and 20 g
white cheese and 1.5 dL orange juice. The meal contained 1840 kJ (440 kcal), 69 g carbohydrate,
13.3 g protein, 14.3 g fat. The energy and macronutrient content of the test meal were calculated
using “Kostholdsplanleggeren” [34]. The meal had to be consumed within 15 min and was followed
by postprandial blood sampling. Blood was drawn from an antecubital vein prior to the test meal
(−20 min), at 0 min (i.e., immediately after the meal was consumed), and thereafter at 20, 40, 60, 80,
100 and 120 min. No coffee or tea were served during test hours, but we allowed free drinking of water.
We handed 8 weeks supply of the pre-packed test material (active or placebo) to the participants at
the end of the baseline study visit. They started the intervention on the following day and took the
supplement daily, 10 min before breakfast, for 8 weeks. Since the participants met fasting at both study
visit, they did not take the study supplement at home before the end of study visit.
2.4. Test Material
The test material was manufactured by Firmenich Bjørge Biomarin AS (Ålesund, Norway),
and delivered pre-packed in sealed plastic-coated aluminium bags. It was a lemon-flavored powder to
be mixed with 100 mL cold water before ingestion. The powder bags with intervention material (CPH)
contained 4 g of hydrolysed cod protein, 5 g glucose hydrate, 2 g maltodextrin, 0.025 g tastegram
powder flavour, 0.1 g lemongrass durarome taste and 0.7 g citric acid. The placebo contained 6.5 g of
maltodextrin, 0.2 g citric acid, and was otherwise identical to the intervention material. It was not
possible to identify the CPH-material from the placebo, according to flavour or appearance.
The CPH was made by enzymatic hydrolysis of fresh frozen meat (cutting and trimmings) of
Atlantic cod (Gadus morhua), adding the enzyme preparation Protamex® (Novozymes AS, Copenhagen,
Denmark) for 45 min, at 55 ◦C and pH 7.0. This was followed by inactivation of the enzyme, with heating
to 90 ◦C for 15 min. The peptide containing water-soluble fraction (the hydrolysate) was separated
from the indigested residue, followed by ultrafiltration and dehydration of the soluble phase to a 50%
dry matter concentrate. This was spray-dried to a powder. The spray-dried CPH powder contained
89% crude protein and <0.2% fat, 0% carbohydrate, <3.0% water, 10% ash, 0.1% NaCl, 1.7% sodium
and 0.07% chloride, by weight. Free amino acids accounted for 4.8% of the total amino acids in the
hydrolysate, and the ratio between essential amino acids: non-essential amino acids was 0.70. Analysis
of the molecular weight distribution, as well as the composition of amino acids and taurine content of
the spray dried CPH powder is given in a previous publication [35].
2.5. Analyses of Blood Samples
Albumin, prealbumin, leucocytes, thrombocytes, hemoglobin, sodium, potassium, alanine
aminotransferase, alkaline phosphatase, creatinine and aspartate aminotransferase, were analyzed at
inclusion and end of study by standard accredited methods at Department of Medical Biochemistry
and Pharmacology, Haukeland University Hospital (HUH), and Department of Medical Biochemistry,
Ålesund Hospital.
Serum for analyses of hs-CRP, adiponectin, leptin and inflammatory markers were obtained by
centrifugation of full blood at 2000× g at room temperature (20 ◦C) for 10 min after 30–60 min of
coagulation, using serum separator cloth activator tubes. Hs-CRP was analyzed by standard accredited
methods at the Department of Medical Biochemistry and Pharmacology, HUH. Serum adiponectin and
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leptin were analyzed using Human Adiponectin High Sensitivity ELISA kit (Cat. No.: RD191023100,
Biovendor, Brno, Czech Republic) and Human Leptin ELISA, Clinical Range kit (Cat. No: RD191001100,
Biovendor) respectively. TNF-α and IL 1β, IL 6, and IL 8 were analyzed by the Cytokine human
ultrasensitive magnetic 10-plex panel for LuminexTM platform (Cat.No: LHC6004M, Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA). Leptin, adiponectin, as well as the inflammatory
markers, were only measured and analyzed in the fasted stated.
Samples for ghrelin measurement were collected in Vacuette® EDTA Aprotinin tubes (Item No:
454261, Greiner Bio-One International GmbH, Kremsmünster, Austria), added 34 µL 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride (AEBSF) Ready-made solution (Item No: SBR00015,
Sigma-Aldrich, Saint-Louis, MO, USA), right after blood sampling. Plasma for fasting and postprandial
ghrelin at baseline and end of study was obtained by centrifugation of EDTA blood at 1800× g at
−4 ◦C for 10 min, within 20 min after blood sampling. Ghrelin levels were analyzed using the Ghrelin
Acylated Human Easy Sampling ELISA (Cat.No: RA194062500R, Biovendor)
2.6. Randomization
To allocate the study participants, we used wCRF®, a randomization and data collection system
developed by the Norwegian University of Science and Technology, Trondheim, Norway. The random
assignment order was created using block randomization, and we stratified for center (Ålesund or
Bergen). A person with no direct involvement in the study coded the test materials and the participants,
as well as all study personnel involved in the study implementation and data handling, were blinded
to group allocation.
2.7. Statistical Analyses
We performed statistical analyses using IBM SPSS Statistics for Windows, Version 26.0 (IBM Corp.,
Armonk, NY, USA) and GraphPad Prism version 8.4.2 (GraphPad Software, Inc., San Diego, CA, USA).
The Shapiro-Wilk test and histograms were used to evaluate normality. For data not following a normal
distribution and not improved by log-transformation, we used non-parametric tests. The Wilcoxon’s
Signed Rank Test was used to investigate changes from baseline to end of study within groups, and
the Independent Samples Mann Whitney U Test was used to compare changes (8 weeks—baseline)
between the CPH and placebo group at end of study. These data (adiponectin, leptin, hs-CRP and
inflammatory markers) are presented as median and interquartile range. A linear mixed-effects model
with repeated measures was used to examine group differences over time for fasting and postprandial
measurements of ghrelin. A Pearson’s correlation coefficient analysis was used to examine relationship
between fasting levels of acylated ghrelin at baseline and change in body weight (kg) and BMI (kg/m2).
The level of significance was set to p < 0.05. A power calculation was not done in the original study due
to lack of data to base it upon [30]. Therefore, no estimation of sample size of the current measurements
was done prior to the study. According to protocol, we planned to recruit 60 subjects in the study,
which is a number similar to what have been reported in other supplementation studies with low
doses of cod protein [15,36].
3. Results
3.1. Participant Characteristics
We screened a total of 147 participants for compliance with inclusion and exclusion criteria by
telephone and invited 68 participants for a screening visit. Fifty-eight attended the screening visit and
30 participants were included and completed the intervention according to study protocol (Figure 1).
Baseline characteristic are presented in Table 1.
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3.2. Adiponectin and Leptin
No statistically significant differences between the groups were observed for adiponectin (p = 0.806)
or leptin (p = 0.367) at baseline. At end of study, the fasting adiponectin concentration was significantly
increased within the CPH group (baseline: 7.98 (5.68, 11.06) µg/mL, end study: 8.84 (6.06, 13.7) µg/mL),
p = 0.008), with no changes observed within the placebo group (baseline: 7.89 µg/mL (7.06, 10.53),
end of study: 7.82 (7.07, 11.90) µg/mL, p = 0.910) (Figure 2a). The median adiponectin change
(8 weeks—baseline) in the CPH group was 0.56 (0.25, 1.71) µg/mL, and −0.12 (−0.56, 1.07) µg/mL in the
placebo group. When comparing the change in fasting levels of adiponectin, no statistically significant
difference between groups was observed (p = 0.089).
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Figure 2. Fasting serum levels of adiponectin (a) and leptin (b) in participants with metabolic syndrome
at baseline and after 8 weeks supplementation (end study) with cod protein hydrolysate (CPH) (n = 15)
or placebo (n = 15). The red horizontal line shows the median levels. p-values within groups were
calculated using the Wilcoxon’s Signed Rank Test. Statistically significant p-values are marked with an
asterisk (*).
No statistically significant differences in leptin levels within the CPH (baseline: 36.2 (18.2,
44.6) ng/mL, end study: 30.8 (16.8, 40.0) ng/mL, p = 0.733) or placebo group (baseline: 45.7 (17.1, 52.5)
ng/mL end study: 39.6 (20.8, 59.6) ng/mL, p = 0.910) were observed from baseline to end of study
(Figure 2b). The median leptin change in the CPH group was 0.30 (−3.27, 4.94) ng/mL, and 0.012 (−4.24,
8.98) ng/mL in the placebo group. When comparing the change in fasting levels of leptin, we did not
observe any statistically significant difference between groups (p = 0.967).
3.3. Acylated Ghrelin Levels
At baseline, the levels of acylated ghrelin were 77.8 (196.2) pg/mL in the CPH group, and 24.9
(20.8) pg/mL in the placebo group. Adjusted for time and visit, the acylated ghrelin levels were on
average 51.1 pg/mL higher for the CPH group compared to placebo, but the linear mixed effects model
with repeated measures analysis did not reveal any statistically significant differences between the
groups (95% CI: (−54.5, 157.0), p = 0.330). We observed no statistically significant change in acylated
ghrelin levels from baseline to end of study visit in either of the groups (overall change: 0.03 pg/mL,
95% CI: (−1.50, 1.53), p = 0.937) (Figure 3). There were no significant interactions between group and
visit (baseline vs. end of study, p = 0.749), group and time (p = 0.693), time and visit (p = 0.794) or
between group, visit and time (p = 0.853) for acylated ghrelin.
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as a separate segment on the graph. Graph (c) presents the change (calculated as 8 weeks—baseline) 
in acylated ghrelin during the intervention in the CPH group (solid line) compared to the placebo 
group (dotted line). 
No correlations were observed between fasting concentration of acylated ghrelin and body 
weight (kg) (r = 0.075, p = 0.700) or BMI (r = 0.172, p = 0.372) for the whole group at baseline (results 
are presented for n = 29, one participant excluded from the correlation analysis due to high levels). 
Furthermore, no correlations were observed between changes in fasting acylated ghrelin levels and 
changes in body weight (kg) (r = −0.144, p = 0.457) or BMI (r = −0.146, p = 0.448). 
3.4. Inflammatory Parameters 
The values of hs-CRP and inflammatory markers in serum are shown in Table 2. The serum 
concentrations of the cytokines were low, but detectable.  
Table 2. The concentration of inflammatory markers in serum samples collected before and 
after 8 weeks supplementation with cod protein hydrolysate (CPH) (n = 15) or placebo (n = 
15). 
 
Baseline 8 Weeks 
p-Value1 p-Value2 
Median 25th, 75th Percentile Median 25th, 75th Percentile 
Hs-CRP, mg/L  0.029* 
 CPH 4.0 1.0, 4.0 4.0 2.0, 6.0 0.021*  
 Placebo 3.0 1.5, 7.0 3.0 2.0, 7.0 0.389  
IL-1 β, pg/mL  0.567 
 CPH 0.13 0.13, 0.41 0.13 0.13, 0.41 0.574  
 Placebo  0.13 0.13, 0.41 0.13 0.13, 0.41 0.589  
IL-6, pg/mL  0.935 
 CPH 1.04 0.52, 1.77 0.90 0.74, 1.48 0.394  
 Placebo 1.19 0.75, 1.34 1.04 0.59, 1.34 0.396  
IL-8, pg/mL  0.174 
 CPH 15.8 11.9, 20.3  17.6 14.0, 22.5 0.096  
 Placebo 18.1 15.1, 26.9 16.7 12.2, 23.0 0.281  
TNF-α, pg/mL  0.935 
 CPH 0.57 0.22, 0.93 0.93 0.22, 0.93 0.573  
 Placebo 0.22 0.11, 0.93 0.57 0.22, 0.93 0.280  
Hs-CRP; high-sensitivity C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor alpha. The 
data are presented ad median and interquartile range. (1) p-values within groups are based on 
Wilcoxon`s Signed Rank Test. (2) p-values between groups are based on Mann Whitney U Test. 
Statistically significant p-values are marked with an asterisk (*). 
No differences between the groups were observed for hs-CRP or any of the other inflammatory 
mediators at baseline. The concentrations of IL-1β, IL-6, IL-8 or TNF-α did not change during the 
Figure 3. Fasting and postprandial acylated levels of ghrelin after a standardized breakfast meal at
baseline (solid line) and end of study (dotted line) in participants that received supplementation with
cod protein hydrolysate (CPH) (n = 15) (a) or placebo (n = 15) (b) for 8 weeks. In the CPH group, one
individual had much higher levels of acylated ghrelin compared to the rest of the group and is shown
as a separate segment on the graph. Graph (c) presents the change (calculated as 8 weeks—baseline) in
acylated ghrelin during the intervention in the CPH group (solid line) compared to the placebo group
(dotted line).
No correlations were observ d betw en fasting concentration of acylated ghr lin and body weight
(kg) (r = 0.075, p = 0.700) or BMI ( = 0.172, p = 0.372) for the w ole group at baseline (results are
presented for n = 29, one participant exclude from the correlation analysi due to high levels).
Furthermore, no cor elations were observed betwe n changes in fasting acylated ghrelin levels and
changes in body weight (kg) (r = − . 4, p 0.146, p = 0. 48).
3.4. Inflammatory Parameters
The values of hs-CRP and inflammatory markers in serum are shown in Table 2. The serum
concentrations of the cytokines were low, but detectable.
No differences between the groups were observed for hs-CRP or any of the other inflammatory
mediators at bas line. The concentrations of IL-1β, IL-6, IL-8 or TNF-α did not change duri g the
course of the study and were not affected by supplementation with CPH (Table 2). After 8 weeks,
the fasting level of hs-CRP was significantly higher within the CPH group, with no changes observed
within the placebo group (Table 2). The median hs-CRP change in the CPH group was 0.1 (0.0, 2.0) mg/L,
and −0.1 (−1.0, 0.55) mg/L in the placebo group. When comparing the change in f sting levels of
hs-CRP, the distribution in the CPH group was significantly different from the placebo group (p = 0.029)
(Table 2). Two participants in the placebo group were excluded from the statistical analysis of hs-CRP
due to the use of lipid-lowering drugs (simvastatin, atorvastatin), because these are known to affect the
levels of hs-CRP [37]. The statistical significance of results did not change if they were included in the
statistical analysis of hs-CRP.
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Table 2. The concentration of inflammatory markers in serum samples collected before and after 8
weeks supplementation with cod protein hydrolysate (CPH) (n = 15) or placebo (n = 15).
Baseline 8 Weeks
p-Value 1 p-Value 2
Median 25th, 75thPercentile Median
25th, 75th
Percentile
Hs-CRP, mg/L 0.029 *
CPH 4.0 1.0, 4.0 4.0 2.0, 6.0 0.021 *
Placebo 3.0 1.5, 7.0 3.0 2.0, 7.0 0.389
IL-1β, pg/mL 0.567
CPH 0.13 0.13, 0.41 0.13 0.13, 0.41 0.574
Placebo 0.13 0.13, 0.41 0.13 0.13, 0.41 0.589
IL-6, pg/mL 0.935
CPH 1.04 0.52, 1.77 0.90 0.74, 1.48 0.394
Placebo 1.19 0.75, 1.34 1.04 0.59, 1.34 0.396
IL-8, pg/mL 0.174
CPH 15.8 11.9, 20.3 17.6 14.0, 22.5 0.096
Placebo 18.1 15.1, 26.9 16.7 12.2, 23.0 0.281
TNF-α, pg/mL 0.935
CPH 0.57 0.22, 0.93 0.93 0.22, 0.93 0.573
Placebo 0.22 0.11, 0.93 0.57 0.22, 0.93 0.280
Hs-CRP; high-sensitivity C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor alpha. The data are
presented ad median and interquartile range. (1) p-values within groups are based on Wilcoxon’s Signed Rank Test.
(2) p-values between groups are based on Mann Whitney U Test. Statistically significant p-values are marked with
an asterisk (*).
3.5. Adverse Effects
The blood tests taken for safety purposes were all within normal range. Seven subjects reported
discomfort during the intervention period: four in the CPH group and three in the placebo group.
In the CPH group, two subjects reported heartburn, two reported nausea at the beginning of the
intervention period, and one reported that the supplement tasted bad and caused retching. In the
placebo group, one reported itchy rash in the face, one reported nausea and one reported myalgia, but
all three subjects were unsure if the symptoms were related to the intervention.
4. Discussion
The main objective of the present study was to investigate whether daily supplementation with
low doses of CPH for 8 weeks would have an effect on circulating levels of ghrelin, adiponectin,
leptin and different inflammatory markers in subjects with MetS. We hypothesized that 8 weeks
supplementation with CPH would lead to a beneficial effect on circulating leptin levels and reduced
inflammatory markers, as well as increased circulating levels of adiponectin and a suppressing effect
on postprandial levels of ghrelin. These possibly beneficial effects were hypothesized to occur due to
the presences of small peptides, mainly di- and tripeptides, suggested to be absorbed rapidly from
the gastrointestinal tract and possibly influencing pathways involved in regulation of appetite and
inflammation. Here, we show that 4 g of CPH for 8 weeks did not influence fasting and postprandial
concentrations of acylated ghrelin or fasting levels of adiponectin, leptin or the inflammatory markers,
when compared to placebo in individuals with MetS.
A daily supplementation with 4 g of CPH was sufficient to increase fasting serum adiponectin
levels within the CPH group, with no change in serum levels of leptin in circulation. These results are
in agreement with a previous study in healthy overweight and obese subjects receiving 2.5 g of cod
protein (not hydrolyzed) for 8 weeks [23]. Observing the individual levels of adiponectin (Figure 2a),
it is apparent that there are individual variations. Since the increased levels of adiponectin only were
found within the CPH group and not when comparing the groups after intervention, the results should
be interpreted with caution and should be explored in further studies. Still, these findings are of
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interest and suggests that hydrolyzed protein from lean fish may have beneficial effects on adiponectin
concentration. We hypothesize that an effect may be mediated by rapidly absorbed di- and tripeptides
present in the hydrolyzed supplement, containing bioactive sequences affecting metabolic pathways in
the cells and thereby increasing the levels of adiponectin. Compared to the recommended daily protein
intake in healthy individuals (e.g., 0.8–1.5 g protein/kg body weight/day) [38], the amount of protein in
the supplement is very low, and it is plausible that it is not the increased protein content per se that
is responsible for the possible metabolic effect. Bioactive peptide sequences with effect on glucose
metabolism, blood pressure and lipids have been identified in other fish protein hydrolysates [39].
We have not tested for the presences of these specific known bioactive sequences in our hydrolysate,
which is a limitation of the study, and the possible mechanism of action is therefore only a hypothesis.
No effects on fasting or postprandial levels of acylated ghrelin were observed after supplementation
with CPH, which is in line with what we observed after giving one single dose of CPH to normal
weight adults [29]. In contrast to our previous study, we used a higher dose, over a longer period,
and a population with metabolic disturbances in the current study. We still did not observe any effects
on circulating acylated ghrelin. In the previous study we assessed self-reported feeling of satiety and
hunger [29]. An assessment of appetite was not included, which would have been an improvement
of the study design seen in relation to ghrelin. By including validated questionnaires for reporting
appetite and a free eating lunch at each study visit, we would be able to calculate energy intake
and assess whether supplementation with CPH for 8 weeks led to lower energy intake, and thereby
suggesting a suppressing effect on appetite.
Fish has been proposed to have anti-inflammatory properties, and reduced levels of CRP have been
linked to fish consumption [13]. A diet with cod protein reduced the levels of hs-CRP in insulin-resistant
subjects [14], whereas others have reported of no effect on CRP levels or other inflammatory markers
after a high intake of cod in normal-weight [40] or overweight subjects [41]. No effect on CRP levels
was observed in an intervention study with overweight and obese subjects supplemented with similar
amount of cod protein (intact protein) as used in the current trial [15]. We observed higher levels of
hs-CRP after supplementation with CPH for 8 weeks, when compared to placebo, but did not observe
any changes in other inflammatory markers. An increased level of CRP was reported in elderly subjects
living in a nursing home setting given 5.2 g of fish protein (blue whiting) for 6 weeks (compared to
placebo) [42], however, this group is not comparable to our study population. Overall, the higher
levels of hs-CRP in the CPH group is difficult to interpret. It is possible that the small sample size
might have influenced the results, or that some individuals may have had some on-going low-grade
inflammation without disclosing a problem. When comparing the overall fasting levels of hs-CRP in
both groups in our study with a previous study by Delongui et al. [43], our levels are similar to the
levels reported in obese subjects and higher compared to normal weight subjects, emphasizing how
BMI may affect CRP levels [43].
There are certain strengths and limitations to the study. Firstly, the randomized, double-blinded
design is a strength. A cross-over design would potentially have been an even better design, with each
subject serving as his/her own control and allowing us to recruit fewer subjects without compromising
the strength of the study [44]. Since this would have resulted in a long intervention period and
possibly higher dropout rate, we chose to conduct the current study as a parallel group study. Secondly,
adjusting the CPH dosage to the body weight of each participant could have further strengthened
the design, as it would reduce the effect of variation in body weight. It was not practically feasible,
and we chose to use a dose similar to what has previously been effective [15,36,45]. Thirdly, the lack of
a power analysis is a weakness when interpreting the data, but there was no relevant data to base such
calculation upon. As we had difficulties recruiting, we did not reach our target of 60 subjects (with 30
individuals in each treatment arm), which might have further affected the results. In particular we had
difficulties recruiting males and a predominance of female participants were included in the study. Due
to limited resources and time constraint, the inclusion of new participants was stopped in September
2019. It cannot be ruled out that our results might have changed in a larger study, so replication from
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future studies are necessary to examine the robustness of our findings, in particular related to fasting
levels of serum adiponectin and hs-CRP.
5. Conclusions
To conclude, our study showed that a daily supplement of 4 g of CPH for 8 weeks was not
sufficient to affect fasting or postprandial levels of ghrelin, or fasting levels of adiponectin, leptin or
inflammatory markers in overweight and obese subjects with MetS.
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changed to “(…), with no significant effects on lipid markers in other studies” 
Page 25 Misspelling: “(…) defined as “a person’s weight in kilogram (kg) divided by the 
square of hens heights in meters (kg/m2)” changed to “(…) defined as “person’s 
weight in kilogram divided by the square of his height in meters (kg/m2)” 
 
Paper I: Page 5, Line 7, first paragraph “To EDTA blood sampling tubes were added (…)” – 
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